id	sid	tid	token	lemma	pos
ajlm-1625	1	1	abstract	abstract	ADJ
ajlm-1625	1	2	introduction	introduction	NOUN
ajlm-1625	1	3	methods	method	NOUN
ajlm-1625	1	4	results	result	VERB
ajlm-1625	1	5	discussion	discussion	NOUN
ajlm-1625	1	6	acknowledgements	acknowledgement	NOUN
ajlm-1625	1	7	references	reference	NOUN
ajlm-1625	1	8	about	about	ADP
ajlm-1625	1	9	the	the	DET
ajlm-1625	1	10	author(s	author(s	NOUN
ajlm-1625	1	11	)	)	PUNCT
ajlm-1625	1	12	koumpingnin	koumpingnin	PROPN
ajlm-1625	1	13	nebie	nebie	PROPN
ajlm-1625	1	14	national	national	ADJ
ajlm-1625	1	15	blood	blood	NOUN
ajlm-1625	1	16	center	center	NOUN
ajlm-1625	1	17	of	of	ADP
ajlm-1625	1	18	ouagadougou	ouagadougou	PROPN
ajlm-1625	1	19	,	,	PUNCT
ajlm-1625	1	20	ouagadougou	ouagadougou	PROPN
ajlm-1625	1	21	,	,	PUNCT
ajlm-1625	1	22	burkina	burkina	PROPN
ajlm-1625	1	23	faso	faso	PROPN
ajlm-1625	1	24	laboratory	laboratory	PROPN
ajlm-1625	1	25	of	of	ADP
ajlm-1625	1	26	haematology	haematology	NOUN
ajlm-1625	1	27	,	,	PUNCT
ajlm-1625	1	28	department	department	NOUN
ajlm-1625	1	29	of	of	ADP
ajlm-1625	1	30	fundamental	fundamental	ADJ
ajlm-1625	1	31	sciences	science	NOUN
ajlm-1625	1	32	,	,	PUNCT
ajlm-1625	1	33	health	health	NOUN
ajlm-1625	1	34	sciences	sciences	PROPN
ajlm-1625	1	35	research	research	NOUN
ajlm-1625	1	36	and	and	CCONJ
ajlm-1625	1	37	training	training	NOUN
ajlm-1625	1	38	unit	unit	NOUN
ajlm-1625	1	39	,	,	PUNCT
ajlm-1625	1	40	university	university	PROPN
ajlm-1625	1	41	joseph	joseph	PROPN
ajlm-1625	1	42	ki	ki	PROPN
ajlm-1625	1	43	-	-	PUNCT
ajlm-1625	1	44	zerbo	zerbo	PROPN
ajlm-1625	1	45	,	,	PUNCT
ajlm-1625	1	46	ouagadougou	ouagadougou	PROPN
ajlm-1625	1	47	,	,	PUNCT
ajlm-1625	1	48	burkina	burkina	PROPN
ajlm-1625	1	49	faso	faso	PROPN
ajlm-1625	1	50	salam	salam	PROPN
ajlm-1625	1	51	sawadogo	sawadogo	VERB
ajlm-1625	1	52	national	national	ADJ
ajlm-1625	1	53	blood	blood	NOUN
ajlm-1625	1	54	center	center	NOUN
ajlm-1625	1	55	of	of	ADP
ajlm-1625	1	56	ouagadougou	ouagadougou	PROPN
ajlm-1625	1	57	,	,	PUNCT
ajlm-1625	1	58	ouagadougou	ouagadougou	PROPN
ajlm-1625	1	59	,	,	PUNCT
ajlm-1625	1	60	burkina	burkina	PROPN
ajlm-1625	1	61	faso	faso	PROPN
ajlm-1625	1	62	laboratory	laboratory	PROPN
ajlm-1625	1	63	of	of	ADP
ajlm-1625	1	64	haematology	haematology	NOUN
ajlm-1625	1	65	,	,	PUNCT
ajlm-1625	1	66	department	department	NOUN
ajlm-1625	1	67	of	of	ADP
ajlm-1625	1	68	fundamental	fundamental	ADJ
ajlm-1625	1	69	sciences	science	NOUN
ajlm-1625	1	70	,	,	PUNCT
ajlm-1625	1	71	health	health	NOUN
ajlm-1625	1	72	sciences	sciences	PROPN
ajlm-1625	1	73	research	research	NOUN
ajlm-1625	1	74	and	and	CCONJ
ajlm-1625	1	75	training	training	NOUN
ajlm-1625	1	76	unit	unit	NOUN
ajlm-1625	1	77	,	,	PUNCT
ajlm-1625	1	78	university	university	PROPN
ajlm-1625	1	79	joseph	joseph	PROPN
ajlm-1625	1	80	ki	ki	PROPN
ajlm-1625	1	81	-	-	PUNCT
ajlm-1625	1	82	zerbo	zerbo	PROPN
ajlm-1625	1	83	,	,	PUNCT
ajlm-1625	1	84	ouagadougou	ouagadougou	PROPN
ajlm-1625	1	85	,	,	PUNCT
ajlm-1625	1	86	burkina	burkina	PROPN
ajlm-1625	1	87	faso	faso	PROPN
ajlm-1625	2	1	salifo	salifo	PROPN
ajlm-1625	2	2	sawadogo	sawadogo	PROPN
ajlm-1625	2	3	national	national	PROPN
ajlm-1625	2	4	institute	institute	PROPN
ajlm-1625	2	5	for	for	ADP
ajlm-1625	2	6	medical	medical	ADJ
ajlm-1625	2	7	sciences	science	NOUN
ajlm-1625	2	8	,	,	PUNCT
ajlm-1625	2	9	university	university	NOUN
ajlm-1625	2	10	nazi	nazi	PROPN
ajlm-1625	2	11	boni	boni	PROPN
ajlm-1625	2	12	,	,	PUNCT
ajlm-1625	2	13	bobo	bobo	NOUN
ajlm-1625	2	14	-	-	PUNCT
ajlm-1625	2	15	dioulasso	dioulasso	PROPN
ajlm-1625	2	16	,	,	PUNCT
ajlm-1625	2	17	burkina	burkina	PROPN
ajlm-1625	2	18	faso	faso	PROPN
ajlm-1625	2	19	souro	souro	PROPN
ajlm-1625	2	20	sanou	sanou	PROPN
ajlm-1625	3	1	teaching	teaching	NOUN
ajlm-1625	3	2	hospital	hospital	NOUN
ajlm-1625	3	3	,	,	PUNCT
ajlm-1625	3	4	bobo	bobo	NOUN
ajlm-1625	3	5	-	-	PUNCT
ajlm-1625	3	6	dioulasso	dioulasso	PROPN
ajlm-1625	3	7	,	,	PUNCT
ajlm-1625	3	8	burkina	burkina	PROPN
ajlm-1625	3	9	faso	faso	PROPN
ajlm-1625	3	10	jérôme	jérôme	PROPN
ajlm-1625	3	11	koulidiati	koulidiati	PROPN
ajlm-1625	3	12	laboratory	laboratory	PROPN
ajlm-1625	3	13	of	of	ADP
ajlm-1625	3	14	haematology	haematology	NOUN
ajlm-1625	3	15	,	,	PUNCT
ajlm-1625	3	16	department	department	NOUN
ajlm-1625	3	17	of	of	ADP
ajlm-1625	3	18	fundamental	fundamental	ADJ
ajlm-1625	3	19	sciences	science	NOUN
ajlm-1625	3	20	,	,	PUNCT
ajlm-1625	3	21	health	health	NOUN
ajlm-1625	3	22	sciences	sciences	PROPN
ajlm-1625	3	23	research	research	NOUN
ajlm-1625	3	24	and	and	CCONJ
ajlm-1625	3	25	training	training	NOUN
ajlm-1625	3	26	unit	unit	NOUN
ajlm-1625	3	27	,	,	PUNCT
ajlm-1625	3	28	university	university	PROPN
ajlm-1625	3	29	joseph	joseph	PROPN
ajlm-1625	3	30	ki	ki	PROPN
ajlm-1625	3	31	-	-	PUNCT
ajlm-1625	3	32	zerbo	zerbo	PROPN
ajlm-1625	3	33	,	,	PUNCT
ajlm-1625	3	34	ouagadougou	ouagadougou	PROPN
ajlm-1625	3	35	,	,	PUNCT
ajlm-1625	3	36	burkina	burkina	PROPN
ajlm-1625	3	37	faso	faso	PROPN
ajlm-1625	3	38	yalgado	yalgado	PROPN
ajlm-1625	3	39	ouedraogo	ouedraogo	VERB
ajlm-1625	3	40	teaching	teach	VERB
ajlm-1625	3	41	hospital	hospital	NOUN
ajlm-1625	3	42	,	,	PUNCT
ajlm-1625	3	43	ouagadougou	ouagadougou	PROPN
ajlm-1625	3	44	,	,	PUNCT
ajlm-1625	3	45	burkina	burkina	PROPN
ajlm-1625	3	46	faso	faso	PROPN
ajlm-1625	3	47	habi	habi	PROPN
ajlm-1625	3	48	y.a	y.a	PROPN
ajlm-1625	3	49	.	.	PROPN
ajlm-1625	3	50	lengani	lengani	PROPN
ajlm-1625	3	51	yalgado	yalgado	PROPN
ajlm-1625	3	52	ouedraogo	ouedraogo	VERB
ajlm-1625	3	53	teaching	teach	VERB
ajlm-1625	3	54	hospital	hospital	NOUN
ajlm-1625	3	55	,	,	PUNCT
ajlm-1625	3	56	ouagadougou	ouagadougou	PROPN
ajlm-1625	3	57	,	,	PUNCT
ajlm-1625	3	58	burkina	burkina	PROPN
ajlm-1625	3	59	faso	faso	PROPN
ajlm-1625	3	60	abdoul	abdoul	PROPN
ajlm-1625	4	1	g.	g.	PROPN
ajlm-1625	4	2	sawadogo	sawadogo	VERB
ajlm-1625	4	3	national	national	ADJ
ajlm-1625	4	4	blood	blood	NOUN
ajlm-1625	4	5	center	center	NOUN
ajlm-1625	4	6	of	of	ADP
ajlm-1625	4	7	ouagadougou	ouagadougou	PROPN
ajlm-1625	4	8	,	,	PUNCT
ajlm-1625	4	9	ouagadougou	ouagadougou	PROPN
ajlm-1625	4	10	,	,	PUNCT
ajlm-1625	4	11	burkina	burkina	PROPN
ajlm-1625	4	12	faso	faso	PROPN
ajlm-1625	4	13	jérôme	jérôme	PROPN
ajlm-1625	4	14	babinet	babinet	PROPN
ajlm-1625	4	15	centre	centre	PROPN
ajlm-1625	4	16	national	national	PROPN
ajlm-1625	4	17	de	de	X
ajlm-1625	4	18	référence	référence	NOUN
ajlm-1625	4	19	pour	pour	X
ajlm-1625	4	20	les	les	PROPN
ajlm-1625	4	21	groupes	groupe	NOUN
ajlm-1625	4	22	sanguins	sanguin	NOUN
ajlm-1625	4	23	(	(	PUNCT
ajlm-1625	4	24	cnrgs	cnrg	NOUN
ajlm-1625	4	25	)	)	PUNCT
ajlm-1625	4	26	,	,	PUNCT
ajlm-1625	4	27	national	national	PROPN
ajlm-1625	4	28	institute	institute	NOUN
ajlm-1625	4	29	for	for	ADP
ajlm-1625	4	30	blood	blood	NOUN
ajlm-1625	4	31	transfusion	transfusion	NOUN
ajlm-1625	4	32	,	,	PUNCT
ajlm-1625	4	33	paris	paris	PROPN
ajlm-1625	4	34	,	,	PUNCT
ajlm-1625	4	35	france	france	PROPN
ajlm-1625	4	36	mohammed	mohammed	PROPN
ajlm-1625	4	37	khalloufi	khalloufi	PROPN
ajlm-1625	4	38	french	french	ADJ
ajlm-1625	4	39	establishment	establishment	NOUN
ajlm-1625	4	40	of	of	ADP
ajlm-1625	4	41	blood	blood	NOUN
ajlm-1625	4	42	,	,	PUNCT
ajlm-1625	4	43	bobigny	bobigny	NOUN
ajlm-1625	4	44	,	,	PUNCT
ajlm-1625	4	45	france	france	PROPN
ajlm-1625	4	46	saliou	saliou	PROPN
ajlm-1625	4	47	diop	diop	PROPN
ajlm-1625	4	48	department	department	PROPN
ajlm-1625	4	49	of	of	ADP
ajlm-1625	4	50	haematology	haematology	PROPN
ajlm-1625	4	51	,	,	PUNCT
ajlm-1625	4	52	university	university	NOUN
ajlm-1625	4	53	cheikh	cheikh	PROPN
ajlm-1625	4	54	anta	anta	PROPN
ajlm-1625	4	55	diop	diop	PROPN
ajlm-1625	4	56	,	,	PUNCT
ajlm-1625	4	57	dakar	dakar	NOUN
ajlm-1625	4	58	,	,	PUNCT
ajlm-1625	4	59	senegal	senegal	NOUN
ajlm-1625	4	60	eléonore	eléonore	ADV
ajlm-1625	4	61	kafando	kafando	PROPN
ajlm-1625	4	62	laboratory	laboratory	PROPN
ajlm-1625	4	63	of	of	ADP
ajlm-1625	4	64	haematology	haematology	PROPN
ajlm-1625	4	65	,	,	PUNCT
ajlm-1625	4	66	department	department	NOUN
ajlm-1625	4	67	of	of	ADP
ajlm-1625	4	68	fundamental	fundamental	ADJ
ajlm-1625	4	69	sciences	science	NOUN
ajlm-1625	4	70	,	,	PUNCT
ajlm-1625	4	71	health	health	NOUN
ajlm-1625	4	72	sciences	sciences	PROPN
ajlm-1625	4	73	research	research	NOUN
ajlm-1625	4	74	and	and	CCONJ
ajlm-1625	4	75	training	training	NOUN
ajlm-1625	4	76	unit	unit	NOUN
ajlm-1625	4	77	,	,	PUNCT
ajlm-1625	4	78	university	university	PROPN
ajlm-1625	4	79	joseph	joseph	PROPN
ajlm-1625	4	80	ki	ki	PROPN
ajlm-1625	4	81	-	-	PUNCT
ajlm-1625	4	82	zerbo	zerbo	PROPN
ajlm-1625	4	83	,	,	PUNCT
ajlm-1625	4	84	ouagadougou	ouagadougou	PROPN
ajlm-1625	4	85	,	,	PUNCT
ajlm-1625	4	86	burkina	burkina	PROPN
ajlm-1625	4	87	faso	faso	PROPN
ajlm-1625	4	88	laboratory	laboratory	PROPN
ajlm-1625	4	89	of	of	ADP
ajlm-1625	4	90	haematology	haematology	NOUN
ajlm-1625	4	91	,	,	PUNCT
ajlm-1625	4	92	paediatric	paediatric	ADJ
ajlm-1625	4	93	teaching	teaching	NOUN
ajlm-1625	4	94	hospital	hospital	NOUN
ajlm-1625	4	95	charles	charles	PROPN
ajlm-1625	4	96	de	de	X
ajlm-1625	4	97	gaulle	gaulle	PROPN
ajlm-1625	4	98	,	,	PUNCT
ajlm-1625	4	99	ouagadougou	ouagadougou	PROPN
ajlm-1625	4	100	,	,	PUNCT
ajlm-1625	4	101	burkina	burkina	PROPN
ajlm-1625	4	102	faso	faso	PROPN
ajlm-1625	4	103	citation	citation	PROPN
ajlm-1625	4	104	nebie	nebie	PROPN
ajlm-1625	4	105	k	k	PROPN
ajlm-1625	4	106	,	,	PUNCT
ajlm-1625	4	107	sawadogo	sawadogo	PROPN
ajlm-1625	4	108	s	s	PART
ajlm-1625	4	109	,	,	PUNCT
ajlm-1625	4	110	sawadogo	sawadogo	PROPN
ajlm-1625	4	111	s	s	PART
ajlm-1625	4	112	,	,	PUNCT
ajlm-1625	4	113	et	et	PROPN
ajlm-1625	4	114	al	al	PROPN
ajlm-1625	4	115	.	.	PROPN
ajlm-1625	4	116	red	red	ADJ
ajlm-1625	4	117	blood	blood	NOUN
ajlm-1625	4	118	cell	cell	NOUN
ajlm-1625	4	119	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	4	120	in	in	ADP
ajlm-1625	4	121	multi	multi	ADJ
ajlm-1625	4	122	-	-	ADJ
ajlm-1625	4	123	transfused	transfused	ADJ
ajlm-1625	4	124	patients	patient	NOUN
ajlm-1625	4	125	from	from	ADP
ajlm-1625	4	126	an	an	DET
ajlm-1625	4	127	haemodialysis	haemodialysis	NOUN
ajlm-1625	4	128	service	service	NOUN
ajlm-1625	4	129	in	in	ADP
ajlm-1625	4	130	burkina	burkina	PROPN
ajlm-1625	4	131	faso	faso	PROPN
ajlm-1625	4	132	.	.	PUNCT
ajlm-1625	5	1	afr	afr	PROPN
ajlm-1625	5	2	j	j	PROPN
ajlm-1625	5	3	lab	lab	PROPN
ajlm-1625	5	4	med	med	PROPN
ajlm-1625	5	5	.	.	PUNCT
ajlm-1625	6	1	2022;11(1	2022;11(1	NUM
ajlm-1625	6	2	)	)	PUNCT
ajlm-1625	6	3	,	,	PUNCT
ajlm-1625	6	4	a1625	a1625	NOUN
ajlm-1625	6	5	.	.	PUNCT
ajlm-1625	7	1	https://doi.org/10.4102/ajlm.v11i1.1625	https://doi.org/10.4102/ajlm.v11i1.1625	NOUN
ajlm-1625	7	2	original	original	ADJ
ajlm-1625	7	3	research	research	NOUN
ajlm-1625	7	4	red	red	ADJ
ajlm-1625	7	5	blood	blood	NOUN
ajlm-1625	7	6	cell	cell	NOUN
ajlm-1625	7	7	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	7	8	in	in	ADP
ajlm-1625	7	9	multi	multi	ADJ
ajlm-1625	7	10	-	-	ADJ
ajlm-1625	7	11	transfused	transfused	ADJ
ajlm-1625	7	12	patients	patient	NOUN
ajlm-1625	7	13	from	from	ADP
ajlm-1625	7	14	an	an	DET
ajlm-1625	7	15	haemodialysis	haemodialysis	NOUN
ajlm-1625	7	16	service	service	NOUN
ajlm-1625	7	17	in	in	ADP
ajlm-1625	7	18	burkina	burkina	PROPN
ajlm-1625	7	19	faso	faso	PROPN
ajlm-1625	7	20	koumpingnin	koumpingnin	PROPN
ajlm-1625	7	21	nebie	nebie	PROPN
ajlm-1625	7	22	,	,	PUNCT
ajlm-1625	7	23	salam	salam	PROPN
ajlm-1625	7	24	sawadogo	sawadogo	PROPN
ajlm-1625	7	25	,	,	PUNCT
ajlm-1625	7	26	salifo	salifo	PROPN
ajlm-1625	7	27	sawadogo	sawadogo	PROPN
ajlm-1625	7	28	,	,	PUNCT
ajlm-1625	7	29	jérôme	jérôme	PROPN
ajlm-1625	7	30	koulidiati	koulidiati	PROPN
ajlm-1625	7	31	,	,	PUNCT
ajlm-1625	7	32	habi	habi	PROPN
ajlm-1625	7	33	y.a	y.a	PROPN
ajlm-1625	7	34	.	.	PROPN
ajlm-1625	7	35	lengani	lengani	PROPN
ajlm-1625	7	36	,	,	PUNCT
ajlm-1625	7	37	abdoul	abdoul	PROPN
ajlm-1625	7	38	g.	g.	PROPN
ajlm-1625	7	39	sawadogo	sawadogo	PROPN
ajlm-1625	7	40	,	,	PUNCT
ajlm-1625	7	41	jérôme	jérôme	PROPN
ajlm-1625	7	42	babinet	babinet	PROPN
ajlm-1625	7	43	,	,	PUNCT
ajlm-1625	7	44	mohammed	mohammed	PROPN
ajlm-1625	7	45	khalloufi	khalloufi	PROPN
ajlm-1625	7	46	,	,	PUNCT
ajlm-1625	7	47	saliou	saliou	NOUN
ajlm-1625	7	48	diop	diop	PROPN
ajlm-1625	7	49	,	,	PUNCT
ajlm-1625	7	50	eléonore	eléonore	ADJ
ajlm-1625	7	51	kafando	kafando	PROPN
ajlm-1625	7	52	received	receive	VERB
ajlm-1625	7	53	:	:	PUNCT
ajlm-1625	7	54	12	12	NUM
ajlm-1625	7	55	may	may	PROPN
ajlm-1625	7	56	2021	2021	NUM
ajlm-1625	7	57	;	;	PUNCT
ajlm-1625	7	58	accepted	accept	VERB
ajlm-1625	7	59	:	:	PUNCT
ajlm-1625	7	60	26	26	NUM
ajlm-1625	7	61	may	may	PROPN
ajlm-1625	7	62	2022	2022	NUM
ajlm-1625	7	63	;	;	PUNCT
ajlm-1625	7	64	published	publish	VERB
ajlm-1625	7	65	:	:	PUNCT
ajlm-1625	7	66	26	26	NUM
ajlm-1625	7	67	sept	sept	PROPN
ajlm-1625	7	68	.	.	PROPN
ajlm-1625	7	69	2022	2022	NUM
ajlm-1625	7	70	copyright	copyright	NOUN
ajlm-1625	7	71	:	:	PUNCT
ajlm-1625	7	72	©	©	PROPN
ajlm-1625	7	73	2022	2022	NUM
ajlm-1625	7	74	.	.	PUNCT
ajlm-1625	8	1	the	the	DET
ajlm-1625	8	2	author(s	author(s	PROPN
ajlm-1625	8	3	)	)	PUNCT
ajlm-1625	8	4	.	.	PUNCT
ajlm-1625	9	1	licensee	licensee	NOUN
ajlm-1625	9	2	:	:	PUNCT
ajlm-1625	9	3	aosis	aosis	NOUN
ajlm-1625	9	4	.	.	PUNCT
ajlm-1625	10	1	this	this	PRON
ajlm-1625	10	2	is	be	AUX
ajlm-1625	10	3	an	an	DET
ajlm-1625	10	4	open	open	ADJ
ajlm-1625	10	5	access	access	NOUN
ajlm-1625	10	6	article	article	NOUN
ajlm-1625	10	7	distributed	distribute	VERB
ajlm-1625	10	8	under	under	ADP
ajlm-1625	10	9	the	the	DET
ajlm-1625	10	10	terms	term	NOUN
ajlm-1625	10	11	of	of	ADP
ajlm-1625	10	12	the	the	DET
ajlm-1625	10	13	creative	creative	ADJ
ajlm-1625	10	14	commons	common	NOUN
ajlm-1625	10	15	attribution	attribution	NOUN
ajlm-1625	10	16	license	license	NOUN
ajlm-1625	10	17	,	,	PUNCT
ajlm-1625	10	18	which	which	PRON
ajlm-1625	10	19	permits	permit	VERB
ajlm-1625	10	20	unrestricted	unrestricted	ADJ
ajlm-1625	10	21	use	use	NOUN
ajlm-1625	10	22	,	,	PUNCT
ajlm-1625	10	23	distribution	distribution	NOUN
ajlm-1625	10	24	,	,	PUNCT
ajlm-1625	10	25	and	and	CCONJ
ajlm-1625	10	26	reproduction	reproduction	NOUN
ajlm-1625	10	27	in	in	ADP
ajlm-1625	10	28	any	any	DET
ajlm-1625	10	29	medium	medium	NOUN
ajlm-1625	10	30	,	,	PUNCT
ajlm-1625	10	31	provided	provide	VERB
ajlm-1625	10	32	the	the	DET
ajlm-1625	10	33	original	original	ADJ
ajlm-1625	10	34	work	work	NOUN
ajlm-1625	10	35	is	be	AUX
ajlm-1625	10	36	properly	properly	ADV
ajlm-1625	10	37	cited	cite	VERB
ajlm-1625	10	38	.	.	PUNCT
ajlm-1625	11	1	abstract	abstract	ADJ
ajlm-1625	11	2	background	background	NOUN
ajlm-1625	11	3	:	:	PUNCT
ajlm-1625	11	4	in	in	ADP
ajlm-1625	11	5	burkina	burkina	PROPN
ajlm-1625	11	6	faso	faso	PROPN
ajlm-1625	11	7	,	,	PUNCT
ajlm-1625	11	8	red	red	ADJ
ajlm-1625	11	9	blood	blood	NOUN
ajlm-1625	11	10	cell	cell	NOUN
ajlm-1625	11	11	(	(	PUNCT
ajlm-1625	11	12	rbc	rbc	PROPN
ajlm-1625	11	13	)	)	PUNCT
ajlm-1625	11	14	transfusion	transfusion	NOUN
ajlm-1625	11	15	remains	remain	VERB
ajlm-1625	11	16	the	the	DET
ajlm-1625	11	17	crucial	crucial	ADJ
ajlm-1625	11	18	anaemia	anaemia	NOUN
ajlm-1625	11	19	treatment	treatment	NOUN
ajlm-1625	11	20	following	follow	VERB
ajlm-1625	11	21	chronic	chronic	ADJ
ajlm-1625	11	22	renal	renal	ADJ
ajlm-1625	11	23	failure	failure	NOUN
ajlm-1625	11	24	(	(	PUNCT
ajlm-1625	11	25	crf	crf	NOUN
ajlm-1625	11	26	)	)	PUNCT
ajlm-1625	11	27	as	as	ADP
ajlm-1625	11	28	erythropoietin	erythropoietin	ADJ
ajlm-1625	11	29	and	and	CCONJ
ajlm-1625	11	30	its	its	PRON
ajlm-1625	11	31	analogues	analogue	NOUN
ajlm-1625	11	32	are	be	AUX
ajlm-1625	11	33	unavailable	unavailable	ADJ
ajlm-1625	11	34	.	.	PUNCT
ajlm-1625	12	1	however	however	ADV
ajlm-1625	12	2	,	,	PUNCT
ajlm-1625	12	3	blood	blood	NOUN
ajlm-1625	12	4	group	group	NOUN
ajlm-1625	12	5	matching	match	VERB
ajlm-1625	12	6	beyond	beyond	ADP
ajlm-1625	12	7	the	the	DET
ajlm-1625	12	8	abo	abo	NOUN
ajlm-1625	12	9	and	and	CCONJ
ajlm-1625	12	10	rhesus	rhesus	NOUN
ajlm-1625	12	11	is	be	AUX
ajlm-1625	12	12	not	not	PART
ajlm-1625	12	13	common	common	ADJ
ajlm-1625	12	14	in	in	ADP
ajlm-1625	12	15	burkina	burkina	PROPN
ajlm-1625	12	16	faso	faso	PROPN
ajlm-1625	12	17	.	.	PUNCT
ajlm-1625	13	1	thus	thus	ADV
ajlm-1625	13	2	,	,	PUNCT
ajlm-1625	13	3	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	13	4	is	be	AUX
ajlm-1625	13	5	a	a	DET
ajlm-1625	13	6	potential	potential	ADJ
ajlm-1625	13	7	issue	issue	NOUN
ajlm-1625	13	8	for	for	ADP
ajlm-1625	13	9	transfused	transfused	ADJ
ajlm-1625	13	10	patients	patient	NOUN
ajlm-1625	13	11	.	.	PUNCT
ajlm-1625	14	1	objective	objective	NOUN
ajlm-1625	14	2	:	:	PUNCT
ajlm-1625	14	3	our	our	PRON
ajlm-1625	14	4	study	study	NOUN
ajlm-1625	14	5	aimed	aim	VERB
ajlm-1625	14	6	to	to	PART
ajlm-1625	14	7	identify	identify	VERB
ajlm-1625	14	8	anti	anti	ADJ
ajlm-1625	14	9	-	-	ADJ
ajlm-1625	14	10	erythrocyte	erythrocyte	ADJ
ajlm-1625	14	11	antibodies	antibody	NOUN
ajlm-1625	14	12	in	in	ADP
ajlm-1625	14	13	multi	multi	ADJ
ajlm-1625	14	14	-	-	ADJ
ajlm-1625	14	15	transfused	transfused	ADJ
ajlm-1625	14	16	crf	crf	NOUN
ajlm-1625	14	17	patients	patient	NOUN
ajlm-1625	14	18	at	at	ADP
ajlm-1625	14	19	the	the	DET
ajlm-1625	14	20	yalgado	yalgado	NOUN
ajlm-1625	14	21	ouedraogo	ouedraogo	ADJ
ajlm-1625	14	22	teaching	teaching	NOUN
ajlm-1625	14	23	hospital	hospital	NOUN
ajlm-1625	14	24	,	,	PUNCT
ajlm-1625	14	25	ouagadougou	ouagadougou	PROPN
ajlm-1625	14	26	,	,	PUNCT
ajlm-1625	14	27	burkina	burkina	PROPN
ajlm-1625	14	28	faso	faso	PROPN
ajlm-1625	14	29	.	.	PUNCT
ajlm-1625	15	1	methods	method	NOUN
ajlm-1625	15	2	:	:	PUNCT
ajlm-1625	15	3	this	this	DET
ajlm-1625	15	4	cross	cross	ADJ
ajlm-1625	15	5	-	-	ADJ
ajlm-1625	15	6	sectional	sectional	ADJ
ajlm-1625	15	7	study	study	NOUN
ajlm-1625	15	8	,	,	PUNCT
ajlm-1625	15	9	conducted	conduct	VERB
ajlm-1625	15	10	from	from	ADP
ajlm-1625	15	11	october	october	PROPN
ajlm-1625	15	12	2018	2018	NUM
ajlm-1625	15	13	to	to	ADP
ajlm-1625	15	14	november	november	PROPN
ajlm-1625	15	15	2019	2019	NUM
ajlm-1625	15	16	,	,	PUNCT
ajlm-1625	15	17	included	include	VERB
ajlm-1625	15	18	crf	crf	NOUN
ajlm-1625	15	19	patients	patient	NOUN
ajlm-1625	15	20	who	who	PRON
ajlm-1625	15	21	had	have	AUX
ajlm-1625	15	22	received	receive	VERB
ajlm-1625	15	23	at	at	ADP
ajlm-1625	15	24	least	least	ADV
ajlm-1625	15	25	two	two	NUM
ajlm-1625	15	26	rbc	rbc	PROPN
ajlm-1625	15	27	units	unit	NOUN
ajlm-1625	15	28	.	.	PUNCT
ajlm-1625	16	1	we	we	PRON
ajlm-1625	16	2	screened	screen	VERB
ajlm-1625	16	3	patients	patient	NOUN
ajlm-1625	16	4	for	for	ADP
ajlm-1625	16	5	the	the	DET
ajlm-1625	16	6	presence	presence	NOUN
ajlm-1625	16	7	of	of	ADP
ajlm-1625	16	8	rbc	rbc	PROPN
ajlm-1625	16	9	antibodies	antibodie	VERB
ajlm-1625	16	10	using	use	VERB
ajlm-1625	16	11	three	three	NUM
ajlm-1625	16	12	commercial	commercial	ADJ
ajlm-1625	16	13	cells	cell	NOUN
ajlm-1625	16	14	panels	panel	NOUN
ajlm-1625	16	15	and	and	CCONJ
ajlm-1625	16	16	identified	identify	VERB
ajlm-1625	16	17	antibody	antibody	NOUN
ajlm-1625	16	18	specificities	specificity	NOUN
ajlm-1625	16	19	for	for	ADP
ajlm-1625	16	20	positive	positive	ADJ
ajlm-1625	16	21	screenings	screening	NOUN
ajlm-1625	16	22	using	use	VERB
ajlm-1625	16	23	11	11	NUM
ajlm-1625	16	24	cells	cell	NOUN
ajlm-1625	16	25	panels	panel	NOUN
ajlm-1625	16	26	for	for	ADP
ajlm-1625	16	27	an	an	DET
ajlm-1625	16	28	indirect	indirect	ADJ
ajlm-1625	16	29	antiglobulin	antiglobulin	NOUN
ajlm-1625	16	30	test	test	NOUN
ajlm-1625	16	31	(	(	PUNCT
ajlm-1625	16	32	iat	iat	PROPN
ajlm-1625	16	33	)	)	PUNCT
ajlm-1625	16	34	in	in	ADP
ajlm-1625	16	35	a	a	DET
ajlm-1625	16	36	low	low	ADJ
ajlm-1625	16	37	ionic	ionic	ADJ
ajlm-1625	16	38	strength	strength	NOUN
ajlm-1625	16	39	microcolumn	microcolumn	NOUN
ajlm-1625	16	40	gel	gel	NOUN
ajlm-1625	16	41	-	-	PUNCT
ajlm-1625	16	42	card	card	NOUN
ajlm-1625	16	43	system	system	NOUN
ajlm-1625	16	44	.	.	PUNCT
ajlm-1625	17	1	results	result	NOUN
ajlm-1625	17	2	:	:	PUNCT
ajlm-1625	17	3	two	two	NUM
ajlm-1625	17	4	hundred	hundred	NUM
ajlm-1625	17	5	and	and	CCONJ
ajlm-1625	17	6	thirty	thirty	NUM
ajlm-1625	17	7	-	-	PUNCT
ajlm-1625	17	8	five	five	NUM
ajlm-1625	17	9	patients	patient	NOUN
ajlm-1625	17	10	(	(	PUNCT
ajlm-1625	17	11	45.1	45.1	NUM
ajlm-1625	17	12	%	%	NOUN
ajlm-1625	17	13	female	female	NOUN
ajlm-1625	17	14	;	;	PUNCT
ajlm-1625	17	15	average	average	ADJ
ajlm-1625	17	16	age	age	NOUN
ajlm-1625	17	17	:	:	PUNCT
ajlm-1625	17	18	41.5	41.5	NUM
ajlm-1625	17	19	years	year	NOUN
ajlm-1625	17	20	)	)	PUNCT
ajlm-1625	17	21	were	be	AUX
ajlm-1625	17	22	included	include	VERB
ajlm-1625	17	23	.	.	PUNCT
ajlm-1625	18	1	the	the	DET
ajlm-1625	18	2	median	median	ADJ
ajlm-1625	18	3	number	number	NOUN
ajlm-1625	18	4	of	of	ADP
ajlm-1625	18	5	blood	blood	NOUN
ajlm-1625	18	6	units	unit	NOUN
ajlm-1625	18	7	received	receive	VERB
ajlm-1625	18	8	per	per	ADP
ajlm-1625	18	9	patient	patient	NOUN
ajlm-1625	18	10	was	be	AUX
ajlm-1625	18	11	10	10	NUM
ajlm-1625	18	12	(	(	PUNCT
ajlm-1625	18	13	interquartile	interquartile	ADJ
ajlm-1625	18	14	range	range	NOUN
ajlm-1625	18	15	:	:	PUNCT
ajlm-1625	18	16	5–20	5–20	NUM
ajlm-1625	18	17	)	)	PUNCT
ajlm-1625	18	18	.	.	PUNCT
ajlm-1625	19	1	the	the	DET
ajlm-1625	19	2	overall	overall	ADJ
ajlm-1625	19	3	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	19	4	rate	rate	NOUN
ajlm-1625	19	5	was	be	AUX
ajlm-1625	19	6	5.9	5.9	NUM
ajlm-1625	19	7	%	%	NOUN
ajlm-1625	19	8	(	(	PUNCT
ajlm-1625	19	9	14/235	14/235	NUM
ajlm-1625	19	10	)	)	PUNCT
ajlm-1625	19	11	.	.	PUNCT
ajlm-1625	20	1	antibodies	antibody	NOUN
ajlm-1625	20	2	identified	identify	VERB
ajlm-1625	20	3	included	include	VERB
ajlm-1625	20	4	:	:	PUNCT
ajlm-1625	20	5	anti	anti	ADJ
ajlm-1625	20	6	-	-	ADJ
ajlm-1625	20	7	d	d	ADJ
ajlm-1625	20	8	(	(	PUNCT
ajlm-1625	20	9	1	1	NUM
ajlm-1625	20	10	case	case	NOUN
ajlm-1625	20	11	)	)	PUNCT
ajlm-1625	20	12	,	,	PUNCT
ajlm-1625	20	13	anti	anti	ADJ
ajlm-1625	20	14	-	-	ADJ
ajlm-1625	20	15	c	c	ADJ
ajlm-1625	20	16	(	(	PUNCT
ajlm-1625	20	17	1	1	NUM
ajlm-1625	20	18	case	case	NOUN
ajlm-1625	20	19	)	)	PUNCT
ajlm-1625	20	20	,	,	PUNCT
ajlm-1625	20	21	anti	anti	ADJ
ajlm-1625	20	22	-	-	ADJ
ajlm-1625	20	23	d+c	d+c	X
ajlm-1625	20	24	(	(	PUNCT
ajlm-1625	20	25	4	4	NUM
ajlm-1625	20	26	cases	case	NOUN
ajlm-1625	20	27	)	)	PUNCT
ajlm-1625	20	28	,	,	PUNCT
ajlm-1625	20	29	anti	anti	ADJ
ajlm-1625	20	30	-	-	ADJ
ajlm-1625	20	31	cw	cw	ADJ
ajlm-1625	20	32	(	(	PUNCT
ajlm-1625	20	33	1	1	NUM
ajlm-1625	20	34	case	case	NOUN
ajlm-1625	20	35	)	)	PUNCT
ajlm-1625	20	36	,	,	PUNCT
ajlm-1625	20	37	anti	anti	ADJ
ajlm-1625	20	38	-	-	ADJ
ajlm-1625	20	39	e	e	ADJ
ajlm-1625	20	40	(	(	PUNCT
ajlm-1625	20	41	1	1	NUM
ajlm-1625	20	42	case	case	NOUN
ajlm-1625	20	43	)	)	PUNCT
ajlm-1625	20	44	,	,	PUNCT
ajlm-1625	20	45	anti	anti	ADJ
ajlm-1625	20	46	-	-	ADJ
ajlm-1625	20	47	s	s	X
ajlm-1625	20	48	(	(	PUNCT
ajlm-1625	20	49	1	1	NUM
ajlm-1625	20	50	case	case	NOUN
ajlm-1625	20	51	)	)	PUNCT
ajlm-1625	20	52	and	and	CCONJ
ajlm-1625	20	53	anti	anti	ADJ
ajlm-1625	20	54	-	-	ADJ
ajlm-1625	20	55	lea	lea	ADJ
ajlm-1625	20	56	(	(	PUNCT
ajlm-1625	20	57	1	1	NUM
ajlm-1625	20	58	case	case	NOUN
ajlm-1625	20	59	)	)	PUNCT
ajlm-1625	20	60	.	.	PUNCT
ajlm-1625	21	1	in	in	ADP
ajlm-1625	21	2	four	four	NUM
ajlm-1625	21	3	positive	positive	ADJ
ajlm-1625	21	4	patients	patient	NOUN
ajlm-1625	21	5	,	,	PUNCT
ajlm-1625	21	6	the	the	DET
ajlm-1625	21	7	specificity	specificity	NOUN
ajlm-1625	21	8	of	of	ADP
ajlm-1625	21	9	the	the	DET
ajlm-1625	21	10	antibodies	antibody	NOUN
ajlm-1625	21	11	was	be	AUX
ajlm-1625	21	12	indeterminate	indeterminate	ADJ
ajlm-1625	21	13	.	.	PUNCT
ajlm-1625	22	1	no	no	DET
ajlm-1625	22	2	risk	risk	NOUN
ajlm-1625	22	3	factors	factor	NOUN
ajlm-1625	22	4	were	be	AUX
ajlm-1625	22	5	associated	associate	VERB
ajlm-1625	22	6	with	with	ADP
ajlm-1625	22	7	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	22	8	.	.	PUNCT
ajlm-1625	23	1	conclusion	conclusion	NOUN
ajlm-1625	23	2	:	:	PUNCT
ajlm-1625	23	3	in	in	ADP
ajlm-1625	23	4	burkina	burkina	PROPN
ajlm-1625	23	5	faso	faso	PROPN
ajlm-1625	23	6	,	,	PUNCT
ajlm-1625	23	7	screening	screen	VERB
ajlm-1625	23	8	for	for	ADP
ajlm-1625	23	9	rbc	rbc	PROPN
ajlm-1625	23	10	alloantibodies	alloantibody	NOUN
ajlm-1625	23	11	should	should	AUX
ajlm-1625	23	12	be	be	AUX
ajlm-1625	23	13	mandated	mandate	VERB
ajlm-1625	23	14	for	for	ADP
ajlm-1625	23	15	patients	patient	NOUN
ajlm-1625	23	16	at	at	ADP
ajlm-1625	23	17	risk	risk	NOUN
ajlm-1625	23	18	.	.	PUNCT
ajlm-1625	24	1	the	the	DET
ajlm-1625	24	2	high	high	ADJ
ajlm-1625	24	3	rate	rate	NOUN
ajlm-1625	24	4	of	of	ADP
ajlm-1625	24	5	indeterminate	indeterminate	ADJ
ajlm-1625	24	6	antibodies	antibody	NOUN
ajlm-1625	24	7	suggests	suggest	VERB
ajlm-1625	24	8	the	the	DET
ajlm-1625	24	9	need	need	NOUN
ajlm-1625	24	10	to	to	PART
ajlm-1625	24	11	develop	develop	VERB
ajlm-1625	24	12	a	a	DET
ajlm-1625	24	13	local	local	ADJ
ajlm-1625	24	14	rbc	rbc	PROPN
ajlm-1625	24	15	antibody	antibody	NOUN
ajlm-1625	24	16	panel	panel	NOUN
ajlm-1625	24	17	adapted	adapt	VERB
ajlm-1625	24	18	to	to	ADP
ajlm-1625	24	19	the	the	DET
ajlm-1625	24	20	local	local	ADJ
ajlm-1625	24	21	population	population	NOUN
ajlm-1625	24	22	.	.	PUNCT
ajlm-1625	25	1	keywords	keyword	NOUN
ajlm-1625	25	2	:	:	PUNCT
ajlm-1625	25	3	blood	blood	NOUN
ajlm-1625	25	4	transfusion	transfusion	NOUN
ajlm-1625	25	5	;	;	PUNCT
ajlm-1625	25	6	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	25	7	;	;	PUNCT
ajlm-1625	25	8	rbc	rbc	PROPN
ajlm-1625	25	9	antibody	antibody	NOUN
ajlm-1625	25	10	;	;	PUNCT
ajlm-1625	25	11	crf	crf	PROPN
ajlm-1625	25	12	;	;	PUNCT
ajlm-1625	25	13	burkina	burkina	PROPN
ajlm-1625	25	14	faso	faso	PROPN
ajlm-1625	25	15	.	.	PUNCT
ajlm-1625	26	1	introduction	introduction	NOUN
ajlm-1625	26	2	blood	blood	NOUN
ajlm-1625	26	3	transfusion	transfusion	NOUN
ajlm-1625	26	4	,	,	PUNCT
ajlm-1625	26	5	specifically	specifically	ADV
ajlm-1625	26	6	the	the	DET
ajlm-1625	26	7	transfusion	transfusion	NOUN
ajlm-1625	26	8	of	of	ADP
ajlm-1625	26	9	red	red	ADJ
ajlm-1625	26	10	blood	blood	NOUN
ajlm-1625	26	11	cells	cell	NOUN
ajlm-1625	26	12	(	(	PUNCT
ajlm-1625	26	13	rbc	rbc	PROPN
ajlm-1625	26	14	)	)	PUNCT
ajlm-1625	26	15	,	,	PUNCT
ajlm-1625	26	16	significantly	significantly	ADV
ajlm-1625	26	17	contributes	contribute	VERB
ajlm-1625	26	18	to	to	ADP
ajlm-1625	26	19	the	the	DET
ajlm-1625	26	20	modern	modern	ADJ
ajlm-1625	26	21	healthcare	healthcare	NOUN
ajlm-1625	26	22	system	system	NOUN
ajlm-1625	26	23	.	.	PUNCT
ajlm-1625	27	1	every	every	DET
ajlm-1625	27	2	day	day	NOUN
ajlm-1625	27	3	,	,	PUNCT
ajlm-1625	27	4	blood	blood	NOUN
ajlm-1625	27	5	transfusion	transfusion	NOUN
ajlm-1625	27	6	saves	save	VERB
ajlm-1625	27	7	lives	life	NOUN
ajlm-1625	27	8	in	in	ADP
ajlm-1625	27	9	developing	develop	VERB
ajlm-1625	27	10	countries	country	NOUN
ajlm-1625	27	11	where	where	SCONJ
ajlm-1625	27	12	acute	acute	NOUN
ajlm-1625	27	13	anaemia	anaemia	NOUN
ajlm-1625	27	14	caused	cause	VERB
ajlm-1625	27	15	by	by	ADP
ajlm-1625	27	16	malaria	malaria	NOUN
ajlm-1625	27	17	,	,	PUNCT
ajlm-1625	27	18	sickle	sickle	NOUN
ajlm-1625	27	19	cell	cell	NOUN
ajlm-1625	27	20	disease	disease	NOUN
ajlm-1625	27	21	(	(	PUNCT
ajlm-1625	27	22	scd	scd	NOUN
ajlm-1625	27	23	)	)	PUNCT
ajlm-1625	27	24	,	,	PUNCT
ajlm-1625	27	25	pregnancy	pregnancy	NOUN
ajlm-1625	27	26	-	-	PUNCT
ajlm-1625	27	27	related	relate	VERB
ajlm-1625	27	28	events	event	NOUN
ajlm-1625	27	29	and	and	CCONJ
ajlm-1625	27	30	other	other	ADJ
ajlm-1625	27	31	trauma	trauma	NOUN
ajlm-1625	27	32	remains	remain	VERB
ajlm-1625	27	33	high	high	ADJ
ajlm-1625	27	34	or	or	CCONJ
ajlm-1625	27	35	is	be	AUX
ajlm-1625	27	36	on	on	ADP
ajlm-1625	27	37	the	the	DET
ajlm-1625	27	38	rise	rise	NOUN
ajlm-1625	27	39	.	.	PUNCT
ajlm-1625	28	1	for	for	ADP
ajlm-1625	28	2	example	example	NOUN
ajlm-1625	28	3	,	,	PUNCT
ajlm-1625	28	4	in	in	ADP
ajlm-1625	28	5	burkina	burkina	PROPN
ajlm-1625	28	6	faso	faso	PROPN
ajlm-1625	28	7	,	,	PUNCT
ajlm-1625	28	8	around	around	ADP
ajlm-1625	28	9	103	103	NUM
ajlm-1625	28	10	731	731	NUM
ajlm-1625	28	11	rbc	rbc	PROPN
ajlm-1625	28	12	units	unit	NOUN
ajlm-1625	28	13	were	be	AUX
ajlm-1625	28	14	used	use	VERB
ajlm-1625	28	15	in	in	ADP
ajlm-1625	28	16	2017.1	2017.1	NUM
ajlm-1625	28	17	however	however	ADV
ajlm-1625	28	18	,	,	PUNCT
ajlm-1625	28	19	this	this	PRON
ajlm-1625	28	20	did	do	AUX
ajlm-1625	28	21	not	not	PART
ajlm-1625	28	22	meet	meet	VERB
ajlm-1625	28	23	the	the	DET
ajlm-1625	28	24	transfusion	transfusion	NOUN
ajlm-1625	28	25	needs	need	NOUN
ajlm-1625	28	26	of	of	ADP
ajlm-1625	28	27	the	the	DET
ajlm-1625	28	28	country	country	NOUN
ajlm-1625	28	29	.	.	PUNCT
ajlm-1625	29	1	moreover	moreover	ADV
ajlm-1625	29	2	,	,	PUNCT
ajlm-1625	29	3	this	this	DET
ajlm-1625	29	4	number	number	NOUN
ajlm-1625	29	5	is	be	AUX
ajlm-1625	29	6	far	far	ADV
ajlm-1625	29	7	lower	low	ADJ
ajlm-1625	29	8	than	than	ADP
ajlm-1625	29	9	the	the	DET
ajlm-1625	29	10	theoretical	theoretical	ADJ
ajlm-1625	29	11	needs	need	NOUN
ajlm-1625	29	12	of	of	ADP
ajlm-1625	29	13	around	around	ADP
ajlm-1625	29	14	196	196	NUM
ajlm-1625	29	15	000–580	000–580	NUM
ajlm-1625	29	16	000	000	NUM
ajlm-1625	29	17	per	per	ADP
ajlm-1625	29	18	the	the	DET
ajlm-1625	29	19	world	world	PROPN
ajlm-1625	29	20	health	health	PROPN
ajlm-1625	29	21	organization	organization	PROPN
ajlm-1625	29	22	estimation	estimation	NOUN
ajlm-1625	29	23	method	method	PROPN
ajlm-1625	29	24	iii	iii	X
ajlm-1625	29	25	(	(	PUNCT
ajlm-1625	29	26	i.e.	i.e.	X
ajlm-1625	29	27	1	1	NUM
ajlm-1625	29	28	%	%	NOUN
ajlm-1625	29	29	–	–	PUNCT
ajlm-1625	29	30	3	3	NUM
ajlm-1625	29	31	%	%	NOUN
ajlm-1625	29	32	of	of	ADP
ajlm-1625	29	33	the	the	DET
ajlm-1625	29	34	19.5	19.5	NUM
ajlm-1625	29	35	million	million	NUM
ajlm-1625	29	36	inhabitants).2	inhabitants).2	PROPN
ajlm-1625	29	37	besides	besides	SCONJ
ajlm-1625	29	38	the	the	DET
ajlm-1625	29	39	chronic	chronic	ADJ
ajlm-1625	29	40	blood	blood	NOUN
ajlm-1625	29	41	shortage	shortage	NOUN
ajlm-1625	29	42	,	,	PUNCT
ajlm-1625	29	43	developing	develop	VERB
ajlm-1625	29	44	countries	country	NOUN
ajlm-1625	29	45	also	also	ADV
ajlm-1625	29	46	face	face	VERB
ajlm-1625	29	47	poor	poor	ADJ
ajlm-1625	29	48	quality	quality	NOUN
ajlm-1625	29	49	of	of	ADP
ajlm-1625	29	50	blood	blood	NOUN
ajlm-1625	29	51	products	product	NOUN
ajlm-1625	29	52	and	and	CCONJ
ajlm-1625	29	53	their	their	PRON
ajlm-1625	29	54	unsafe	unsafe	ADJ
ajlm-1625	29	55	use.3	use.3	ADV
ajlm-1625	29	56	indeed	indeed	ADV
ajlm-1625	29	57	,	,	PUNCT
ajlm-1625	29	58	residual	residual	ADJ
ajlm-1625	29	59	risks	risk	NOUN
ajlm-1625	29	60	of	of	ADP
ajlm-1625	29	61	transfusion	transfusion	NOUN
ajlm-1625	29	62	-	-	PUNCT
ajlm-1625	29	63	transmitted	transmit	VERB
ajlm-1625	29	64	infections	infection	NOUN
ajlm-1625	29	65	remain	remain	VERB
ajlm-1625	29	66	high4,5	high4,5	PROPN
ajlm-1625	29	67	due	due	ADP
ajlm-1625	29	68	to	to	ADP
ajlm-1625	29	69	inadequacies	inadequacy	NOUN
ajlm-1625	29	70	in	in	ADP
ajlm-1625	29	71	blood	blood	NOUN
ajlm-1625	29	72	donor	donor	NOUN
ajlm-1625	29	73	selection	selection	NOUN
ajlm-1625	29	74	and	and	CCONJ
ajlm-1625	29	75	retention	retention	NOUN
ajlm-1625	29	76	and	and	CCONJ
ajlm-1625	29	77	laboratory	laboratory	NOUN
ajlm-1625	29	78	screening	screening	NOUN
ajlm-1625	29	79	of	of	ADP
ajlm-1625	29	80	blood	blood	NOUN
ajlm-1625	29	81	donations	donation	NOUN
ajlm-1625	29	82	.	.	PUNCT
ajlm-1625	30	1	furthermore	furthermore	ADV
ajlm-1625	30	2	,	,	PUNCT
ajlm-1625	30	3	blood	blood	NOUN
ajlm-1625	30	4	transfusion	transfusion	NOUN
ajlm-1625	30	5	adverse	adverse	ADJ
ajlm-1625	30	6	events	event	NOUN
ajlm-1625	30	7	are	be	AUX
ajlm-1625	30	8	underestimated	underestimate	VERB
ajlm-1625	30	9	due	due	ADP
ajlm-1625	30	10	to	to	ADP
ajlm-1625	30	11	the	the	DET
ajlm-1625	30	12	weakness	weakness	NOUN
ajlm-1625	30	13	or	or	CCONJ
ajlm-1625	30	14	nonexistence	nonexistence	NOUN
ajlm-1625	30	15	of	of	ADP
ajlm-1625	30	16	haemovigilance	haemovigilance	NOUN
ajlm-1625	30	17	and	and	CCONJ
ajlm-1625	30	18	quality	quality	NOUN
ajlm-1625	30	19	management	management	NOUN
ajlm-1625	30	20	systems.6,7	systems.6,7	PROPN
ajlm-1625	30	21	finally	finally	ADV
ajlm-1625	30	22	,	,	PUNCT
ajlm-1625	30	23	although	although	SCONJ
ajlm-1625	30	24	transfusion	transfusion	NOUN
ajlm-1625	30	25	-	-	PUNCT
ajlm-1625	30	26	transmitted	transmit	VERB
ajlm-1625	30	27	infections	infection	NOUN
ajlm-1625	30	28	and	and	CCONJ
ajlm-1625	30	29	major	major	ADJ
ajlm-1625	30	30	blood	blood	NOUN
ajlm-1625	30	31	groups	group	NOUN
ajlm-1625	30	32	matching	match	VERB
ajlm-1625	30	33	errors	error	NOUN
ajlm-1625	30	34	are	be	AUX
ajlm-1625	30	35	worrying	worry	VERB
ajlm-1625	30	36	,	,	PUNCT
ajlm-1625	30	37	blood	blood	NOUN
ajlm-1625	30	38	transfusion	transfusion	NOUN
ajlm-1625	30	39	safety	safety	NOUN
ajlm-1625	30	40	issues	issue	NOUN
ajlm-1625	30	41	,	,	PUNCT
ajlm-1625	30	42	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	30	43	and	and	CCONJ
ajlm-1625	30	44	the	the	DET
ajlm-1625	30	45	occurrence	occurrence	NOUN
ajlm-1625	30	46	of	of	ADP
ajlm-1625	30	47	alloantibody	alloantibody	NOUN
ajlm-1625	30	48	are	be	AUX
ajlm-1625	30	49	also	also	ADV
ajlm-1625	30	50	pressing	press	VERB
ajlm-1625	30	51	issues	issue	NOUN
ajlm-1625	30	52	,	,	PUNCT
ajlm-1625	30	53	especially	especially	ADV
ajlm-1625	30	54	in	in	ADP
ajlm-1625	30	55	multi	multi	ADJ
ajlm-1625	30	56	-	-	ADJ
ajlm-1625	30	57	transfused	transfused	ADJ
ajlm-1625	30	58	patients	patient	NOUN
ajlm-1625	30	59	such	such	ADJ
ajlm-1625	30	60	as	as	ADP
ajlm-1625	30	61	those	those	DET
ajlm-1625	30	62	undergoing	undergo	VERB
ajlm-1625	30	63	haemodialysis	haemodialysis	NOUN
ajlm-1625	30	64	for	for	ADP
ajlm-1625	30	65	chronic	chronic	ADJ
ajlm-1625	30	66	renal	renal	ADJ
ajlm-1625	30	67	failure	failure	NOUN
ajlm-1625	30	68	(	(	PUNCT
ajlm-1625	30	69	crf).4,8,9,10	crf).4,8,9,10	X
ajlm-1625	30	70	anaemia	anaemia	NOUN
ajlm-1625	30	71	is	be	AUX
ajlm-1625	30	72	highly	highly	ADV
ajlm-1625	30	73	prevalent	prevalent	ADJ
ajlm-1625	30	74	in	in	ADP
ajlm-1625	30	75	end	end	NOUN
ajlm-1625	30	76	-	-	PUNCT
ajlm-1625	30	77	stage	stage	NOUN
ajlm-1625	30	78	renal	renal	ADJ
ajlm-1625	30	79	disease	disease	NOUN
ajlm-1625	30	80	patients	patient	NOUN
ajlm-1625	30	81	,	,	PUNCT
ajlm-1625	30	82	often	often	ADV
ajlm-1625	30	83	non	non	ADJ
ajlm-1625	30	84	-	-	ADJ
ajlm-1625	30	85	regenerative	regenerative	ADJ
ajlm-1625	30	86	normochromic	normochromic	ADJ
ajlm-1625	30	87	normocytic	normocytic	ADJ
ajlm-1625	30	88	anaemia	anaemia	NOUN
ajlm-1625	30	89	caused	cause	VERB
ajlm-1625	30	90	by	by	ADP
ajlm-1625	30	91	inadequate	inadequate	ADJ
ajlm-1625	30	92	renal	renal	ADJ
ajlm-1625	30	93	erythropoietin	erythropoietin	NOUN
ajlm-1625	30	94	production	production	NOUN
ajlm-1625	30	95	.	.	PUNCT
ajlm-1625	31	1	erythropoietin	erythropoietin	NOUN
ajlm-1625	31	2	infusions	infusion	NOUN
ajlm-1625	31	3	or	or	CCONJ
ajlm-1625	31	4	other	other	ADJ
ajlm-1625	31	5	erythropoietin	erythropoietin	NOUN
ajlm-1625	31	6	-	-	PUNCT
ajlm-1625	31	7	stimulating	stimulate	VERB
ajlm-1625	31	8	agents	agent	NOUN
ajlm-1625	31	9	manage	manage	VERB
ajlm-1625	31	10	anaemia	anaemia	NOUN
ajlm-1625	31	11	in	in	ADP
ajlm-1625	31	12	end	end	NOUN
ajlm-1625	31	13	-	-	PUNCT
ajlm-1625	31	14	stage	stage	NOUN
ajlm-1625	31	15	renal	renal	ADJ
ajlm-1625	31	16	disease	disease	NOUN
ajlm-1625	31	17	patients	patient	NOUN
ajlm-1625	31	18	.	.	PUNCT
ajlm-1625	32	1	the	the	DET
ajlm-1625	32	2	united	united	PROPN
ajlm-1625	32	3	states	states	PROPN
ajlm-1625	32	4	food	food	PROPN
ajlm-1625	32	5	and	and	CCONJ
ajlm-1625	32	6	drug	drug	NOUN
ajlm-1625	32	7	administration	administration	NOUN
ajlm-1625	32	8	recommends	recommend	VERB
ajlm-1625	32	9	an	an	DET
ajlm-1625	32	10	erythropoietin	erythropoietin	ADJ
ajlm-1625	32	11	haemoglobin	haemoglobin	NOUN
ajlm-1625	32	12	target	target	NOUN
ajlm-1625	32	13	range	range	NOUN
ajlm-1625	32	14	of	of	ADP
ajlm-1625	32	15	100	100	NUM
ajlm-1625	32	16	g	g	NOUN
ajlm-1625	32	17	/	/	SYM
ajlm-1625	32	18	l	l	NOUN
ajlm-1625	32	19	–	–	PUNCT
ajlm-1625	32	20	120	120	NUM
ajlm-1625	32	21	g	g	NOUN
ajlm-1625	32	22	/	/	SYM
ajlm-1625	32	23	l11	l11	PROPN
ajlm-1625	32	24	and	and	CCONJ
ajlm-1625	32	25	expressly	expressly	ADV
ajlm-1625	32	26	states	state	VERB
ajlm-1625	32	27	that	that	SCONJ
ajlm-1625	32	28	erythropoietin	erythropoietin	NOUN
ajlm-1625	32	29	-	-	PUNCT
ajlm-1625	32	30	stimulating	stimulate	VERB
ajlm-1625	32	31	agents	agent	NOUN
ajlm-1625	32	32	should	should	AUX
ajlm-1625	32	33	be	be	AUX
ajlm-1625	32	34	used	use	VERB
ajlm-1625	32	35	to	to	PART
ajlm-1625	32	36	increase	increase	VERB
ajlm-1625	32	37	haemoglobin	haemoglobin	NOUN
ajlm-1625	32	38	only	only	ADV
ajlm-1625	32	39	to	to	ADP
ajlm-1625	32	40	the	the	DET
ajlm-1625	32	41	level	level	NOUN
ajlm-1625	32	42	necessary	necessary	ADJ
ajlm-1625	32	43	to	to	PART
ajlm-1625	32	44	avoid	avoid	VERB
ajlm-1625	32	45	transfusion.11,12,13	transfusion.11,12,13	PROPN
ajlm-1625	32	46	in	in	ADP
ajlm-1625	32	47	2016	2016	NUM
ajlm-1625	32	48	,	,	PUNCT
ajlm-1625	32	49	an	an	DET
ajlm-1625	32	50	expert	expert	NOUN
ajlm-1625	32	51	committee	committee	NOUN
ajlm-1625	32	52	advocated	advocate	VERB
ajlm-1625	32	53	for	for	ADP
ajlm-1625	32	54	including	include	VERB
ajlm-1625	32	55	erythropoietin	erythropoietin	NOUN
ajlm-1625	32	56	-	-	PUNCT
ajlm-1625	32	57	stimulating	stimulate	VERB
ajlm-1625	32	58	agents	agent	NOUN
ajlm-1625	32	59	in	in	ADP
ajlm-1625	32	60	the	the	DET
ajlm-1625	32	61	world	world	PROPN
ajlm-1625	32	62	health	health	PROPN
ajlm-1625	32	63	organization	organization	PROPN
ajlm-1625	32	64	model	model	NOUN
ajlm-1625	32	65	list	list	NOUN
ajlm-1625	32	66	of	of	ADP
ajlm-1625	32	67	essential	essential	ADJ
ajlm-1625	32	68	medicines	medicine	NOUN
ajlm-1625	32	69	to	to	PART
ajlm-1625	32	70	reduce	reduce	VERB
ajlm-1625	32	71	the	the	DET
ajlm-1625	32	72	need	need	NOUN
ajlm-1625	32	73	for	for	ADP
ajlm-1625	32	74	transfusions	transfusion	NOUN
ajlm-1625	32	75	in	in	ADP
ajlm-1625	32	76	patients	patient	NOUN
ajlm-1625	32	77	with	with	ADP
ajlm-1625	32	78	end	end	NOUN
ajlm-1625	32	79	-	-	PUNCT
ajlm-1625	32	80	stage	stage	NOUN
ajlm-1625	32	81	chronic	chronic	ADJ
ajlm-1625	32	82	kidney	kidney	NOUN
ajlm-1625	32	83	disease	disease	NOUN
ajlm-1625	32	84	.	.	PUNCT
ajlm-1625	33	1	erythropoietin	erythropoietin	NOUN
ajlm-1625	33	2	-	-	PUNCT
ajlm-1625	33	3	stimulating	stimulate	VERB
ajlm-1625	33	4	agents	agent	NOUN
ajlm-1625	33	5	prevent	prevent	VERB
ajlm-1625	33	6	transfusion	transfusion	NOUN
ajlm-1625	33	7	-	-	PUNCT
ajlm-1625	33	8	related	relate	VERB
ajlm-1625	33	9	risks	risk	NOUN
ajlm-1625	33	10	,	,	PUNCT
ajlm-1625	33	11	facility	facility	NOUN
ajlm-1625	33	12	requirements	requirement	NOUN
ajlm-1625	33	13	,	,	PUNCT
ajlm-1625	33	14	and	and	CCONJ
ajlm-1625	33	15	risk	risk	NOUN
ajlm-1625	33	16	management	management	NOUN
ajlm-1625	33	17	costs	cost	NOUN
ajlm-1625	33	18	in	in	ADP
ajlm-1625	33	19	the	the	DET
ajlm-1625	33	20	event	event	NOUN
ajlm-1625	33	21	of	of	ADP
ajlm-1625	33	22	possible	possible	ADJ
ajlm-1625	33	23	harm	harm	NOUN
ajlm-1625	33	24	(	(	PUNCT
ajlm-1625	33	25	infections	infection	NOUN
ajlm-1625	33	26	,	,	PUNCT
ajlm-1625	33	27	haemosiderosis).14	haemosiderosis).14	PROPN
ajlm-1625	33	28	however	however	ADV
ajlm-1625	33	29	,	,	PUNCT
ajlm-1625	33	30	erythropoietin	erythropoietin	NOUN
ajlm-1625	33	31	-	-	PUNCT
ajlm-1625	33	32	stimulating	stimulate	VERB
ajlm-1625	33	33	agents	agent	NOUN
ajlm-1625	33	34	treatments	treatment	NOUN
ajlm-1625	33	35	are	be	AUX
ajlm-1625	33	36	out	out	ADP
ajlm-1625	33	37	of	of	ADP
ajlm-1625	33	38	reach	reach	NOUN
ajlm-1625	33	39	for	for	ADP
ajlm-1625	33	40	most	most	ADJ
ajlm-1625	33	41	patients	patient	NOUN
ajlm-1625	33	42	in	in	ADP
ajlm-1625	33	43	our	our	PRON
ajlm-1625	33	44	context	context	NOUN
ajlm-1625	33	45	.	.	PUNCT
ajlm-1625	34	1	therefore	therefore	ADV
ajlm-1625	34	2	,	,	PUNCT
ajlm-1625	34	3	rbc	rbc	PROPN
ajlm-1625	34	4	transfusion	transfusion	NOUN
ajlm-1625	34	5	is	be	AUX
ajlm-1625	34	6	used	use	VERB
ajlm-1625	34	7	to	to	PART
ajlm-1625	34	8	manage	manage	VERB
ajlm-1625	34	9	crf	crf	NOUN
ajlm-1625	34	10	-	-	PUNCT
ajlm-1625	34	11	related	relate	VERB
ajlm-1625	34	12	anaemia	anaemia	NOUN
ajlm-1625	34	13	and	and	CCONJ
ajlm-1625	34	14	scd	scd	NOUN
ajlm-1625	34	15	patients	patient	NOUN
ajlm-1625	34	16	.	.	PUNCT
ajlm-1625	35	1	meanwhile	meanwhile	ADV
ajlm-1625	35	2	,	,	PUNCT
ajlm-1625	35	3	our	our	PRON
ajlm-1625	35	4	country	country	NOUN
ajlm-1625	35	5	faces	face	VERB
ajlm-1625	35	6	poor	poor	ADJ
ajlm-1625	35	7	pre	pre	ADJ
ajlm-1625	35	8	-	-	ADJ
ajlm-1625	35	9	transfusion	transfusion	ADJ
ajlm-1625	35	10	compatibility	compatibility	NOUN
ajlm-1625	35	11	practices	practice	NOUN
ajlm-1625	35	12	;	;	PUNCT
ajlm-1625	35	13	abo	abo	VERB
ajlm-1625	35	14	and	and	CCONJ
ajlm-1625	35	15	rhd	rhd	PROPN
ajlm-1625	35	16	matching	matching	NOUN
ajlm-1625	35	17	is	be	AUX
ajlm-1625	35	18	the	the	DET
ajlm-1625	35	19	only	only	ADJ
ajlm-1625	35	20	mandatory	mandatory	ADJ
ajlm-1625	35	21	screening	screening	NOUN
ajlm-1625	35	22	for	for	ADP
ajlm-1625	35	23	rbc	rbc	PROPN
ajlm-1625	35	24	transfusions	transfusion	NOUN
ajlm-1625	35	25	.	.	PUNCT
ajlm-1625	36	1	no	no	DET
ajlm-1625	36	2	other	other	ADJ
ajlm-1625	36	3	blood	blood	NOUN
ajlm-1625	36	4	group	group	NOUN
ajlm-1625	36	5	is	be	AUX
ajlm-1625	36	6	considered	consider	VERB
ajlm-1625	36	7	,	,	PUNCT
ajlm-1625	36	8	and	and	CCONJ
ajlm-1625	36	9	no	no	DET
ajlm-1625	36	10	alloantibody	alloantibody	ADJ
ajlm-1625	36	11	screening	screening	NOUN
ajlm-1625	36	12	or	or	CCONJ
ajlm-1625	36	13	compatibility	compatibility	NOUN
ajlm-1625	36	14	test	test	NOUN
ajlm-1625	36	15	is	be	AUX
ajlm-1625	36	16	performed.15	performed.15	NOUN
ajlm-1625	36	17	given	give	VERB
ajlm-1625	36	18	this	this	DET
ajlm-1625	36	19	context	context	NOUN
ajlm-1625	36	20	,	,	PUNCT
ajlm-1625	36	21	high	high	ADJ
ajlm-1625	36	22	rbc	rbc	PROPN
ajlm-1625	36	23	alloantibodies	alloantibody	NOUN
ajlm-1625	36	24	frequency	frequency	NOUN
ajlm-1625	36	25	is	be	AUX
ajlm-1625	36	26	expected	expect	VERB
ajlm-1625	36	27	among	among	ADP
ajlm-1625	36	28	transfused	transfused	ADJ
ajlm-1625	36	29	patients	patient	NOUN
ajlm-1625	36	30	;	;	PUNCT
ajlm-1625	36	31	however	however	ADV
ajlm-1625	36	32	,	,	PUNCT
ajlm-1625	36	33	there	there	PRON
ajlm-1625	36	34	is	be	VERB
ajlm-1625	36	35	a	a	DET
ajlm-1625	36	36	paucity	paucity	NOUN
ajlm-1625	36	37	of	of	ADP
ajlm-1625	36	38	data	datum	NOUN
ajlm-1625	36	39	on	on	ADP
ajlm-1625	36	40	this	this	PRON
ajlm-1625	36	41	.	.	PUNCT
ajlm-1625	37	1	thus	thus	ADV
ajlm-1625	37	2	,	,	PUNCT
ajlm-1625	37	3	this	this	DET
ajlm-1625	37	4	study	study	NOUN
ajlm-1625	37	5	determined	determine	VERB
ajlm-1625	37	6	the	the	DET
ajlm-1625	37	7	frequency	frequency	NOUN
ajlm-1625	37	8	of	of	ADP
ajlm-1625	37	9	anti	anti	ADJ
ajlm-1625	37	10	-	-	ADJ
ajlm-1625	37	11	erythrocyte	erythrocyte	ADJ
ajlm-1625	37	12	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	37	13	and	and	CCONJ
ajlm-1625	37	14	identified	identify	VERB
ajlm-1625	37	15	alloantibody	alloantibody	ADJ
ajlm-1625	37	16	specificities	specificity	NOUN
ajlm-1625	37	17	among	among	ADP
ajlm-1625	37	18	crf	crf	PROPN
ajlm-1625	37	19	multi	multi	ADJ
ajlm-1625	37	20	-	-	ADJ
ajlm-1625	37	21	transfused	transfused	ADJ
ajlm-1625	37	22	patients	patient	NOUN
ajlm-1625	37	23	in	in	ADP
ajlm-1625	37	24	yalgado	yalgado	PROPN
ajlm-1625	37	25	ouedraogo	ouedraogo	PROPN
ajlm-1625	37	26	teaching	teaching	NOUN
ajlm-1625	37	27	hospital	hospital	NOUN
ajlm-1625	37	28	,	,	PUNCT
ajlm-1625	37	29	ouagadougou	ouagadougou	PROPN
ajlm-1625	37	30	,	,	PUNCT
ajlm-1625	37	31	burkina	burkina	PROPN
ajlm-1625	37	32	faso	faso	PROPN
ajlm-1625	37	33	.	.	PUNCT
ajlm-1625	38	1	methods	method	NOUN
ajlm-1625	38	2	ethical	ethical	ADJ
ajlm-1625	38	3	considerations	consideration	NOUN
ajlm-1625	38	4	both	both	CCONJ
ajlm-1625	38	5	the	the	DET
ajlm-1625	38	6	yalgado	yalgado	NOUN
ajlm-1625	38	7	ouedraogo	ouedraogo	VERB
ajlm-1625	38	8	teaching	teach	VERB
ajlm-1625	38	9	hospital	hospital	NOUN
ajlm-1625	38	10	direction	direction	NOUN
ajlm-1625	38	11	and	and	CCONJ
ajlm-1625	38	12	the	the	DET
ajlm-1625	38	13	internal	internal	ADJ
ajlm-1625	38	14	ethical	ethical	ADJ
ajlm-1625	38	15	committee	committee	NOUN
ajlm-1625	38	16	of	of	ADP
ajlm-1625	38	17	the	the	DET
ajlm-1625	38	18	national	national	ADJ
ajlm-1625	38	19	blood	blood	NOUN
ajlm-1625	38	20	transfusion	transfusion	NOUN
ajlm-1625	38	21	centre	centre	NOUN
ajlm-1625	38	22	(	(	PUNCT
ajlm-1625	38	23	authorisation	authorisation	NOUN
ajlm-1625	38	24	no	no	INTJ
ajlm-1625	38	25	.	.	PUNCT
ajlm-1625	38	26	015	015	NUM
ajlm-1625	38	27	/	/	SYM
ajlm-1625	38	28	cnts	cnts	PROPN
ajlm-1625	38	29	/	/	SYM
ajlm-1625	38	30	dg	dg	PROPN
ajlm-1625	38	31	/	/	SYM
ajlm-1625	38	32	cirs	cir	NOUN
ajlm-1625	38	33	,	,	PUNCT
ajlm-1625	38	34	03/23/2018	03/23/2018	NOUN
ajlm-1625	38	35	)	)	PUNCT
ajlm-1625	38	36	approved	approve	VERB
ajlm-1625	38	37	the	the	DET
ajlm-1625	38	38	study	study	NOUN
ajlm-1625	38	39	.	.	PUNCT
ajlm-1625	39	1	the	the	DET
ajlm-1625	39	2	nurses	nurse	NOUN
ajlm-1625	39	3	and	and	CCONJ
ajlm-1625	39	4	the	the	DET
ajlm-1625	39	5	medical	medical	ADJ
ajlm-1625	39	6	doctor	doctor	NOUN
ajlm-1625	39	7	in	in	ADP
ajlm-1625	39	8	charge	charge	NOUN
ajlm-1625	39	9	of	of	ADP
ajlm-1625	39	10	the	the	DET
ajlm-1625	39	11	interview	interview	NOUN
ajlm-1625	39	12	and	and	CCONJ
ajlm-1625	39	13	other	other	ADJ
ajlm-1625	39	14	data	data	NOUN
ajlm-1625	39	15	collection	collection	NOUN
ajlm-1625	39	16	obtained	obtain	VERB
ajlm-1625	39	17	verbal	verbal	ADJ
ajlm-1625	39	18	informed	inform	VERB
ajlm-1625	39	19	consent	consent	NOUN
ajlm-1625	39	20	.	.	PUNCT
ajlm-1625	40	1	also	also	ADV
ajlm-1625	40	2	,	,	PUNCT
ajlm-1625	40	3	the	the	DET
ajlm-1625	40	4	data	datum	NOUN
ajlm-1625	40	5	were	be	AUX
ajlm-1625	40	6	password	password	NOUN
ajlm-1625	40	7	protected	protect	VERB
ajlm-1625	40	8	and	and	CCONJ
ajlm-1625	40	9	accessible	accessible	ADJ
ajlm-1625	40	10	only	only	ADV
ajlm-1625	40	11	by	by	ADP
ajlm-1625	40	12	the	the	DET
ajlm-1625	40	13	first	first	ADJ
ajlm-1625	40	14	author	author	NOUN
ajlm-1625	40	15	.	.	PUNCT
ajlm-1625	41	1	results	result	NOUN
ajlm-1625	41	2	were	be	AUX
ajlm-1625	41	3	shared	share	VERB
ajlm-1625	41	4	with	with	ADP
ajlm-1625	41	5	staff	staff	NOUN
ajlm-1625	41	6	and	and	CCONJ
ajlm-1625	41	7	patients	patient	NOUN
ajlm-1625	41	8	and	and	CCONJ
ajlm-1625	41	9	used	use	VERB
ajlm-1625	41	10	to	to	PART
ajlm-1625	41	11	influence	influence	VERB
ajlm-1625	41	12	patients	patient	NOUN
ajlm-1625	41	13	’	'	PUNCT
ajlm-1625	41	14	future	future	ADJ
ajlm-1625	41	15	transfusions	transfusion	NOUN
ajlm-1625	41	16	.	.	PUNCT
ajlm-1625	42	1	study	study	NOUN
ajlm-1625	42	2	setting	set	VERB
ajlm-1625	42	3	this	this	DET
ajlm-1625	42	4	study	study	NOUN
ajlm-1625	42	5	was	be	AUX
ajlm-1625	42	6	conducted	conduct	VERB
ajlm-1625	42	7	in	in	ADP
ajlm-1625	42	8	the	the	DET
ajlm-1625	42	9	nephrology	nephrology	NOUN
ajlm-1625	42	10	and	and	CCONJ
ajlm-1625	42	11	haemodialysis	haemodialysis	NOUN
ajlm-1625	42	12	unit	unit	NOUN
ajlm-1625	42	13	of	of	ADP
ajlm-1625	42	14	the	the	DET
ajlm-1625	42	15	teaching	teaching	NOUN
ajlm-1625	42	16	hospital	hospital	NOUN
ajlm-1625	42	17	yalgado	yalgado	NOUN
ajlm-1625	42	18	ouedraogo	ouedraogo	NOUN
ajlm-1625	42	19	of	of	ADP
ajlm-1625	42	20	ouagadougou	ouagadougou	PROPN
ajlm-1625	42	21	,	,	PUNCT
ajlm-1625	42	22	burkina	burkina	PROPN
ajlm-1625	42	23	faso	faso	PROPN
ajlm-1625	42	24	,	,	PUNCT
ajlm-1625	42	25	where	where	SCONJ
ajlm-1625	42	26	about	about	ADV
ajlm-1625	42	27	400	400	NUM
ajlm-1625	42	28	patients	patient	NOUN
ajlm-1625	42	29	with	with	ADP
ajlm-1625	42	30	chronic	chronic	ADJ
ajlm-1625	42	31	kidney	kidney	NOUN
ajlm-1625	42	32	failure	failure	NOUN
ajlm-1625	42	33	undergo	undergo	VERB
ajlm-1625	42	34	haemodialysis	haemodialysis	NOUN
ajlm-1625	42	35	yearly	yearly	ADV
ajlm-1625	42	36	.	.	PUNCT
ajlm-1625	43	1	we	we	PRON
ajlm-1625	43	2	conducted	conduct	VERB
ajlm-1625	43	3	this	this	DET
ajlm-1625	43	4	cross	cross	ADJ
ajlm-1625	43	5	-	-	ADJ
ajlm-1625	43	6	sectional	sectional	ADJ
ajlm-1625	43	7	study	study	NOUN
ajlm-1625	43	8	from	from	ADP
ajlm-1625	43	9	january	january	PROPN
ajlm-1625	43	10	2018	2018	NUM
ajlm-1625	43	11	to	to	ADP
ajlm-1625	43	12	december	december	PROPN
ajlm-1625	43	13	2019	2019	NUM
ajlm-1625	43	14	and	and	CCONJ
ajlm-1625	43	15	included	include	VERB
ajlm-1625	43	16	haemodialysis	haemodialysis	NOUN
ajlm-1625	43	17	end	end	NOUN
ajlm-1625	43	18	-	-	PUNCT
ajlm-1625	43	19	stage	stage	NOUN
ajlm-1625	43	20	chronic	chronic	ADJ
ajlm-1625	43	21	kidney	kidney	NOUN
ajlm-1625	43	22	failure	failure	NOUN
ajlm-1625	43	23	patients	patient	NOUN
ajlm-1625	43	24	who	who	PRON
ajlm-1625	43	25	had	have	AUX
ajlm-1625	43	26	ever	ever	ADV
ajlm-1625	43	27	received	receive	VERB
ajlm-1625	43	28	rbc	rbc	PROPN
ajlm-1625	43	29	transfusions	transfusion	NOUN
ajlm-1625	43	30	at	at	ADV
ajlm-1625	43	31	least	least	ADJ
ajlm-1625	43	32	twice	twice	ADV
ajlm-1625	43	33	.	.	PUNCT
ajlm-1625	44	1	socio	socio	NOUN
ajlm-1625	44	2	-	-	ADJ
ajlm-1625	44	3	demographic	demographic	ADJ
ajlm-1625	44	4	information	information	NOUN
ajlm-1625	44	5	,	,	PUNCT
ajlm-1625	44	6	clinical	clinical	ADJ
ajlm-1625	44	7	data	datum	NOUN
ajlm-1625	44	8	,	,	PUNCT
ajlm-1625	44	9	and	and	CCONJ
ajlm-1625	44	10	medical	medical	ADJ
ajlm-1625	44	11	history	history	NOUN
ajlm-1625	44	12	of	of	ADP
ajlm-1625	44	13	each	each	DET
ajlm-1625	44	14	included	include	VERB
ajlm-1625	44	15	patient	patient	NOUN
ajlm-1625	44	16	were	be	AUX
ajlm-1625	44	17	recorded	record	VERB
ajlm-1625	44	18	on	on	ADP
ajlm-1625	44	19	a	a	DET
ajlm-1625	44	20	standardised	standardised	ADJ
ajlm-1625	44	21	survey	survey	NOUN
ajlm-1625	44	22	form	form	NOUN
ajlm-1625	44	23	during	during	ADP
ajlm-1625	44	24	an	an	DET
ajlm-1625	44	25	in	in	ADP
ajlm-1625	44	26	-	-	PUNCT
ajlm-1625	44	27	person	person	NOUN
ajlm-1625	44	28	interview	interview	NOUN
ajlm-1625	44	29	with	with	ADP
ajlm-1625	44	30	the	the	DET
ajlm-1625	44	31	medical	medical	ADJ
ajlm-1625	44	32	doctor	doctor	NOUN
ajlm-1625	44	33	responsible	responsible	ADJ
ajlm-1625	44	34	for	for	ADP
ajlm-1625	44	35	the	the	DET
ajlm-1625	44	36	study	study	NOUN
ajlm-1625	44	37	or	or	CCONJ
ajlm-1625	44	38	trained	train	VERB
ajlm-1625	44	39	nurses	nurse	NOUN
ajlm-1625	44	40	.	.	PUNCT
ajlm-1625	45	1	data	datum	NOUN
ajlm-1625	45	2	collected	collect	VERB
ajlm-1625	45	3	include	include	VERB
ajlm-1625	45	4	gender	gender	NOUN
ajlm-1625	45	5	,	,	PUNCT
ajlm-1625	45	6	age	age	NOUN
ajlm-1625	45	7	,	,	PUNCT
ajlm-1625	45	8	date	date	NOUN
ajlm-1625	45	9	of	of	ADP
ajlm-1625	45	10	the	the	DET
ajlm-1625	45	11	first	first	ADJ
ajlm-1625	45	12	transfusion	transfusion	NOUN
ajlm-1625	45	13	,	,	PUNCT
ajlm-1625	45	14	date	date	NOUN
ajlm-1625	45	15	of	of	ADP
ajlm-1625	45	16	the	the	DET
ajlm-1625	45	17	last	last	ADJ
ajlm-1625	45	18	transfusion	transfusion	NOUN
ajlm-1625	45	19	received	receive	VERB
ajlm-1625	45	20	,	,	PUNCT
ajlm-1625	45	21	number	number	NOUN
ajlm-1625	45	22	of	of	ADP
ajlm-1625	45	23	transfusions	transfusion	NOUN
ajlm-1625	45	24	,	,	PUNCT
ajlm-1625	45	25	the	the	DET
ajlm-1625	45	26	total	total	ADJ
ajlm-1625	45	27	number	number	NOUN
ajlm-1625	45	28	of	of	ADP
ajlm-1625	45	29	blood	blood	NOUN
ajlm-1625	45	30	units	unit	NOUN
ajlm-1625	45	31	received	receive	VERB
ajlm-1625	45	32	since	since	SCONJ
ajlm-1625	45	33	crf	crf	PROPN
ajlm-1625	45	34	started	start	VERB
ajlm-1625	45	35	,	,	PUNCT
ajlm-1625	45	36	and	and	CCONJ
ajlm-1625	45	37	number	number	NOUN
ajlm-1625	45	38	and	and	CCONJ
ajlm-1625	45	39	type	type	NOUN
ajlm-1625	45	40	of	of	ADP
ajlm-1625	45	41	adverse	adverse	ADJ
ajlm-1625	45	42	reactions	reaction	NOUN
ajlm-1625	45	43	related	relate	VERB
ajlm-1625	45	44	to	to	ADP
ajlm-1625	45	45	transfusions	transfusion	NOUN
ajlm-1625	45	46	reported	report	VERB
ajlm-1625	45	47	.	.	PUNCT
ajlm-1625	46	1	additionally	additionally	ADV
ajlm-1625	46	2	,	,	PUNCT
ajlm-1625	46	3	the	the	DET
ajlm-1625	46	4	number	number	NOUN
ajlm-1625	46	5	of	of	ADP
ajlm-1625	46	6	pregnancies	pregnancy	NOUN
ajlm-1625	46	7	,	,	PUNCT
ajlm-1625	46	8	live	live	VERB
ajlm-1625	46	9	and	and	CCONJ
ajlm-1625	46	10	still	still	ADV
ajlm-1625	46	11	births	birth	NOUN
ajlm-1625	46	12	,	,	PUNCT
ajlm-1625	46	13	abortions	abortion	NOUN
ajlm-1625	46	14	,	,	PUNCT
ajlm-1625	46	15	and	and	CCONJ
ajlm-1625	46	16	anti	anti	ADJ
ajlm-1625	46	17	-	-	ADJ
ajlm-1625	46	18	d	d	ADJ
ajlm-1625	46	19	injection	injection	NOUN
ajlm-1625	46	20	use	use	NOUN
ajlm-1625	46	21	were	be	AUX
ajlm-1625	46	22	also	also	ADV
ajlm-1625	46	23	reported	report	VERB
ajlm-1625	46	24	for	for	ADP
ajlm-1625	46	25	female	female	ADJ
ajlm-1625	46	26	patients	patient	NOUN
ajlm-1625	46	27	.	.	PUNCT
ajlm-1625	47	1	five	five	NUM
ajlm-1625	47	2	mililitres	mililitre	NOUN
ajlm-1625	47	3	of	of	ADP
ajlm-1625	47	4	blood	blood	NOUN
ajlm-1625	47	5	was	be	AUX
ajlm-1625	47	6	drawn	draw	VERB
ajlm-1625	47	7	from	from	ADP
ajlm-1625	47	8	each	each	DET
ajlm-1625	47	9	patient	patient	NOUN
ajlm-1625	47	10	into	into	ADP
ajlm-1625	47	11	ethylenediaminetetraacetic	ethylenediaminetetraacetic	ADJ
ajlm-1625	47	12	acid	acid	NOUN
ajlm-1625	47	13	tubes	tube	NOUN
ajlm-1625	47	14	.	.	PUNCT
ajlm-1625	48	1	the	the	DET
ajlm-1625	48	2	sample	sample	NOUN
ajlm-1625	48	3	was	be	AUX
ajlm-1625	48	4	centrifuged	centrifuge	VERB
ajlm-1625	48	5	,	,	PUNCT
ajlm-1625	48	6	and	and	CCONJ
ajlm-1625	48	7	the	the	DET
ajlm-1625	48	8	obtained	obtain	VERB
ajlm-1625	48	9	plasma	plasma	NOUN
ajlm-1625	48	10	was	be	AUX
ajlm-1625	48	11	used	use	VERB
ajlm-1625	48	12	for	for	ADP
ajlm-1625	48	13	alloantibodies	alloantibody	NOUN
ajlm-1625	48	14	screening	screening	NOUN
ajlm-1625	48	15	and	and	CCONJ
ajlm-1625	48	16	identification	identification	NOUN
ajlm-1625	48	17	.	.	PUNCT
ajlm-1625	49	1	testing	testing	NOUN
ajlm-1625	49	2	methods	method	NOUN
ajlm-1625	49	3	we	we	PRON
ajlm-1625	49	4	used	use	VERB
ajlm-1625	49	5	the	the	DET
ajlm-1625	49	6	indirect	indirect	ADJ
ajlm-1625	49	7	antiglobulin	antiglobulin	NOUN
ajlm-1625	49	8	test	test	NOUN
ajlm-1625	49	9	method	method	NOUN
ajlm-1625	49	10	with	with	ADP
ajlm-1625	49	11	the	the	DET
ajlm-1625	49	12	gel	gel	NOUN
ajlm-1625	49	13	column	column	NOUN
ajlm-1625	49	14	agglutination	agglutination	NOUN
ajlm-1625	49	15	card	card	NOUN
ajlm-1625	49	16	technique	technique	NOUN
ajlm-1625	49	17	(	(	PUNCT
ajlm-1625	49	18	invitrogel	invitrogel	PROPN
ajlm-1625	49	19	ahg	ahg	PROPN
ajlm-1625	49	20	,	,	PUNCT
ajlm-1625	49	21	mtc	mtc	ADJ
ajlm-1625	49	22	invitro	invitro	ADJ
ajlm-1625	49	23	diagnostics	diagnostic	NOUN
ajlm-1625	49	24	ag	ag	PROPN
ajlm-1625	49	25	,	,	PUNCT
ajlm-1625	49	26	bensheim	bensheim	PROPN
ajlm-1625	49	27	,	,	PUNCT
ajlm-1625	49	28	germany	germany	PROPN
ajlm-1625	49	29	)	)	PUNCT
ajlm-1625	49	30	.	.	PUNCT
ajlm-1625	50	1	in	in	ADP
ajlm-1625	50	2	this	this	DET
ajlm-1625	50	3	technique	technique	NOUN
ajlm-1625	50	4	,	,	PUNCT
ajlm-1625	50	5	the	the	DET
ajlm-1625	50	6	gel	gel	NOUN
ajlm-1625	50	7	column	column	NOUN
ajlm-1625	50	8	contains	contain	VERB
ajlm-1625	50	9	an	an	DET
ajlm-1625	50	10	anti	anti	ADJ
ajlm-1625	50	11	-	-	ADJ
ajlm-1625	50	12	human	human	ADJ
ajlm-1625	50	13	antibody	antibody	NOUN
ajlm-1625	50	14	that	that	PRON
ajlm-1625	50	15	traps	trap	VERB
ajlm-1625	50	16	irregular	irregular	ADJ
ajlm-1625	50	17	antibodies	antibody	NOUN
ajlm-1625	50	18	present	present	ADJ
ajlm-1625	50	19	in	in	ADP
ajlm-1625	50	20	a	a	DET
ajlm-1625	50	21	patient	patient	NOUN
ajlm-1625	50	22	’s	’s	PART
ajlm-1625	50	23	plasma	plasma	NOUN
ajlm-1625	50	24	and	and	CCONJ
ajlm-1625	50	25	fixed	fix	VERB
ajlm-1625	50	26	on	on	ADP
ajlm-1625	51	1	rbc	rbc	PROPN
ajlm-1625	51	2	.	.	PROPN
ajlm-1625	51	3	agglutinated	agglutinated	PROPN
ajlm-1625	51	4	rbcs	rbc	NOUN
ajlm-1625	51	5	are	be	AUX
ajlm-1625	51	6	trapped	trap	VERB
ajlm-1625	51	7	in	in	ADP
ajlm-1625	51	8	the	the	DET
ajlm-1625	51	9	gel	gel	NOUN
ajlm-1625	51	10	column	column	NOUN
ajlm-1625	51	11	,	,	PUNCT
ajlm-1625	51	12	making	make	VERB
ajlm-1625	51	13	the	the	DET
ajlm-1625	51	14	agglutination	agglutination	NOUN
ajlm-1625	51	15	easy	easy	ADJ
ajlm-1625	51	16	to	to	PART
ajlm-1625	51	17	read.16,17	read.16,17	VERB
ajlm-1625	51	18	in	in	ADP
ajlm-1625	51	19	the	the	DET
ajlm-1625	51	20	first	first	ADJ
ajlm-1625	51	21	step	step	NOUN
ajlm-1625	51	22	,	,	PUNCT
ajlm-1625	51	23	a	a	DET
ajlm-1625	51	24	panel	panel	NOUN
ajlm-1625	51	25	of	of	ADP
ajlm-1625	51	26	three	three	NUM
ajlm-1625	51	27	rbc	rbc	PROPN
ajlm-1625	51	28	reagents	reagent	NOUN
ajlm-1625	51	29	(	(	PUNCT
ajlm-1625	51	30	invitrocell	invitrocell	PROPN
ajlm-1625	51	31	screen	screen	PROPN
ajlm-1625	51	32	i	i	PROPN
ajlm-1625	51	33	-	-	PUNCT
ajlm-1625	51	34	ii	ii	PROPN
ajlm-1625	51	35	-	-	PUNCT
ajlm-1625	51	36	ii	ii	NOUN
ajlm-1625	51	37	,	,	PUNCT
ajlm-1625	51	38	mtc	mtc	ADJ
ajlm-1625	51	39	invitro	invitro	ADJ
ajlm-1625	51	40	diagnostics	diagnostic	NOUN
ajlm-1625	51	41	ag	ag	PROPN
ajlm-1625	51	42	,	,	PUNCT
ajlm-1625	51	43	bensheim	bensheim	PROPN
ajlm-1625	51	44	,	,	PUNCT
ajlm-1625	51	45	germany	germany	PROPN
ajlm-1625	51	46	)	)	PUNCT
ajlm-1625	51	47	,	,	PUNCT
ajlm-1625	51	48	that	that	PRON
ajlm-1625	51	49	targets	target	VERB
ajlm-1625	51	50	antigens	antigen	NOUN
ajlm-1625	51	51	d	d	NOUN
ajlm-1625	51	52	,	,	PUNCT
ajlm-1625	51	53	c	c	X
ajlm-1625	51	54	,	,	PUNCT
ajlm-1625	51	55	c	c	X
ajlm-1625	51	56	,	,	PUNCT
ajlm-1625	51	57	e	e	NOUN
ajlm-1625	51	58	,	,	PUNCT
ajlm-1625	51	59	e	e	NOUN
ajlm-1625	51	60	,	,	PUNCT
ajlm-1625	51	61	v	v	NOUN
ajlm-1625	51	62	,	,	PUNCT
ajlm-1625	51	63	cw	cw	NOUN
ajlm-1625	51	64	,	,	PUNCT
ajlm-1625	51	65	k	k	PROPN
ajlm-1625	51	66	,	,	PUNCT
ajlm-1625	51	67	k	k	PROPN
ajlm-1625	51	68	,	,	PUNCT
ajlm-1625	51	69	kpa	kpa	PROPN
ajlm-1625	51	70	,	,	PUNCT
ajlm-1625	51	71	kpb	kpb	PROPN
ajlm-1625	51	72	,	,	PUNCT
ajlm-1625	51	73	jsa	jsa	PROPN
ajlm-1625	51	74	,	,	PUNCT
ajlm-1625	51	75	jsb	jsb	PROPN
ajlm-1625	51	76	,	,	PUNCT
ajlm-1625	51	77	fya	fya	PROPN
ajlm-1625	51	78	,	,	PUNCT
ajlm-1625	51	79	fyb	fyb	PROPN
ajlm-1625	51	80	,	,	PUNCT
ajlm-1625	51	81	jka	jka	PROPN
ajlm-1625	51	82	,	,	PUNCT
ajlm-1625	51	83	jkb	jkb	NOUN
ajlm-1625	51	84	,	,	PUNCT
ajlm-1625	51	85	lea	lea	PROPN
ajlm-1625	51	86	,	,	PUNCT
ajlm-1625	51	87	leb	leb	PROPN
ajlm-1625	51	88	,	,	PUNCT
ajlm-1625	51	89	p1	p1	PROPN
ajlm-1625	51	90	,	,	PUNCT
ajlm-1625	51	91	m	m	PROPN
ajlm-1625	51	92	,	,	PUNCT
ajlm-1625	51	93	n	n	CCONJ
ajlm-1625	51	94	,	,	PUNCT
ajlm-1625	51	95	s	s	PROPN
ajlm-1625	51	96	,	,	PUNCT
ajlm-1625	51	97	s	s	PROPN
ajlm-1625	51	98	,	,	PUNCT
ajlm-1625	51	99	lua	lua	PROPN
ajlm-1625	51	100	,	,	PUNCT
ajlm-1625	51	101	lub	lub	NOUN
ajlm-1625	51	102	and	and	CCONJ
ajlm-1625	51	103	xg*a	xg*a	NOUN
ajlm-1625	51	104	antibodies	antibodie	VERB
ajlm-1625	51	105	,	,	PUNCT
ajlm-1625	51	106	were	be	AUX
ajlm-1625	51	107	used	use	VERB
ajlm-1625	51	108	for	for	ADP
ajlm-1625	51	109	screening	screen	VERB
ajlm-1625	51	110	.	.	PUNCT
ajlm-1625	52	1	samples	sample	NOUN
ajlm-1625	52	2	positive	positive	ADJ
ajlm-1625	52	3	for	for	ADP
ajlm-1625	52	4	any	any	DET
ajlm-1625	52	5	antibody	antibody	NOUN
ajlm-1625	52	6	were	be	AUX
ajlm-1625	52	7	further	far	ADV
ajlm-1625	52	8	tested	test	VERB
ajlm-1625	52	9	to	to	PART
ajlm-1625	52	10	identify	identify	VERB
ajlm-1625	52	11	antibody	antibody	NOUN
ajlm-1625	52	12	specificity	specificity	NOUN
ajlm-1625	52	13	using	use	VERB
ajlm-1625	52	14	an	an	DET
ajlm-1625	52	15	11	11	NUM
ajlm-1625	52	16	rbc	rbc	PROPN
ajlm-1625	52	17	panel	panel	NOUN
ajlm-1625	52	18	(	(	PUNCT
ajlm-1625	52	19	invitrocell	invitrocell	PROPN
ajlm-1625	52	20	ident	ident	PROPN
ajlm-1625	52	21	11	11	NUM
ajlm-1625	52	22	,	,	PUNCT
ajlm-1625	52	23	mtc	mtc	ADJ
ajlm-1625	52	24	invitro	invitro	ADJ
ajlm-1625	52	25	diagnostics	diagnostic	NOUN
ajlm-1625	52	26	ag	ag	PROPN
ajlm-1625	52	27	,	,	PUNCT
ajlm-1625	52	28	bensheim	bensheim	PROPN
ajlm-1625	52	29	,	,	PUNCT
ajlm-1625	52	30	germany	germany	PROPN
ajlm-1625	52	31	)	)	PUNCT
ajlm-1625	52	32	that	that	PRON
ajlm-1625	52	33	targets	target	VERB
ajlm-1625	52	34	the	the	DET
ajlm-1625	52	35	same	same	ADJ
ajlm-1625	52	36	antigens	antigen	NOUN
ajlm-1625	52	37	in	in	ADP
ajlm-1625	52	38	the	the	DET
ajlm-1625	52	39	screening	screening	NOUN
ajlm-1625	52	40	stage	stage	NOUN
ajlm-1625	52	41	.	.	PUNCT
ajlm-1625	53	1	an	an	DET
ajlm-1625	53	2	enzyme	enzyme	NOUN
ajlm-1625	53	3	-	-	PUNCT
ajlm-1625	53	4	treated	treat	VERB
ajlm-1625	53	5	rbc	rbc	PROPN
ajlm-1625	53	6	panel	panel	NOUN
ajlm-1625	53	7	was	be	AUX
ajlm-1625	53	8	not	not	PART
ajlm-1625	53	9	used	use	VERB
ajlm-1625	53	10	.	.	PUNCT
ajlm-1625	54	1	statistical	statistical	ADJ
ajlm-1625	54	2	analyses	analysis	NOUN
ajlm-1625	54	3	we	we	PRON
ajlm-1625	54	4	used	use	VERB
ajlm-1625	54	5	epi	epi	ADJ
ajlm-1625	54	6	-	-	ADJ
ajlm-1625	54	7	infotm	infotm	ADJ
ajlm-1625	54	8	software	software	NOUN
ajlm-1625	54	9	(	(	PUNCT
ajlm-1625	54	10	version	version	NOUN
ajlm-1625	54	11	7.2.2.2	7.2.2.2	NUM
ajlm-1625	54	12	,	,	PUNCT
ajlm-1625	54	13	centers	center	NOUN
ajlm-1625	54	14	for	for	ADP
ajlm-1625	54	15	disease	disease	NOUN
ajlm-1625	54	16	control	control	NOUN
ajlm-1625	54	17	and	and	CCONJ
ajlm-1625	54	18	prevention	prevention	NOUN
ajlm-1625	54	19	,	,	PUNCT
ajlm-1625	54	20	atlanta	atlanta	PROPN
ajlm-1625	54	21	,	,	PUNCT
ajlm-1625	54	22	georgia	georgia	PROPN
ajlm-1625	54	23	,	,	PUNCT
ajlm-1625	54	24	united	united	PROPN
ajlm-1625	54	25	states	states	PROPN
ajlm-1625	54	26	)	)	PUNCT
ajlm-1625	54	27	for	for	ADP
ajlm-1625	54	28	data	datum	NOUN
ajlm-1625	54	29	analysis	analysis	NOUN
ajlm-1625	54	30	.	.	PUNCT
ajlm-1625	55	1	the	the	DET
ajlm-1625	55	2	frequencies	frequency	NOUN
ajlm-1625	55	3	and	and	CCONJ
ajlm-1625	55	4	percentages	percentage	NOUN
ajlm-1625	55	5	are	be	AUX
ajlm-1625	55	6	given	give	VERB
ajlm-1625	55	7	with	with	ADP
ajlm-1625	55	8	a	a	DET
ajlm-1625	55	9	95	95	NUM
ajlm-1625	55	10	%	%	NOUN
ajlm-1625	55	11	confidence	confidence	NOUN
ajlm-1625	55	12	interval	interval	NOUN
ajlm-1625	55	13	.	.	PUNCT
ajlm-1625	56	1	we	we	PRON
ajlm-1625	56	2	used	use	VERB
ajlm-1625	56	3	the	the	DET
ajlm-1625	56	4	chi	chi	ADJ
ajlm-1625	56	5	-	-	PUNCT
ajlm-1625	56	6	square	square	ADJ
ajlm-1625	56	7	test	test	NOUN
ajlm-1625	56	8	to	to	PART
ajlm-1625	56	9	compare	compare	VERB
ajlm-1625	56	10	proportions	proportion	NOUN
ajlm-1625	56	11	,	,	PUNCT
ajlm-1625	56	12	and	and	CCONJ
ajlm-1625	56	13	differences	difference	NOUN
ajlm-1625	56	14	were	be	AUX
ajlm-1625	56	15	considered	consider	VERB
ajlm-1625	56	16	significant	significant	ADJ
ajlm-1625	56	17	for	for	ADP
ajlm-1625	56	18	p	p	X
ajlm-1625	56	19	<	<	X
ajlm-1625	56	20	0.05	0.05	NUM
ajlm-1625	56	21	.	.	PUNCT
ajlm-1625	57	1	results	result	NOUN
ajlm-1625	57	2	baseline	baseline	VERB
ajlm-1625	57	3	characteristics	characteristic	NOUN
ajlm-1625	57	4	during	during	ADP
ajlm-1625	57	5	the	the	DET
ajlm-1625	57	6	study	study	NOUN
ajlm-1625	57	7	period	period	NOUN
ajlm-1625	57	8	,	,	PUNCT
ajlm-1625	57	9	235	235	NUM
ajlm-1625	57	10	patients	patient	NOUN
ajlm-1625	57	11	with	with	ADP
ajlm-1625	57	12	crf	crf	PROPN
ajlm-1625	57	13	were	be	AUX
ajlm-1625	57	14	included	include	VERB
ajlm-1625	57	15	,	,	PUNCT
ajlm-1625	57	16	comprising	comprise	VERB
ajlm-1625	57	17	45.1	45.1	NUM
ajlm-1625	57	18	%	%	NOUN
ajlm-1625	57	19	(	(	PUNCT
ajlm-1625	57	20	106/235	106/235	NUM
ajlm-1625	57	21	)	)	PUNCT
ajlm-1625	57	22	female	female	ADJ
ajlm-1625	57	23	patients	patient	NOUN
ajlm-1625	57	24	.	.	PUNCT
ajlm-1625	58	1	the	the	DET
ajlm-1625	58	2	mean	mean	ADJ
ajlm-1625	58	3	age	age	NOUN
ajlm-1625	58	4	was	be	AUX
ajlm-1625	58	5	41.9	41.9	NUM
ajlm-1625	58	6	(	(	PUNCT
ajlm-1625	58	7	standard	standard	ADJ
ajlm-1625	58	8	deviation	deviation	NOUN
ajlm-1625	58	9	14.5	14.5	NUM
ajlm-1625	58	10	years	year	NOUN
ajlm-1625	58	11	;	;	PUNCT
ajlm-1625	58	12	median	median	NOUN
ajlm-1625	58	13	41	41	NUM
ajlm-1625	58	14	years	year	NOUN
ajlm-1625	58	15	;	;	PUNCT
ajlm-1625	58	16	range	range	NOUN
ajlm-1625	58	17	15–86	15–86	NUM
ajlm-1625	58	18	years	year	NOUN
ajlm-1625	58	19	)	)	PUNCT
ajlm-1625	58	20	.	.	PUNCT
ajlm-1625	59	1	the	the	DET
ajlm-1625	59	2	mean	mean	ADJ
ajlm-1625	59	3	number	number	NOUN
ajlm-1625	59	4	of	of	ADP
ajlm-1625	59	5	received	receive	VERB
ajlm-1625	59	6	rbc	rbc	PROPN
ajlm-1625	59	7	units	unit	NOUN
ajlm-1625	59	8	was	be	AUX
ajlm-1625	59	9	18	18	NUM
ajlm-1625	59	10	units	unit	NOUN
ajlm-1625	59	11	ranging	range	VERB
ajlm-1625	59	12	from	from	ADP
ajlm-1625	59	13	two	two	NUM
ajlm-1625	59	14	to	to	PART
ajlm-1625	59	15	160	160	NUM
ajlm-1625	59	16	rbc	rbc	PROPN
ajlm-1625	59	17	,	,	PUNCT
ajlm-1625	59	18	while	while	SCONJ
ajlm-1625	59	19	the	the	DET
ajlm-1625	59	20	median	median	ADJ
ajlm-1625	59	21	number	number	NOUN
ajlm-1625	59	22	of	of	ADP
ajlm-1625	59	23	received	receive	VERB
ajlm-1625	59	24	blood	blood	NOUN
ajlm-1625	59	25	units	unit	NOUN
ajlm-1625	59	26	per	per	ADP
ajlm-1625	59	27	patient	patient	NOUN
ajlm-1625	59	28	was	be	AUX
ajlm-1625	59	29	10	10	NUM
ajlm-1625	59	30	(	(	PUNCT
ajlm-1625	59	31	interquartile	interquartile	ADJ
ajlm-1625	59	32	range	range	NOUN
ajlm-1625	59	33	:	:	PUNCT
ajlm-1625	59	34	5–20	5–20	NUM
ajlm-1625	59	35	)	)	PUNCT
ajlm-1625	59	36	.	.	PUNCT
ajlm-1625	60	1	about	about	ADV
ajlm-1625	60	2	55.2	55.2	NUM
ajlm-1625	60	3	%	%	NOUN
ajlm-1625	60	4	(	(	PUNCT
ajlm-1625	60	5	128/232	128/232	NUM
ajlm-1625	60	6	)	)	PUNCT
ajlm-1625	60	7	had	have	AUX
ajlm-1625	60	8	received	receive	VERB
ajlm-1625	60	9	more	more	ADJ
ajlm-1625	60	10	than	than	ADP
ajlm-1625	60	11	10	10	NUM
ajlm-1625	60	12	rbc	rbc	PROPN
ajlm-1625	60	13	units	unit	NOUN
ajlm-1625	60	14	(	(	PUNCT
ajlm-1625	60	15	table	table	NOUN
ajlm-1625	60	16	1	1	NUM
ajlm-1625	60	17	)	)	PUNCT
ajlm-1625	60	18	.	.	PUNCT
ajlm-1625	61	1	table	table	NOUN
ajlm-1625	61	2	1	1	NUM
ajlm-1625	61	3	:	:	PUNCT
ajlm-1625	61	4	 	 	SPACE
ajlm-1625	61	5	social	social	ADJ
ajlm-1625	61	6	and	and	CCONJ
ajlm-1625	61	7	demographic	demographic	ADJ
ajlm-1625	61	8	characteristics	characteristic	NOUN
ajlm-1625	61	9	of	of	ADP
ajlm-1625	61	10	patients	patient	NOUN
ajlm-1625	61	11	with	with	ADP
ajlm-1625	61	12	chronic	chronic	ADJ
ajlm-1625	61	13	renal	renal	ADJ
ajlm-1625	61	14	failure	failure	NOUN
ajlm-1625	61	15	,	,	PUNCT
ajlm-1625	61	16	yalgado	yalgado	NOUN
ajlm-1625	61	17	ouedraogo	ouedraogo	VERB
ajlm-1625	61	18	teaching	teach	VERB
ajlm-1625	61	19	hospital	hospital	NOUN
ajlm-1625	61	20	of	of	ADP
ajlm-1625	61	21	ouagadougou	ouagadougou	PROPN
ajlm-1625	61	22	,	,	PUNCT
ajlm-1625	61	23	burkina	burkina	PROPN
ajlm-1625	61	24	faso	faso	PROPN
ajlm-1625	61	25	,	,	PUNCT
ajlm-1625	61	26	2018	2018	NUM
ajlm-1625	61	27	.	.	PUNCT
ajlm-1625	62	1	red	red	ADJ
ajlm-1625	62	2	blood	blood	NOUN
ajlm-1625	62	3	cell	cell	NOUN
ajlm-1625	62	4	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	62	5	prevalence	prevalence	NOUN
ajlm-1625	62	6	of	of	ADP
ajlm-1625	62	7	the	the	DET
ajlm-1625	62	8	235	235	NUM
ajlm-1625	62	9	patients	patient	NOUN
ajlm-1625	62	10	included	include	VERB
ajlm-1625	62	11	,	,	PUNCT
ajlm-1625	62	12	14	14	NUM
ajlm-1625	62	13	had	have	VERB
ajlm-1625	62	14	alloantibodies	alloantibody	NOUN
ajlm-1625	62	15	,	,	PUNCT
ajlm-1625	62	16	representing	represent	VERB
ajlm-1625	62	17	an	an	DET
ajlm-1625	62	18	overall	overall	ADJ
ajlm-1625	62	19	positivity	positivity	NOUN
ajlm-1625	62	20	rate	rate	NOUN
ajlm-1625	62	21	of	of	ADP
ajlm-1625	62	22	5.9	5.9	NUM
ajlm-1625	62	23	%	%	NOUN
ajlm-1625	62	24	.	.	PUNCT
ajlm-1625	63	1	four	four	NUM
ajlm-1625	63	2	of	of	ADP
ajlm-1625	63	3	the	the	DET
ajlm-1625	63	4	14	14	NUM
ajlm-1625	63	5	patients	patient	NOUN
ajlm-1625	63	6	(	(	PUNCT
ajlm-1625	63	7	28.6	28.6	NUM
ajlm-1625	63	8	%	%	NOUN
ajlm-1625	63	9	)	)	PUNCT
ajlm-1625	63	10	had	have	VERB
ajlm-1625	63	11	indeterminate	indeterminate	ADJ
ajlm-1625	63	12	antibody	antibody	NOUN
ajlm-1625	63	13	specificity	specificity	NOUN
ajlm-1625	63	14	.	.	PUNCT
ajlm-1625	64	1	in	in	ADP
ajlm-1625	64	2	10	10	NUM
ajlm-1625	64	3	patients	patient	NOUN
ajlm-1625	64	4	,	,	PUNCT
ajlm-1625	64	5	14	14	NUM
ajlm-1625	64	6	antibodies	antibody	NOUN
ajlm-1625	64	7	were	be	AUX
ajlm-1625	64	8	identified	identify	VERB
ajlm-1625	64	9	:	:	PUNCT
ajlm-1625	64	10	5	5	NUM
ajlm-1625	64	11	anti	anti	ADJ
ajlm-1625	64	12	-	-	ADJ
ajlm-1625	64	13	d	d	ADJ
ajlm-1625	64	14	,	,	PUNCT
ajlm-1625	64	15	5	5	NUM
ajlm-1625	64	16	anti	anti	ADJ
ajlm-1625	64	17	-	-	ADJ
ajlm-1625	64	18	c	c	ADJ
ajlm-1625	64	19	,	,	PUNCT
ajlm-1625	64	20	1	1	NUM
ajlm-1625	64	21	anti	anti	ADJ
ajlm-1625	64	22	-	-	ADJ
ajlm-1625	64	23	e	e	ADJ
ajlm-1625	64	24	,	,	PUNCT
ajlm-1625	64	25	1	1	NUM
ajlm-1625	64	26	anti	anti	ADJ
ajlm-1625	64	27	-	-	ADJ
ajlm-1625	64	28	cw	cw	ADJ
ajlm-1625	64	29	,	,	PUNCT
ajlm-1625	64	30	1	1	NUM
ajlm-1625	64	31	anti	anti	X
ajlm-1625	64	32	s	s	PROPN
ajlm-1625	64	33	,	,	PUNCT
ajlm-1625	64	34	1	1	NUM
ajlm-1625	64	35	anti	anti	ADJ
ajlm-1625	64	36	-	-	ADJ
ajlm-1625	64	37	lea	lea	ADJ
ajlm-1625	64	38	;	;	PUNCT
ajlm-1625	64	39	four	four	NUM
ajlm-1625	64	40	patients	patient	NOUN
ajlm-1625	64	41	were	be	AUX
ajlm-1625	64	42	positive	positive	ADJ
ajlm-1625	64	43	for	for	ADP
ajlm-1625	64	44	both	both	CCONJ
ajlm-1625	64	45	anti	anti	ADJ
ajlm-1625	64	46	-	-	ADJ
ajlm-1625	64	47	d	d	ADJ
ajlm-1625	64	48	and	and	CCONJ
ajlm-1625	64	49	anti	anti	ADJ
ajlm-1625	64	50	-	-	ADJ
ajlm-1625	64	51	c	c	ADJ
ajlm-1625	64	52	(	(	PUNCT
ajlm-1625	64	53	table	table	NOUN
ajlm-1625	64	54	2	2	NUM
ajlm-1625	64	55	)	)	PUNCT
ajlm-1625	64	56	.	.	PUNCT
ajlm-1625	65	1	table	table	NOUN
ajlm-1625	65	2	2	2	NUM
ajlm-1625	65	3	:	:	PUNCT
ajlm-1625	65	4	 	 	SPACE
ajlm-1625	65	5	characteristics	characteristic	NOUN
ajlm-1625	65	6	of	of	ADP
ajlm-1625	65	7	patients	patient	NOUN
ajlm-1625	65	8	with	with	ADP
ajlm-1625	65	9	red	red	ADJ
ajlm-1625	65	10	blood	blood	NOUN
ajlm-1625	65	11	cell	cell	NOUN
ajlm-1625	65	12	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	65	13	,	,	PUNCT
ajlm-1625	65	14	yalgado	yalgado	NOUN
ajlm-1625	65	15	ouedraogo	ouedraogo	VERB
ajlm-1625	65	16	teaching	teach	VERB
ajlm-1625	65	17	hospital	hospital	NOUN
ajlm-1625	65	18	of	of	ADP
ajlm-1625	65	19	ouagadougou	ouagadougou	PROPN
ajlm-1625	65	20	,	,	PUNCT
ajlm-1625	65	21	burkina	burkina	PROPN
ajlm-1625	65	22	faso	faso	PROPN
ajlm-1625	65	23	,	,	PUNCT
ajlm-1625	65	24	2018.†	2018.†	NUM
ajlm-1625	65	25	most	most	ADJ
ajlm-1625	65	26	antibodies	antibodie	VERB
ajlm-1625	65	27	(	(	PUNCT
ajlm-1625	65	28	12	12	NUM
ajlm-1625	65	29	of	of	ADP
ajlm-1625	65	30	14	14	NUM
ajlm-1625	65	31	;	;	PUNCT
ajlm-1625	65	32	85.7	85.7	NUM
ajlm-1625	65	33	%	%	NOUN
ajlm-1625	65	34	)	)	PUNCT
ajlm-1625	65	35	were	be	AUX
ajlm-1625	65	36	of	of	ADP
ajlm-1625	65	37	the	the	DET
ajlm-1625	65	38	anti	anti	ADJ
ajlm-1625	65	39	-	-	ADJ
ajlm-1625	65	40	rh	rh	ADJ
ajlm-1625	65	41	blood	blood	NOUN
ajlm-1625	65	42	group	group	NOUN
ajlm-1625	65	43	antigens	antigen	NOUN
ajlm-1625	65	44	,	,	PUNCT
ajlm-1625	65	45	with	with	ADP
ajlm-1625	65	46	anti	anti	ADJ
ajlm-1625	65	47	-	-	ADJ
ajlm-1625	65	48	d	d	ADJ
ajlm-1625	65	49	and	and	CCONJ
ajlm-1625	65	50	anti	anti	ADJ
ajlm-1625	65	51	-	-	NOUN
ajlm-1625	65	52	c	c	ADJ
ajlm-1625	65	53	being	be	AUX
ajlm-1625	65	54	the	the	DET
ajlm-1625	65	55	most	most	ADV
ajlm-1625	65	56	prevalent	prevalent	ADJ
ajlm-1625	65	57	,	,	PUNCT
ajlm-1625	65	58	each	each	PRON
ajlm-1625	65	59	accounting	account	VERB
ajlm-1625	65	60	for	for	ADP
ajlm-1625	65	61	35.7	35.7	NUM
ajlm-1625	65	62	%	%	NOUN
ajlm-1625	65	63	(	(	PUNCT
ajlm-1625	65	64	table	table	NOUN
ajlm-1625	65	65	3	3	NUM
ajlm-1625	65	66	)	)	PUNCT
ajlm-1625	65	67	.	.	PUNCT
ajlm-1625	66	1	table	table	NOUN
ajlm-1625	66	2	3	3	NUM
ajlm-1625	66	3	:	:	PUNCT
ajlm-1625	66	4	 	 	SPACE
ajlm-1625	66	5	specificity	specificity	NOUN
ajlm-1625	66	6	and	and	CCONJ
ajlm-1625	66	7	frequency	frequency	NOUN
ajlm-1625	66	8	of	of	ADP
ajlm-1625	66	9	alloantibodies	alloantibody	NOUN
ajlm-1625	66	10	found	find	VERB
ajlm-1625	66	11	among	among	ADP
ajlm-1625	66	12	multi	multi	ADJ
ajlm-1625	66	13	-	-	ADJ
ajlm-1625	66	14	transfused	transfused	ADJ
ajlm-1625	66	15	patients	patient	NOUN
ajlm-1625	66	16	of	of	ADP
ajlm-1625	66	17	the	the	DET
ajlm-1625	66	18	yalgado	yalgado	NOUN
ajlm-1625	66	19	ouedraogo	ouedraogo	ADJ
ajlm-1625	66	20	teaching	teach	VERB
ajlm-1625	66	21	hospital	hospital	NOUN
ajlm-1625	66	22	of	of	ADP
ajlm-1625	66	23	ouagadougou	ouagadougou	PROPN
ajlm-1625	66	24	,	,	PUNCT
ajlm-1625	66	25	burkina	burkina	PROPN
ajlm-1625	66	26	faso	faso	PROPN
ajlm-1625	66	27	,	,	PUNCT
ajlm-1625	66	28	2018.†	2018.†	NUM
ajlm-1625	66	29	red	red	ADJ
ajlm-1625	66	30	blood	blood	NOUN
ajlm-1625	66	31	cell	cell	NOUN
ajlm-1625	66	32	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	66	33	risk	risk	NOUN
ajlm-1625	66	34	factors	factor	NOUN
ajlm-1625	66	35	there	there	PRON
ajlm-1625	66	36	were	be	VERB
ajlm-1625	66	37	no	no	DET
ajlm-1625	66	38	differences	difference	NOUN
ajlm-1625	66	39	in	in	ADP
ajlm-1625	66	40	the	the	DET
ajlm-1625	66	41	mean	mean	ADJ
ajlm-1625	66	42	age	age	NOUN
ajlm-1625	66	43	(	(	PUNCT
ajlm-1625	66	44	43.3	43.3	NUM
ajlm-1625	66	45	vs	vs	ADP
ajlm-1625	66	46	41.8	41.8	NUM
ajlm-1625	66	47	years	year	NOUN
ajlm-1625	66	48	,	,	PUNCT
ajlm-1625	66	49	p	p	NOUN
ajlm-1625	66	50	=	=	NOUN
ajlm-1625	66	51	0.21	0.21	NUM
ajlm-1625	66	52	)	)	PUNCT
ajlm-1625	66	53	and	and	CCONJ
ajlm-1625	66	54	the	the	DET
ajlm-1625	66	55	mean	mean	ADJ
ajlm-1625	66	56	number	number	NOUN
ajlm-1625	66	57	of	of	ADP
ajlm-1625	66	58	blood	blood	NOUN
ajlm-1625	66	59	units	unit	NOUN
ajlm-1625	66	60	received	receive	VERB
ajlm-1625	66	61	(	(	PUNCT
ajlm-1625	66	62	13.0	13.0	NUM
ajlm-1625	66	63	vs	vs	ADP
ajlm-1625	66	64	15.7	15.7	NUM
ajlm-1625	66	65	rbc	rbc	PROPN
ajlm-1625	66	66	units	unit	NOUN
ajlm-1625	66	67	,	,	PUNCT
ajlm-1625	66	68	p	p	NOUN
ajlm-1625	66	69	=	=	NOUN
ajlm-1625	66	70	0.36	0.36	NUM
ajlm-1625	66	71	)	)	PUNCT
ajlm-1625	66	72	between	between	ADP
ajlm-1625	66	73	immunised	immunise	VERB
ajlm-1625	66	74	and	and	CCONJ
ajlm-1625	66	75	non	non	ADJ
ajlm-1625	66	76	-	-	ADJ
ajlm-1625	66	77	immunised	immunised	ADJ
ajlm-1625	66	78	patients	patient	NOUN
ajlm-1625	66	79	.	.	PUNCT
ajlm-1625	67	1	the	the	DET
ajlm-1625	67	2	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	67	3	rate	rate	NOUN
ajlm-1625	67	4	was	be	AUX
ajlm-1625	67	5	higher	high	ADJ
ajlm-1625	67	6	in	in	ADP
ajlm-1625	67	7	patients	patient	NOUN
ajlm-1625	67	8	who	who	PRON
ajlm-1625	67	9	had	have	AUX
ajlm-1625	67	10	received	receive	VERB
ajlm-1625	67	11	more	more	ADJ
ajlm-1625	67	12	than	than	ADP
ajlm-1625	67	13	10	10	NUM
ajlm-1625	67	14	rbc	rbc	PROPN
ajlm-1625	67	15	units	unit	NOUN
ajlm-1625	67	16	(	(	PUNCT
ajlm-1625	67	17	7.4	7.4	NUM
ajlm-1625	67	18	%	%	NOUN
ajlm-1625	67	19	vs	vs	ADP
ajlm-1625	67	20	2.3	2.3	NUM
ajlm-1625	67	21	%	%	NOUN
ajlm-1625	67	22	,	,	PUNCT
ajlm-1625	67	23	p	p	X
ajlm-1625	67	24	=	=	NOUN
ajlm-1625	67	25	0.12	0.12	NUM
ajlm-1625	67	26	)	)	PUNCT
ajlm-1625	67	27	,	,	PUNCT
ajlm-1625	67	28	but	but	CCONJ
ajlm-1625	67	29	this	this	DET
ajlm-1625	67	30	difference	difference	NOUN
ajlm-1625	67	31	was	be	AUX
ajlm-1625	67	32	statistically	statistically	ADV
ajlm-1625	67	33	insignificant	insignificant	ADJ
ajlm-1625	67	34	.	.	PUNCT
ajlm-1625	68	1	there	there	PRON
ajlm-1625	68	2	were	be	VERB
ajlm-1625	68	3	no	no	DET
ajlm-1625	68	4	other	other	ADJ
ajlm-1625	68	5	factors	factor	NOUN
ajlm-1625	68	6	associated	associate	VERB
ajlm-1625	68	7	with	with	ADP
ajlm-1625	68	8	alloantibodies	alloantibody	NOUN
ajlm-1625	68	9	(	(	PUNCT
ajlm-1625	68	10	table	table	NOUN
ajlm-1625	68	11	4	4	NUM
ajlm-1625	68	12	)	)	PUNCT
ajlm-1625	68	13	.	.	PUNCT
ajlm-1625	69	1	table	table	NOUN
ajlm-1625	69	2	4	4	NUM
ajlm-1625	69	3	:	:	PUNCT
ajlm-1625	69	4	 	 	SPACE
ajlm-1625	69	5	factors	factor	NOUN
ajlm-1625	69	6	associated	associate	VERB
ajlm-1625	69	7	with	with	ADP
ajlm-1625	69	8	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	69	9	in	in	ADP
ajlm-1625	69	10	multi	multi	ADJ
ajlm-1625	69	11	-	-	ADJ
ajlm-1625	69	12	transfused	transfused	ADJ
ajlm-1625	69	13	patients	patient	NOUN
ajlm-1625	69	14	with	with	ADP
ajlm-1625	69	15	chronic	chronic	ADJ
ajlm-1625	69	16	renal	renal	ADJ
ajlm-1625	69	17	failure	failure	NOUN
ajlm-1625	69	18	,	,	PUNCT
ajlm-1625	69	19	yalgado	yalgado	NOUN
ajlm-1625	69	20	ouedraogo	ouedraogo	VERB
ajlm-1625	69	21	teaching	teach	VERB
ajlm-1625	69	22	hospital	hospital	NOUN
ajlm-1625	69	23	,	,	PUNCT
ajlm-1625	69	24	ouagadougou	ouagadougou	PROPN
ajlm-1625	69	25	,	,	PUNCT
ajlm-1625	69	26	burkina	burkina	PROPN
ajlm-1625	69	27	faso	faso	PROPN
ajlm-1625	69	28	,	,	PUNCT
ajlm-1625	69	29	2018	2018	NUM
ajlm-1625	69	30	.	.	PUNCT
ajlm-1625	70	1	discussion	discussion	NOUN
ajlm-1625	70	2	our	our	PRON
ajlm-1625	70	3	study	study	NOUN
ajlm-1625	70	4	aimed	aim	VERB
ajlm-1625	70	5	at	at	ADP
ajlm-1625	70	6	determining	determine	VERB
ajlm-1625	70	7	the	the	DET
ajlm-1625	70	8	frequency	frequency	NOUN
ajlm-1625	70	9	and	and	CCONJ
ajlm-1625	70	10	the	the	DET
ajlm-1625	70	11	specificity	specificity	NOUN
ajlm-1625	70	12	of	of	ADP
ajlm-1625	70	13	alloantibodies	alloantibody	NOUN
ajlm-1625	70	14	among	among	ADP
ajlm-1625	70	15	the	the	DET
ajlm-1625	70	16	multi	multi	ADJ
ajlm-1625	70	17	-	-	ADJ
ajlm-1625	70	18	transfused	transfused	ADJ
ajlm-1625	70	19	haemodialysis	haemodialysis	NOUN
ajlm-1625	70	20	crf	crf	NOUN
ajlm-1625	70	21	patients	patient	NOUN
ajlm-1625	70	22	at	at	ADP
ajlm-1625	70	23	the	the	DET
ajlm-1625	70	24	teaching	teaching	NOUN
ajlm-1625	70	25	hospital	hospital	NOUN
ajlm-1625	70	26	yalgado	yalgado	NOUN
ajlm-1625	70	27	ouedraogo	ouedraogo	NOUN
ajlm-1625	70	28	of	of	ADP
ajlm-1625	70	29	ouagadougou	ouagadougou	PROPN
ajlm-1625	70	30	(	(	PUNCT
ajlm-1625	70	31	burkina	burkina	PROPN
ajlm-1625	70	32	faso	faso	PROPN
ajlm-1625	70	33	)	)	PUNCT
ajlm-1625	70	34	.	.	PUNCT
ajlm-1625	71	1	we	we	PRON
ajlm-1625	71	2	found	find	VERB
ajlm-1625	71	3	an	an	DET
ajlm-1625	71	4	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	71	5	rate	rate	NOUN
ajlm-1625	71	6	of	of	ADP
ajlm-1625	71	7	5.9	5.9	NUM
ajlm-1625	71	8	%	%	NOUN
ajlm-1625	71	9	with	with	ADP
ajlm-1625	71	10	antibodies	antibody	NOUN
ajlm-1625	71	11	mainly	mainly	ADV
ajlm-1625	71	12	of	of	ADP
ajlm-1625	71	13	the	the	DET
ajlm-1625	71	14	anti	anti	ADJ
ajlm-1625	71	15	-	-	ADJ
ajlm-1625	71	16	rh	rh	ADJ
ajlm-1625	71	17	blood	blood	NOUN
ajlm-1625	71	18	group	group	NOUN
ajlm-1625	71	19	antigens	antigen	NOUN
ajlm-1625	71	20	specificity	specificity	NOUN
ajlm-1625	71	21	.	.	PUNCT
ajlm-1625	72	1	this	this	DET
ajlm-1625	72	2	study	study	NOUN
ajlm-1625	72	3	overviews	overview	NOUN
ajlm-1625	72	4	of	of	ADP
ajlm-1625	72	5	rbc	rbc	PROPN
ajlm-1625	72	6	immunological	immunological	ADJ
ajlm-1625	72	7	risks	risk	NOUN
ajlm-1625	72	8	among	among	ADP
ajlm-1625	72	9	patients	patient	NOUN
ajlm-1625	72	10	with	with	ADP
ajlm-1625	72	11	chronic	chronic	ADJ
ajlm-1625	72	12	diseases	disease	NOUN
ajlm-1625	72	13	who	who	PRON
ajlm-1625	72	14	are	be	AUX
ajlm-1625	72	15	lifelong	lifelong	ADJ
ajlm-1625	72	16	blood	blood	NOUN
ajlm-1625	72	17	transfusion	transfusion	NOUN
ajlm-1625	72	18	patients	patient	NOUN
ajlm-1625	72	19	.	.	PUNCT
ajlm-1625	73	1	although	although	SCONJ
ajlm-1625	73	2	there	there	PRON
ajlm-1625	73	3	have	have	AUX
ajlm-1625	73	4	been	be	AUX
ajlm-1625	73	5	recent	recent	ADJ
ajlm-1625	73	6	changes	change	NOUN
ajlm-1625	73	7	in	in	ADP
ajlm-1625	73	8	the	the	DET
ajlm-1625	73	9	blood	blood	NOUN
ajlm-1625	73	10	transfusion	transfusion	NOUN
ajlm-1625	73	11	system	system	NOUN
ajlm-1625	73	12	in	in	ADP
ajlm-1625	73	13	burkina	burkina	PROPN
ajlm-1625	73	14	faso	faso	PROPN
ajlm-1625	73	15	,	,	PUNCT
ajlm-1625	73	16	including	include	VERB
ajlm-1625	73	17	the	the	DET
ajlm-1625	73	18	replacement	replacement	NOUN
ajlm-1625	73	19	of	of	ADP
ajlm-1625	73	20	multiple	multiple	ADJ
ajlm-1625	73	21	hospital	hospital	NOUN
ajlm-1625	73	22	-	-	PUNCT
ajlm-1625	73	23	based	base	VERB
ajlm-1625	73	24	blood	blood	NOUN
ajlm-1625	73	25	banks	bank	NOUN
ajlm-1625	73	26	with	with	ADP
ajlm-1625	73	27	a	a	DET
ajlm-1625	73	28	centralised	centralised	ADJ
ajlm-1625	73	29	system	system	NOUN
ajlm-1625	73	30	,	,	PUNCT
ajlm-1625	73	31	standardisation	standardisation	NOUN
ajlm-1625	73	32	and	and	CCONJ
ajlm-1625	73	33	harmonisation	harmonisation	NOUN
ajlm-1625	73	34	of	of	ADP
ajlm-1625	73	35	practices,6,18,19,20	practices,6,18,19,20	NUM
ajlm-1625	73	36	improved	improve	VERB
ajlm-1625	73	37	blood	blood	NOUN
ajlm-1625	73	38	collection	collection	NOUN
ajlm-1625	73	39	and	and	CCONJ
ajlm-1625	73	40	infectious	infectious	ADJ
ajlm-1625	73	41	disease	disease	NOUN
ajlm-1625	73	42	screening	screening	NOUN
ajlm-1625	73	43	,	,	PUNCT
ajlm-1625	73	44	some	some	DET
ajlm-1625	73	45	improvements	improvement	NOUN
ajlm-1625	73	46	towards	towards	ADP
ajlm-1625	73	47	managing	manage	VERB
ajlm-1625	73	48	blood	blood	NOUN
ajlm-1625	73	49	recipients	recipient	NOUN
ajlm-1625	73	50	are	be	AUX
ajlm-1625	73	51	necessary	necessary	ADJ
ajlm-1625	73	52	.	.	PUNCT
ajlm-1625	74	1	for	for	ADP
ajlm-1625	74	2	example	example	NOUN
ajlm-1625	74	3	,	,	PUNCT
ajlm-1625	74	4	compactibility	compactibility	NOUN
ajlm-1625	74	5	screening	screening	NOUN
ajlm-1625	74	6	is	be	AUX
ajlm-1625	74	7	still	still	ADV
ajlm-1625	74	8	limited	limit	VERB
ajlm-1625	74	9	to	to	ADP
ajlm-1625	74	10	the	the	DET
ajlm-1625	74	11	abo	abo	NOUN
ajlm-1625	74	12	and	and	CCONJ
ajlm-1625	74	13	rhd	rhd	PROPN
ajlm-1625	74	14	antigens	antigen	NOUN
ajlm-1625	74	15	,	,	PUNCT
ajlm-1625	74	16	contrary	contrary	ADV
ajlm-1625	74	17	to	to	ADP
ajlm-1625	74	18	obtainable	obtainable	ADJ
ajlm-1625	74	19	standards	standard	NOUN
ajlm-1625	74	20	in	in	ADP
ajlm-1625	74	21	high	high	ADJ
ajlm-1625	74	22	-	-	PUNCT
ajlm-1625	74	23	income	income	NOUN
ajlm-1625	74	24	countries	country	NOUN
ajlm-1625	74	25	,	,	PUNCT
ajlm-1625	74	26	where	where	SCONJ
ajlm-1625	74	27	rare	rare	ADJ
ajlm-1625	74	28	groups	group	NOUN
ajlm-1625	74	29	,	,	PUNCT
ajlm-1625	74	30	at	at	ADP
ajlm-1625	74	31	least	least	ADJ
ajlm-1625	74	32	rh	rh	PROPN
ajlm-1625	74	33	-	-	PUNCT
ajlm-1625	74	34	kell	kell	PROPN
ajlm-1625	74	35	major	major	ADJ
ajlm-1625	74	36	antigens	antigen	NOUN
ajlm-1625	74	37	,	,	PUNCT
ajlm-1625	74	38	are	be	AUX
ajlm-1625	74	39	screened	screen	VERB
ajlm-1625	74	40	for	for	ADP
ajlm-1625	74	41	before	before	ADP
ajlm-1625	74	42	transfusion	transfusion	NOUN
ajlm-1625	74	43	.	.	PUNCT
ajlm-1625	75	1	moreover	moreover	ADV
ajlm-1625	75	2	,	,	PUNCT
ajlm-1625	75	3	in	in	ADP
ajlm-1625	75	4	burkina	burkina	PROPN
ajlm-1625	75	5	faso	faso	PROPN
ajlm-1625	75	6	,	,	PUNCT
ajlm-1625	75	7	alloantibody	alloantibody	NOUN
ajlm-1625	75	8	screening	screen	VERB
ajlm-1625	75	9	tests	test	NOUN
ajlm-1625	75	10	and	and	CCONJ
ajlm-1625	75	11	laboratory	laboratory	NOUN
ajlm-1625	75	12	compatibility	compatibility	NOUN
ajlm-1625	75	13	tests	test	NOUN
ajlm-1625	75	14	using	use	VERB
ajlm-1625	75	15	at	at	ADV
ajlm-1625	75	16	least	least	ADJ
ajlm-1625	75	17	an	an	DET
ajlm-1625	75	18	indirect	indirect	ADJ
ajlm-1625	75	19	antibody	antibody	NOUN
ajlm-1625	75	20	test	test	NOUN
ajlm-1625	75	21	as	as	SCONJ
ajlm-1625	75	22	recommended	recommend	VERB
ajlm-1625	75	23	is	be	AUX
ajlm-1625	75	24	not	not	PART
ajlm-1625	75	25	implemented	implement	VERB
ajlm-1625	75	26	:	:	PUNCT
ajlm-1625	75	27	the	the	DET
ajlm-1625	75	28	patient	patient	NOUN
ajlm-1625	75	29	’s	’s	PART
ajlm-1625	75	30	plasma	plasma	NOUN
ajlm-1625	75	31	and	and	CCONJ
ajlm-1625	75	32	a	a	DET
ajlm-1625	75	33	sample	sample	NOUN
ajlm-1625	75	34	of	of	ADP
ajlm-1625	75	35	the	the	DET
ajlm-1625	75	36	rbc	rbc	PROPN
ajlm-1625	75	37	units	unit	NOUN
ajlm-1625	75	38	are	be	AUX
ajlm-1625	75	39	tested	test	VERB
ajlm-1625	75	40	for	for	ADP
ajlm-1625	75	41	agglutination	agglutination	NOUN
ajlm-1625	75	42	on	on	ADP
ajlm-1625	75	43	a	a	DET
ajlm-1625	75	44	glass	glass	NOUN
ajlm-1625	75	45	surface	surface	NOUN
ajlm-1625	75	46	.	.	PUNCT
ajlm-1625	76	1	this	this	DET
ajlm-1625	76	2	study	study	NOUN
ajlm-1625	76	3	was	be	AUX
ajlm-1625	76	4	the	the	DET
ajlm-1625	76	5	first	first	ADJ
ajlm-1625	76	6	in	in	ADP
ajlm-1625	76	7	the	the	DET
ajlm-1625	76	8	country	country	NOUN
ajlm-1625	76	9	to	to	PART
ajlm-1625	76	10	use	use	VERB
ajlm-1625	76	11	the	the	DET
ajlm-1625	76	12	gel	gel	NOUN
ajlm-1625	76	13	column	column	NOUN
ajlm-1625	76	14	card	card	NOUN
ajlm-1625	76	15	method	method	NOUN
ajlm-1625	76	16	,	,	PUNCT
ajlm-1625	76	17	one	one	NUM
ajlm-1625	76	18	of	of	ADP
ajlm-1625	76	19	the	the	DET
ajlm-1625	76	20	current	current	ADJ
ajlm-1625	76	21	best	good	ADJ
ajlm-1625	76	22	methods	method	NOUN
ajlm-1625	76	23	for	for	ADP
ajlm-1625	76	24	alloantibody	alloantibody	ADJ
ajlm-1625	76	25	screening	screening	NOUN
ajlm-1625	76	26	.	.	PUNCT
ajlm-1625	77	1	nevertheless	nevertheless	ADV
ajlm-1625	77	2	,	,	PUNCT
ajlm-1625	77	3	the	the	DET
ajlm-1625	77	4	study	study	NOUN
ajlm-1625	77	5	presents	present	VERB
ajlm-1625	77	6	some	some	DET
ajlm-1625	77	7	limitations	limitation	NOUN
ajlm-1625	77	8	as	as	SCONJ
ajlm-1625	77	9	complementary	complementary	ADJ
ajlm-1625	77	10	antibody	antibody	NOUN
ajlm-1625	77	11	identification	identification	NOUN
ajlm-1625	77	12	techniques	technique	NOUN
ajlm-1625	77	13	,	,	PUNCT
ajlm-1625	77	14	such	such	ADJ
ajlm-1625	77	15	as	as	ADP
ajlm-1625	77	16	enzyme	enzyme	NOUN
ajlm-1625	77	17	-	-	PUNCT
ajlm-1625	77	18	treated	treat	VERB
ajlm-1625	77	19	red	red	ADJ
ajlm-1625	77	20	cells	cell	NOUN
ajlm-1625	77	21	reagents	reagent	NOUN
ajlm-1625	77	22	panels	panel	NOUN
ajlm-1625	77	23	(	(	PUNCT
ajlm-1625	77	24	papain	papain	NOUN
ajlm-1625	77	25	,	,	PUNCT
ajlm-1625	77	26	bromelain	bromelain	NOUN
ajlm-1625	77	27	or	or	CCONJ
ajlm-1625	77	28	other	other	ADJ
ajlm-1625	77	29	)	)	PUNCT
ajlm-1625	77	30	or	or	CCONJ
ajlm-1625	77	31	wide	wide	ADJ
ajlm-1625	77	32	-	-	PUNCT
ajlm-1625	77	33	range	range	NOUN
ajlm-1625	77	34	panels	panel	NOUN
ajlm-1625	77	35	,	,	PUNCT
ajlm-1625	77	36	were	be	AUX
ajlm-1625	77	37	not	not	PART
ajlm-1625	77	38	used	use	VERB
ajlm-1625	77	39	.	.	PUNCT
ajlm-1625	78	1	the	the	DET
ajlm-1625	78	2	lack	lack	NOUN
ajlm-1625	78	3	of	of	ADP
ajlm-1625	78	4	complementary	complementary	ADJ
ajlm-1625	78	5	identification	identification	NOUN
ajlm-1625	78	6	can	can	AUX
ajlm-1625	78	7	explain	explain	VERB
ajlm-1625	78	8	the	the	DET
ajlm-1625	78	9	high	high	ADJ
ajlm-1625	78	10	rate	rate	NOUN
ajlm-1625	78	11	(	(	PUNCT
ajlm-1625	78	12	4	4	NUM
ajlm-1625	78	13	of	of	ADP
ajlm-1625	78	14	14	14	NUM
ajlm-1625	78	15	;	;	PUNCT
ajlm-1625	78	16	28.7	28.7	NUM
ajlm-1625	78	17	%	%	NOUN
ajlm-1625	78	18	)	)	PUNCT
ajlm-1625	78	19	of	of	ADP
ajlm-1625	78	20	alloantibody	alloantibody	PROPN
ajlm-1625	78	21	undetermined	undetermined	ADJ
ajlm-1625	78	22	specificity	specificity	NOUN
ajlm-1625	78	23	(	(	PUNCT
ajlm-1625	78	24	inconclusive	inconclusive	ADJ
ajlm-1625	78	25	antibody	antibody	NOUN
ajlm-1625	78	26	identification).21	identification).21	PROPN
ajlm-1625	78	27	the	the	DET
ajlm-1625	78	28	overall	overall	ADJ
ajlm-1625	78	29	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	78	30	rate	rate	NOUN
ajlm-1625	78	31	of	of	ADP
ajlm-1625	78	32	5.9	5.9	NUM
ajlm-1625	78	33	%	%	NOUN
ajlm-1625	78	34	among	among	ADP
ajlm-1625	78	35	crf	crf	NOUN
ajlm-1625	78	36	patients	patient	NOUN
ajlm-1625	78	37	undergoing	undergo	VERB
ajlm-1625	78	38	haemodialysis	haemodialysis	NOUN
ajlm-1625	78	39	on	on	ADP
ajlm-1625	78	40	our	our	PRON
ajlm-1625	78	41	study	study	NOUN
ajlm-1625	78	42	is	be	AUX
ajlm-1625	78	43	consistent	consistent	ADJ
ajlm-1625	78	44	with	with	ADP
ajlm-1625	78	45	the	the	DET
ajlm-1625	78	46	findings	finding	NOUN
ajlm-1625	78	47	of	of	ADP
ajlm-1625	78	48	two	two	NUM
ajlm-1625	78	49	systematic	systematic	ADJ
ajlm-1625	78	50	reviews	review	NOUN
ajlm-1625	78	51	and	and	CCONJ
ajlm-1625	78	52	meta	meta	ADJ
ajlm-1625	78	53	-	-	PUNCT
ajlm-1625	78	54	analysis	analysis	NOUN
ajlm-1625	78	55	studies	study	NOUN
ajlm-1625	78	56	conducted	conduct	VERB
ajlm-1625	78	57	by	by	ADP
ajlm-1625	78	58	ngoma	ngoma	PROPN
ajlm-1625	78	59	et	et	PROPN
ajlm-1625	78	60	al	al	PROPN
ajlm-1625	78	61	.	.	PROPN
ajlm-1625	79	1	in	in	ADP
ajlm-1625	79	2	2015	2015	NUM
ajlm-1625	79	3	and	and	CCONJ
ajlm-1625	79	4	boateng	boateng	PROPN
ajlm-1625	79	5	et	et	PROPN
ajlm-1625	79	6	al	al	PROPN
ajlm-1625	79	7	.	.	PROPN
ajlm-1625	80	1	in	in	ADP
ajlm-1625	80	2	2019	2019	NUM
ajlm-1625	80	3	.	.	PUNCT
ajlm-1625	81	1	these	these	DET
ajlm-1625	81	2	studies	study	NOUN
ajlm-1625	81	3	reported	report	VERB
ajlm-1625	81	4	an	an	DET
ajlm-1625	81	5	overall	overall	ADJ
ajlm-1625	81	6	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	81	7	rate	rate	NOUN
ajlm-1625	81	8	of	of	ADP
ajlm-1625	81	9	6.95	6.95	NUM
ajlm-1625	81	10	%	%	NOUN
ajlm-1625	81	11	and	and	CCONJ
ajlm-1625	81	12	7.5	7.5	NUM
ajlm-1625	81	13	%	%	NOUN
ajlm-1625	81	14	in	in	ADP
ajlm-1625	81	15	sub	sub	ADJ
ajlm-1625	81	16	-	-	ADJ
ajlm-1625	81	17	saharan	saharan	ADJ
ajlm-1625	81	18	africa.22,23	africa.22,23	NOUN
ajlm-1625	81	19	our	our	PRON
ajlm-1625	81	20	results	result	NOUN
ajlm-1625	81	21	are	be	AUX
ajlm-1625	81	22	similar	similar	ADJ
ajlm-1625	81	23	to	to	ADP
ajlm-1625	81	24	those	those	PRON
ajlm-1625	81	25	of	of	ADP
ajlm-1625	81	26	kafando	kafando	PROPN
ajlm-1625	81	27	et	et	PROPN
ajlm-1625	81	28	al	al	PROPN
ajlm-1625	81	29	.	.	PROPN
ajlm-1625	81	30	,	,	PUNCT
ajlm-1625	81	31	who	who	PRON
ajlm-1625	81	32	found	find	VERB
ajlm-1625	81	33	an	an	DET
ajlm-1625	81	34	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	81	35	rate	rate	NOUN
ajlm-1625	81	36	of	of	ADP
ajlm-1625	81	37	4.2	4.2	NUM
ajlm-1625	81	38	%	%	NOUN
ajlm-1625	81	39	among	among	ADP
ajlm-1625	81	40	children	child	NOUN
ajlm-1625	81	41	transfused	transfuse	VERB
ajlm-1625	81	42	with	with	ADP
ajlm-1625	81	43	rh	rh	PROPN
ajlm-1625	81	44	-	-	PUNCT
ajlm-1625	81	45	kell	kell	PROPN
ajlm-1625	81	46	unmatched	unmatched	ADJ
ajlm-1625	81	47	blood	blood	NOUN
ajlm-1625	81	48	units.24	units.24	ADJ
ajlm-1625	81	49	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	81	50	rates	rate	NOUN
ajlm-1625	81	51	in	in	ADP
ajlm-1625	81	52	the	the	DET
ajlm-1625	81	53	same	same	ADJ
ajlm-1625	81	54	range	range	NOUN
ajlm-1625	81	55	were	be	AUX
ajlm-1625	81	56	reported	report	VERB
ajlm-1625	81	57	in	in	ADP
ajlm-1625	81	58	uganda	uganda	PROPN
ajlm-1625	81	59	(	(	PUNCT
ajlm-1625	81	60	6.1	6.1	NUM
ajlm-1625	81	61	%	%	NOUN
ajlm-1625	81	62	)	)	PUNCT
ajlm-1625	81	63	,	,	PUNCT
ajlm-1625	81	64	rwanda	rwanda	PROPN
ajlm-1625	81	65	(	(	PUNCT
ajlm-1625	81	66	6.4	6.4	NUM
ajlm-1625	81	67	%	%	NOUN
ajlm-1625	81	68	)	)	PUNCT
ajlm-1625	81	69	,	,	PUNCT
ajlm-1625	81	70	sudan	sudan	PROPN
ajlm-1625	81	71	(	(	PUNCT
ajlm-1625	81	72	4.0	4.0	NUM
ajlm-1625	81	73	%	%	NOUN
ajlm-1625	81	74	)	)	PUNCT
ajlm-1625	81	75	and	and	CCONJ
ajlm-1625	81	76	tanzania	tanzania	PROPN
ajlm-1625	81	77	(	(	PUNCT
ajlm-1625	81	78	4.1	4.1	NUM
ajlm-1625	81	79	%	%	NOUN
ajlm-1625	81	80	)	)	PUNCT
ajlm-1625	81	81	.	.	PUNCT
ajlm-1625	82	1	however	however	ADV
ajlm-1625	82	2	,	,	PUNCT
ajlm-1625	82	3	some	some	PRON
ajlm-1625	82	4	reported	report	VERB
ajlm-1625	82	5	higher	high	ADJ
ajlm-1625	82	6	rates	rate	NOUN
ajlm-1625	82	7	:	:	PUNCT
ajlm-1625	82	8	uganda	uganda	PROPN
ajlm-1625	82	9	in	in	ADP
ajlm-1625	82	10	2010	2010	NUM
ajlm-1625	82	11	(	(	PUNCT
ajlm-1625	82	12	10.2	10.2	NUM
ajlm-1625	82	13	%	%	NOUN
ajlm-1625	82	14	)	)	PUNCT
ajlm-1625	82	15	,	,	PUNCT
ajlm-1625	82	16	mali	mali	VERB
ajlm-1625	82	17	in	in	ADP
ajlm-1625	82	18	2013	2013	NUM
ajlm-1625	82	19	(	(	PUNCT
ajlm-1625	82	20	10.3	10.3	NUM
ajlm-1625	82	21	%	%	NOUN
ajlm-1625	82	22	)	)	PUNCT
ajlm-1625	82	23	and	and	CCONJ
ajlm-1625	82	24	nigeria	nigeria	PROPN
ajlm-1625	82	25	in	in	ADP
ajlm-1625	82	26	2015	2015	NUM
ajlm-1625	82	27	(	(	PUNCT
ajlm-1625	82	28	9.3%).22,25,26,27,28	9.3%).22,25,26,27,28	NOUN
ajlm-1625	82	29	these	these	DET
ajlm-1625	82	30	results	result	NOUN
ajlm-1625	82	31	reflect	reflect	VERB
ajlm-1625	82	32	the	the	DET
ajlm-1625	82	33	poor	poor	ADJ
ajlm-1625	82	34	immunological	immunological	ADJ
ajlm-1625	82	35	safety	safety	NOUN
ajlm-1625	82	36	of	of	ADP
ajlm-1625	82	37	blood	blood	NOUN
ajlm-1625	82	38	transfusions	transfusion	NOUN
ajlm-1625	82	39	in	in	ADP
ajlm-1625	82	40	sub	sub	ADJ
ajlm-1625	82	41	-	-	ADJ
ajlm-1625	82	42	saharan	saharan	ADJ
ajlm-1625	82	43	africa	africa	PROPN
ajlm-1625	82	44	,	,	PUNCT
ajlm-1625	82	45	where	where	SCONJ
ajlm-1625	82	46	blood	blood	NOUN
ajlm-1625	82	47	transfusion	transfusion	NOUN
ajlm-1625	82	48	is	be	AUX
ajlm-1625	82	49	performed	perform	VERB
ajlm-1625	82	50	based	base	VERB
ajlm-1625	82	51	only	only	ADV
ajlm-1625	82	52	on	on	ADP
ajlm-1625	82	53	the	the	DET
ajlm-1625	82	54	blood	blood	NOUN
ajlm-1625	82	55	donor	donor	NOUN
ajlm-1625	82	56	and	and	CCONJ
ajlm-1625	82	57	recipient	recipient	NOUN
ajlm-1625	82	58	abo	abo	ADV
ajlm-1625	82	59	and	and	CCONJ
ajlm-1625	82	60	rhd	rhd	PROPN
ajlm-1625	82	61	antigens	antigen	NOUN
ajlm-1625	82	62	matching	match	VERB
ajlm-1625	82	63	.	.	PUNCT
ajlm-1625	83	1	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	83	2	rates	rate	NOUN
ajlm-1625	83	3	observed	observe	VERB
ajlm-1625	83	4	in	in	ADP
ajlm-1625	83	5	our	our	PRON
ajlm-1625	83	6	study	study	NOUN
ajlm-1625	83	7	and	and	CCONJ
ajlm-1625	83	8	other	other	ADJ
ajlm-1625	83	9	studies	study	NOUN
ajlm-1625	83	10	from	from	ADP
ajlm-1625	83	11	sub	sub	ADJ
ajlm-1625	83	12	-	-	ADJ
ajlm-1625	83	13	saharan	saharan	ADJ
ajlm-1625	83	14	africa	africa	PROPN
ajlm-1625	83	15	are	be	AUX
ajlm-1625	83	16	lower	low	ADJ
ajlm-1625	83	17	than	than	ADP
ajlm-1625	83	18	those	those	PRON
ajlm-1625	83	19	observed	observe	VERB
ajlm-1625	83	20	in	in	ADP
ajlm-1625	83	21	europe	europe	PROPN
ajlm-1625	83	22	and	and	CCONJ
ajlm-1625	83	23	north	north	PROPN
ajlm-1625	83	24	america	america	PROPN
ajlm-1625	83	25	when	when	SCONJ
ajlm-1625	83	26	they	they	PRON
ajlm-1625	83	27	only	only	ADV
ajlm-1625	83	28	screened	screen	VERB
ajlm-1625	83	29	for	for	ADP
ajlm-1625	83	30	abo	abo	NOUN
ajlm-1625	83	31	and	and	CCONJ
ajlm-1625	83	32	rhd	rhd	PROPN
ajlm-1625	83	33	.	.	PUNCT
ajlm-1625	84	1	prevalences	prevalence	NOUN
ajlm-1625	84	2	ranged	range	VERB
ajlm-1625	84	3	from	from	ADP
ajlm-1625	84	4	18	18	NUM
ajlm-1625	84	5	%	%	NOUN
ajlm-1625	84	6	to	to	PART
ajlm-1625	84	7	76	76	NUM
ajlm-1625	84	8	%	%	NOUN
ajlm-1625	84	9	in	in	ADP
ajlm-1625	84	10	the	the	DET
ajlm-1625	84	11	united	united	PROPN
ajlm-1625	84	12	kingdom	kingdom	PROPN
ajlm-1625	84	13	and	and	CCONJ
ajlm-1625	84	14	united	united	PROPN
ajlm-1625	84	15	states.29,30,31,32,33,34	states.29,30,31,32,33,34	PROPN
ajlm-1625	84	16	in	in	ADP
ajlm-1625	84	17	france	france	PROPN
ajlm-1625	84	18	,	,	PUNCT
ajlm-1625	84	19	the	the	DET
ajlm-1625	84	20	rate	rate	NOUN
ajlm-1625	84	21	was	be	AUX
ajlm-1625	84	22	about	about	ADV
ajlm-1625	84	23	30%.35,36	30%.35,36	NUM
ajlm-1625	84	24	despite	despite	SCONJ
ajlm-1625	84	25	the	the	DET
ajlm-1625	84	26	mandatory	mandatory	ADJ
ajlm-1625	84	27	donor	donor	NOUN
ajlm-1625	84	28	and	and	CCONJ
ajlm-1625	84	29	recipient	recipient	NOUN
ajlm-1625	84	30	rh	rh	PROPN
ajlm-1625	84	31	-	-	PUNCT
ajlm-1625	84	32	kell	kell	PROPN
ajlm-1625	84	33	antigens	antigen	NOUN
ajlm-1625	84	34	matching	match	VERB
ajlm-1625	84	35	before	before	ADP
ajlm-1625	84	36	transfusion	transfusion	NOUN
ajlm-1625	84	37	in	in	ADP
ajlm-1625	84	38	these	these	DET
ajlm-1625	84	39	developed	develop	VERB
ajlm-1625	84	40	countries	country	NOUN
ajlm-1625	84	41	,	,	PUNCT
ajlm-1625	84	42	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	84	43	rates	rate	NOUN
ajlm-1625	84	44	in	in	ADP
ajlm-1625	84	45	those	those	DET
ajlm-1625	84	46	settings	setting	NOUN
ajlm-1625	84	47	are	be	AUX
ajlm-1625	84	48	higher	high	ADJ
ajlm-1625	84	49	than	than	SCONJ
ajlm-1625	84	50	ours.34,37,38	ours.34,37,38	ADV
ajlm-1625	84	51	this	this	PRON
ajlm-1625	84	52	serves	serve	VERB
ajlm-1625	84	53	as	as	ADP
ajlm-1625	84	54	a	a	DET
ajlm-1625	84	55	reminder	reminder	NOUN
ajlm-1625	84	56	that	that	SCONJ
ajlm-1625	84	57	the	the	DET
ajlm-1625	84	58	risk	risk	NOUN
ajlm-1625	84	59	of	of	ADP
ajlm-1625	84	60	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	84	61	is	be	AUX
ajlm-1625	84	62	multiparametric	multiparametric	ADJ
ajlm-1625	84	63	,	,	PUNCT
ajlm-1625	84	64	depending	depend	VERB
ajlm-1625	84	65	on	on	ADP
ajlm-1625	84	66	the	the	DET
ajlm-1625	84	67	population	population	NOUN
ajlm-1625	84	68	’s	’s	PART
ajlm-1625	84	69	subgrouping	subgrouping	NOUN
ajlm-1625	84	70	or	or	CCONJ
ajlm-1625	84	71	prevalent	prevalent	ADJ
ajlm-1625	84	72	diseases.30,36	diseases.30,36	NOUN
ajlm-1625	84	73	also	also	ADV
ajlm-1625	84	74	,	,	PUNCT
ajlm-1625	84	75	high	high	ADJ
ajlm-1625	84	76	rates	rate	NOUN
ajlm-1625	84	77	of	of	ADP
ajlm-1625	84	78	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	84	79	could	could	AUX
ajlm-1625	84	80	be	be	AUX
ajlm-1625	84	81	due	due	ADJ
ajlm-1625	84	82	to	to	ADP
ajlm-1625	84	83	antigen	antigen	ADJ
ajlm-1625	84	84	discrepancies	discrepancy	NOUN
ajlm-1625	84	85	between	between	ADP
ajlm-1625	84	86	transfused	transfused	ADJ
ajlm-1625	84	87	rbc	rbc	PROPN
ajlm-1625	84	88	concentrates	concentrate	NOUN
ajlm-1625	84	89	collected	collect	VERB
ajlm-1625	84	90	from	from	ADP
ajlm-1625	84	91	donors	donor	NOUN
ajlm-1625	84	92	with	with	ADP
ajlm-1625	84	93	european	european	PROPN
ajlm-1625	84	94	ancestry	ancestry	PROPN
ajlm-1625	84	95	and	and	CCONJ
ajlm-1625	84	96	scd	scd	NOUN
ajlm-1625	84	97	recipients	recipient	NOUN
ajlm-1625	84	98	who	who	PRON
ajlm-1625	84	99	are	be	AUX
ajlm-1625	84	100	often	often	ADV
ajlm-1625	84	101	of	of	ADP
ajlm-1625	84	102	sub	sub	ADJ
ajlm-1625	84	103	-	-	ADJ
ajlm-1625	84	104	saharan	saharan	ADJ
ajlm-1625	84	105	african	african	PROPN
ajlm-1625	84	106	descent.36,37	descent.36,37	VERB
ajlm-1625	84	107	a	a	DET
ajlm-1625	84	108	similar	similar	ADJ
ajlm-1625	84	109	hypothesis	hypothesis	NOUN
ajlm-1625	84	110	was	be	AUX
ajlm-1625	84	111	assumed	assume	VERB
ajlm-1625	84	112	in	in	ADP
ajlm-1625	84	113	some	some	DET
ajlm-1625	84	114	other	other	ADJ
ajlm-1625	84	115	countries	country	NOUN
ajlm-1625	84	116	with	with	ADP
ajlm-1625	84	117	multi	multi	ADJ
ajlm-1625	84	118	-	-	ADJ
ajlm-1625	84	119	ethnic	ethnic	ADJ
ajlm-1625	84	120	groups	group	NOUN
ajlm-1625	84	121	,	,	PUNCT
ajlm-1625	84	122	such	such	ADJ
ajlm-1625	84	123	as	as	ADP
ajlm-1625	84	124	iran.39	iran.39	NOUN
ajlm-1625	84	125	in	in	ADP
ajlm-1625	84	126	burkina	burkina	PROPN
ajlm-1625	84	127	faso	faso	PROPN
ajlm-1625	84	128	,	,	PUNCT
ajlm-1625	84	129	blood	blood	NOUN
ajlm-1625	84	130	group	group	NOUN
ajlm-1625	84	131	antigen	antigen	ADJ
ajlm-1625	84	132	distribution	distribution	NOUN
ajlm-1625	84	133	is	be	AUX
ajlm-1625	84	134	established	establish	VERB
ajlm-1625	84	135	for	for	ADP
ajlm-1625	84	136	abo	abo	NOUN
ajlm-1625	84	137	and	and	CCONJ
ajlm-1625	84	138	rhd	rhd	PROPN
ajlm-1625	84	139	within	within	ADP
ajlm-1625	84	140	blood	blood	NOUN
ajlm-1625	84	141	donors	donor	NOUN
ajlm-1625	84	142	and	and	CCONJ
ajlm-1625	84	143	patients.40,41	patients.40,41	NOUN
ajlm-1625	84	144	there	there	PRON
ajlm-1625	84	145	is	be	VERB
ajlm-1625	84	146	no	no	DET
ajlm-1625	84	147	data	datum	NOUN
ajlm-1625	84	148	about	about	ADP
ajlm-1625	84	149	rh	rh	PROPN
ajlm-1625	84	150	subgroups	subgroup	NOUN
ajlm-1625	84	151	or	or	CCONJ
ajlm-1625	84	152	other	other	ADJ
ajlm-1625	84	153	important	important	ADJ
ajlm-1625	84	154	rbc	rbc	PROPN
ajlm-1625	84	155	antigens	antigen	NOUN
ajlm-1625	84	156	.	.	PUNCT
ajlm-1625	85	1	it	it	PRON
ajlm-1625	85	2	is	be	AUX
ajlm-1625	85	3	known	know	VERB
ajlm-1625	85	4	that	that	SCONJ
ajlm-1625	85	5	significant	significant	ADJ
ajlm-1625	85	6	differences	difference	NOUN
ajlm-1625	85	7	in	in	ADP
ajlm-1625	85	8	the	the	DET
ajlm-1625	85	9	distribution	distribution	NOUN
ajlm-1625	85	10	of	of	ADP
ajlm-1625	85	11	blood	blood	NOUN
ajlm-1625	85	12	group	group	NOUN
ajlm-1625	85	13	antigens	antigen	NOUN
ajlm-1625	85	14	within	within	ADP
ajlm-1625	85	15	the	the	DET
ajlm-1625	85	16	country	country	NOUN
ajlm-1625	85	17	’s	’s	PART
ajlm-1625	85	18	natural	natural	ADJ
ajlm-1625	85	19	ethnic	ethnic	ADJ
ajlm-1625	85	20	groups	group	NOUN
ajlm-1625	85	21	could	could	AUX
ajlm-1625	85	22	exist	exist	VERB
ajlm-1625	85	23	.	.	PUNCT
ajlm-1625	86	1	sawadogo	sawadogo	PROPN
ajlm-1625	86	2	et	et	PROPN
ajlm-1625	86	3	al	al	PROPN
ajlm-1625	86	4	.	.	PROPN
ajlm-1625	86	5	found	find	VERB
ajlm-1625	86	6	that	that	SCONJ
ajlm-1625	86	7	the	the	DET
ajlm-1625	86	8	phenotype	phenotype	NOUN
ajlm-1625	86	9	o	o	NOUN
ajlm-1625	86	10	was	be	AUX
ajlm-1625	86	11	more	more	ADV
ajlm-1625	86	12	frequent	frequent	ADJ
ajlm-1625	86	13	in	in	ADP
ajlm-1625	86	14	the	the	DET
ajlm-1625	86	15	central	central	ADJ
ajlm-1625	86	16	-	-	PUNCT
ajlm-1625	86	17	west	west	NOUN
ajlm-1625	86	18	,	,	PUNCT
ajlm-1625	86	19	central	central	ADJ
ajlm-1625	86	20	and	and	CCONJ
ajlm-1625	86	21	east	east	ADJ
ajlm-1625	86	22	regions	region	NOUN
ajlm-1625	86	23	corresponding	correspond	VERB
ajlm-1625	86	24	to	to	ADP
ajlm-1625	86	25	‘	'	PUNCT
ajlm-1625	86	26	mossi	mossi	NOUN
ajlm-1625	86	27	’	'	PUNCT
ajlm-1625	86	28	,	,	PUNCT
ajlm-1625	86	29	‘	'	PUNCT
ajlm-1625	86	30	gourounsi	gourounsi	NOUN
ajlm-1625	86	31	’	'	PUNCT
ajlm-1625	86	32	,	,	PUNCT
ajlm-1625	86	33	and	and	CCONJ
ajlm-1625	86	34	‘	'	PUNCT
ajlm-1625	86	35	gourmantché	gourmantché	NOUN
ajlm-1625	86	36	’	'	PUNCT
ajlm-1625	86	37	areas	area	NOUN
ajlm-1625	86	38	,	,	PUNCT
ajlm-1625	86	39	whereas	whereas	SCONJ
ajlm-1625	86	40	the	the	DET
ajlm-1625	86	41	phenotype	phenotype	NOUN
ajlm-1625	86	42	a	a	PRON
ajlm-1625	86	43	and	and	CCONJ
ajlm-1625	86	44	ab	ab	PROPN
ajlm-1625	86	45	were	be	AUX
ajlm-1625	86	46	more	more	ADV
ajlm-1625	86	47	prevalent	prevalent	ADJ
ajlm-1625	86	48	in	in	ADP
ajlm-1625	86	49	‘	'	PUNCT
ajlm-1625	86	50	boucle	boucle	PROPN
ajlm-1625	86	51	du	du	PROPN
ajlm-1625	86	52	mouhoun	mouhoun	PROPN
ajlm-1625	86	53	’	'	PUNCT
ajlm-1625	86	54	and	and	CCONJ
ajlm-1625	86	55	‘	'	PUNCT
ajlm-1625	86	56	hauts	haut	NOUN
ajlm-1625	86	57	-	-	PUNCT
ajlm-1625	86	58	bassins	bassin	NOUN
ajlm-1625	86	59	’	'	PUNCT
ajlm-1625	86	60	regions	region	NOUN
ajlm-1625	86	61	and	and	CCONJ
ajlm-1625	86	62	the	the	DET
ajlm-1625	86	63	‘	'	PUNCT
ajlm-1625	86	64	bwaba	bwaba	NOUN
ajlm-1625	86	65	’	'	PUNCT
ajlm-1625	86	66	and	and	CCONJ
ajlm-1625	86	67	‘	'	PUNCT
ajlm-1625	86	68	bobo	bobo	ADJ
ajlm-1625	86	69	’	'	PUNCT
ajlm-1625	86	70	areas	area	NOUN
ajlm-1625	86	71	.	.	PUNCT
ajlm-1625	87	1	the	the	DET
ajlm-1625	87	2	phenotype	phenotype	NOUN
ajlm-1625	87	3	o	o	NOUN
ajlm-1625	87	4	negative	negative	ADJ
ajlm-1625	87	5	was	be	AUX
ajlm-1625	87	6	infrequent	infrequent	ADJ
ajlm-1625	87	7	in	in	ADP
ajlm-1625	87	8	‘	'	PUNCT
ajlm-1625	87	9	bwaba’.40	bwaba’.40	PROPN
ajlm-1625	87	10	these	these	DET
ajlm-1625	87	11	studies	study	NOUN
ajlm-1625	87	12	suggest	suggest	VERB
ajlm-1625	87	13	that	that	SCONJ
ajlm-1625	87	14	in	in	ADP
ajlm-1625	87	15	burkina	burkina	PROPN
ajlm-1625	87	16	faso	faso	PROPN
ajlm-1625	87	17	,	,	PUNCT
ajlm-1625	87	18	with	with	ADP
ajlm-1625	87	19	more	more	ADJ
ajlm-1625	87	20	than	than	ADP
ajlm-1625	87	21	50	50	NUM
ajlm-1625	87	22	ethnic	ethnic	ADJ
ajlm-1625	87	23	groups	group	NOUN
ajlm-1625	87	24	,	,	PUNCT
ajlm-1625	87	25	dominant	dominant	ADJ
ajlm-1625	87	26	blood	blood	NOUN
ajlm-1625	87	27	groups	group	NOUN
ajlm-1625	87	28	vary	vary	VERB
ajlm-1625	87	29	between	between	ADP
ajlm-1625	87	30	or	or	CCONJ
ajlm-1625	87	31	are	be	AUX
ajlm-1625	87	32	specific	specific	ADJ
ajlm-1625	87	33	to	to	ADP
ajlm-1625	87	34	particular	particular	ADJ
ajlm-1625	87	35	ethnic	ethnic	ADJ
ajlm-1625	87	36	groups	group	NOUN
ajlm-1625	87	37	.	.	PUNCT
ajlm-1625	88	1	thus	thus	ADV
ajlm-1625	88	2	,	,	PUNCT
ajlm-1625	88	3	new	new	ADJ
ajlm-1625	88	4	studies	study	NOUN
ajlm-1625	88	5	should	should	AUX
ajlm-1625	88	6	be	be	AUX
ajlm-1625	88	7	conducted	conduct	VERB
ajlm-1625	88	8	to	to	PART
ajlm-1625	88	9	establish	establish	VERB
ajlm-1625	88	10	blood	blood	NOUN
ajlm-1625	88	11	subgroup	subgroup	NOUN
ajlm-1625	88	12	frequencies	frequency	NOUN
ajlm-1625	88	13	and	and	CCONJ
ajlm-1625	88	14	rbc	rbc	PROPN
ajlm-1625	88	15	matching	matching	NOUN
ajlm-1625	88	16	strategies	strategy	NOUN
ajlm-1625	88	17	in	in	ADP
ajlm-1625	88	18	the	the	DET
ajlm-1625	88	19	country	country	NOUN
ajlm-1625	88	20	.	.	PUNCT
ajlm-1625	89	1	in	in	ADP
ajlm-1625	89	2	our	our	PRON
ajlm-1625	89	3	study	study	NOUN
ajlm-1625	89	4	,	,	PUNCT
ajlm-1625	89	5	the	the	DET
ajlm-1625	89	6	antibody	antibody	NOUN
ajlm-1625	89	7	specificity	specificity	NOUN
ajlm-1625	89	8	of	of	ADP
ajlm-1625	89	9	four	four	NUM
ajlm-1625	89	10	participants	participant	NOUN
ajlm-1625	89	11	of	of	ADP
ajlm-1625	89	12	14	14	NUM
ajlm-1625	89	13	(	(	PUNCT
ajlm-1625	89	14	28.6	28.6	NUM
ajlm-1625	89	15	%	%	NOUN
ajlm-1625	89	16	)	)	PUNCT
ajlm-1625	89	17	was	be	AUX
ajlm-1625	89	18	indeterminate	indeterminate	ADJ
ajlm-1625	89	19	.	.	PUNCT
ajlm-1625	90	1	this	this	DET
ajlm-1625	90	2	impairment	impairment	NOUN
ajlm-1625	90	3	could	could	AUX
ajlm-1625	90	4	be	be	AUX
ajlm-1625	90	5	due	due	ADJ
ajlm-1625	90	6	to	to	ADP
ajlm-1625	90	7	the	the	DET
ajlm-1625	90	8	discrepancy	discrepancy	NOUN
ajlm-1625	90	9	between	between	ADP
ajlm-1625	90	10	the	the	DET
ajlm-1625	90	11	european	european	ADJ
ajlm-1625	90	12	-	-	PUNCT
ajlm-1625	90	13	sourced	source	VERB
ajlm-1625	90	14	red	red	ADJ
ajlm-1625	90	15	cell	cell	NOUN
ajlm-1625	90	16	reagent	reagent	ADJ
ajlm-1625	90	17	panel	panel	NOUN
ajlm-1625	90	18	and	and	CCONJ
ajlm-1625	90	19	our	our	PRON
ajlm-1625	90	20	population	population	NOUN
ajlm-1625	90	21	.	.	PUNCT
ajlm-1625	91	1	this	this	DET
ajlm-1625	91	2	situation	situation	NOUN
ajlm-1625	91	3	highlights	highlight	VERB
ajlm-1625	91	4	the	the	DET
ajlm-1625	91	5	need	need	NOUN
ajlm-1625	91	6	to	to	PART
ajlm-1625	91	7	implement	implement	VERB
ajlm-1625	91	8	local	local	ADJ
ajlm-1625	91	9	panels	panel	NOUN
ajlm-1625	91	10	for	for	ADP
ajlm-1625	91	11	rbc	rbc	PROPN
ajlm-1625	91	12	alloantibodies	alloantibody	NOUN
ajlm-1625	91	13	testing	testing	NOUN
ajlm-1625	91	14	as	as	ADP
ajlm-1625	91	15	with	with	ADP
ajlm-1625	91	16	some	some	DET
ajlm-1625	91	17	other	other	ADJ
ajlm-1625	91	18	lowand	lowand	ADJ
ajlm-1625	91	19	middle	middle	ADJ
ajlm-1625	91	20	-	-	PUNCT
ajlm-1625	91	21	income	income	NOUN
ajlm-1625	91	22	countries.42,43,44	countries.42,43,44	PUNCT
ajlm-1625	91	23	furthermore	furthermore	ADV
ajlm-1625	91	24	,	,	PUNCT
ajlm-1625	91	25	boateng	boateng	PROPN
ajlm-1625	91	26	et	et	PROPN
ajlm-1625	91	27	al	al	PROPN
ajlm-1625	91	28	.	.	PROPN
ajlm-1625	92	1	claim	claim	VERB
ajlm-1625	92	2	that	that	SCONJ
ajlm-1625	92	3	creating	create	VERB
ajlm-1625	92	4	and	and	CCONJ
ajlm-1625	92	5	maintaining	maintain	VERB
ajlm-1625	92	6	a	a	DET
ajlm-1625	92	7	database	database	NOUN
ajlm-1625	92	8	of	of	ADP
ajlm-1625	92	9	phenotyped	phenotype	VERB
ajlm-1625	92	10	blood	blood	NOUN
ajlm-1625	92	11	donors	donor	NOUN
ajlm-1625	92	12	will	will	AUX
ajlm-1625	92	13	facilitate	facilitate	VERB
ajlm-1625	92	14	the	the	DET
ajlm-1625	92	15	selection	selection	NOUN
ajlm-1625	92	16	of	of	ADP
ajlm-1625	92	17	matched	match	VERB
ajlm-1625	92	18	blood	blood	NOUN
ajlm-1625	92	19	components	component	NOUN
ajlm-1625	92	20	for	for	ADP
ajlm-1625	92	21	emergency	emergency	NOUN
ajlm-1625	92	22	transfusions	transfusion	NOUN
ajlm-1625	92	23	as	as	SCONJ
ajlm-1625	92	24	seen	see	VERB
ajlm-1625	92	25	in	in	ADP
ajlm-1625	92	26	sub	sub	ADJ
ajlm-1625	92	27	-	-	ADJ
ajlm-1625	92	28	saharan	saharan	ADJ
ajlm-1625	92	29	africa	africa	PROPN
ajlm-1625	92	30	and	and	CCONJ
ajlm-1625	92	31	help	help	AUX
ajlm-1625	92	32	locally	locally	ADV
ajlm-1625	92	33	manufacture	manufacture	VERB
ajlm-1625	92	34	rbc	rbc	PROPN
ajlm-1625	92	35	reagents	reagent	NOUN
ajlm-1625	92	36	.	.	PUNCT
ajlm-1625	93	1	thus	thus	ADV
ajlm-1625	93	2	,	,	PUNCT
ajlm-1625	93	3	rbc	rbc	PROPN
ajlm-1625	93	4	alloantibodies	alloantibody	NOUN
ajlm-1625	93	5	screening	screen	VERB
ajlm-1625	93	6	may	may	AUX
ajlm-1625	93	7	become	become	VERB
ajlm-1625	93	8	more	more	ADV
ajlm-1625	93	9	economical	economical	ADJ
ajlm-1625	93	10	and	and	CCONJ
ajlm-1625	93	11	sustainable	sustainable	ADJ
ajlm-1625	93	12	for	for	ADP
ajlm-1625	93	13	multi	multi	ADJ
ajlm-1625	93	14	-	-	ADJ
ajlm-1625	93	15	transfused	transfused	ADJ
ajlm-1625	93	16	patients	patient	NOUN
ajlm-1625	93	17	,	,	PUNCT
ajlm-1625	93	18	particularly	particularly	ADV
ajlm-1625	93	19	patients	patient	NOUN
ajlm-1625	93	20	with	with	ADP
ajlm-1625	93	21	scd	scd	PROPN
ajlm-1625	93	22	in	in	ADP
ajlm-1625	93	23	this	this	DET
ajlm-1625	93	24	zone.22	zone.22	NOUN
ajlm-1625	93	25	the	the	DET
ajlm-1625	93	26	majority	majority	NOUN
ajlm-1625	93	27	(	(	PUNCT
ajlm-1625	93	28	85.7	85.7	NUM
ajlm-1625	93	29	%	%	NOUN
ajlm-1625	93	30	)	)	PUNCT
ajlm-1625	93	31	of	of	ADP
ajlm-1625	93	32	the	the	DET
ajlm-1625	93	33	alloantibodies	alloantibody	NOUN
ajlm-1625	93	34	found	find	VERB
ajlm-1625	93	35	in	in	ADP
ajlm-1625	93	36	this	this	DET
ajlm-1625	93	37	study	study	NOUN
ajlm-1625	93	38	were	be	AUX
ajlm-1625	93	39	anti	anti	ADJ
ajlm-1625	93	40	-	-	ADJ
ajlm-1625	93	41	rh	rh	ADJ
ajlm-1625	93	42	group	group	NOUN
ajlm-1625	93	43	antigens	antigen	NOUN
ajlm-1625	93	44	.	.	PUNCT
ajlm-1625	94	1	anti	anti	ADJ
ajlm-1625	94	2	-	-	ADJ
ajlm-1625	94	3	d	d	ADJ
ajlm-1625	94	4	and	and	CCONJ
ajlm-1625	94	5	anti	anti	ADJ
ajlm-1625	94	6	-	-	ADJ
ajlm-1625	94	7	c	c	ADJ
ajlm-1625	94	8	antibodies	antibody	NOUN
ajlm-1625	94	9	accounted	account	VERB
ajlm-1625	94	10	for	for	ADP
ajlm-1625	94	11	35.7	35.7	NUM
ajlm-1625	94	12	%	%	NOUN
ajlm-1625	94	13	,	,	PUNCT
ajlm-1625	94	14	followed	follow	VERB
ajlm-1625	94	15	by	by	ADP
ajlm-1625	94	16	anti	anti	ADJ
ajlm-1625	94	17	-	-	ADJ
ajlm-1625	94	18	e	e	ADJ
ajlm-1625	94	19	and	and	CCONJ
ajlm-1625	94	20	anti	anti	ADJ
ajlm-1625	94	21	-	-	NOUN
ajlm-1625	94	22	cw	cw	NOUN
ajlm-1625	94	23	.	.	NOUN
ajlm-1625	95	1	in	in	ADP
ajlm-1625	95	2	a	a	DET
ajlm-1625	95	3	previous	previous	ADJ
ajlm-1625	95	4	study	study	NOUN
ajlm-1625	95	5	of	of	ADP
ajlm-1625	95	6	children	child	NOUN
ajlm-1625	95	7	who	who	PRON
ajlm-1625	95	8	received	receive	VERB
ajlm-1625	95	9	transfusions	transfusion	NOUN
ajlm-1625	95	10	in	in	ADP
ajlm-1625	95	11	burkina	burkina	PROPN
ajlm-1625	95	12	faso	faso	PROPN
ajlm-1625	95	13	,	,	PUNCT
ajlm-1625	95	14	anti	anti	ADJ
ajlm-1625	95	15	-	-	ADJ
ajlm-1625	95	16	c	c	NOUN
ajlm-1625	95	17	and	and	CCONJ
ajlm-1625	95	18	anti	anti	ADJ
ajlm-1625	95	19	-	-	ADJ
ajlm-1625	95	20	e	e	NOUN
ajlm-1625	95	21	were	be	AUX
ajlm-1625	95	22	the	the	DET
ajlm-1625	95	23	most	most	ADJ
ajlm-1625	95	24	frequent.24	frequent.24	NOUN
ajlm-1625	95	25	in	in	ADP
ajlm-1625	95	26	our	our	PRON
ajlm-1625	95	27	study	study	NOUN
ajlm-1625	95	28	,	,	PUNCT
ajlm-1625	95	29	the	the	DET
ajlm-1625	95	30	two	two	NUM
ajlm-1625	95	31	mainly	mainly	ADV
ajlm-1625	95	32	represented	represent	VERB
ajlm-1625	95	33	antibodies	antibody	NOUN
ajlm-1625	95	34	were	be	AUX
ajlm-1625	95	35	co	co	VERB
ajlm-1625	95	36	-	-	VERB
ajlm-1625	95	37	associated	associated	ADJ
ajlm-1625	95	38	(	(	PUNCT
ajlm-1625	95	39	anti	anti	ADJ
ajlm-1625	95	40	-	-	ADJ
ajlm-1625	95	41	d+c	d+c	ADJ
ajlm-1625	95	42	)	)	PUNCT
ajlm-1625	95	43	in	in	ADP
ajlm-1625	95	44	4	4	NUM
ajlm-1625	95	45	of	of	ADP
ajlm-1625	95	46	14	14	NUM
ajlm-1625	95	47	patients	patient	NOUN
ajlm-1625	95	48	.	.	PUNCT
ajlm-1625	96	1	the	the	DET
ajlm-1625	96	2	predominance	predominance	NOUN
ajlm-1625	96	3	of	of	ADP
ajlm-1625	96	4	rh	rh	PROPN
ajlm-1625	96	5	group	group	PROPN
ajlm-1625	96	6	antibodies	antibodie	VERB
ajlm-1625	96	7	was	be	AUX
ajlm-1625	96	8	also	also	ADV
ajlm-1625	96	9	reported	report	VERB
ajlm-1625	96	10	in	in	ADP
ajlm-1625	96	11	some	some	DET
ajlm-1625	96	12	other	other	ADJ
ajlm-1625	96	13	west	west	ADJ
ajlm-1625	96	14	african	african	ADJ
ajlm-1625	96	15	countries	country	NOUN
ajlm-1625	96	16	,	,	PUNCT
ajlm-1625	96	17	as	as	ADV
ajlm-1625	96	18	well	well	ADV
ajlm-1625	96	19	as	as	ADP
ajlm-1625	96	20	in	in	ADP
ajlm-1625	96	21	côte	côte	NOUN
ajlm-1625	96	22	d’ivoire,45	d’ivoire,45	PROPN
ajlm-1625	96	23	mali,26	mali,26	NOUN
ajlm-1625	96	24	senegal46	senegal46	NOUN
ajlm-1625	96	25	and	and	CCONJ
ajlm-1625	96	26	nigeria,27,47	nigeria,27,47	NOUN
ajlm-1625	96	27	but	but	CCONJ
ajlm-1625	96	28	in	in	ADP
ajlm-1625	96	29	these	these	DET
ajlm-1625	96	30	studies	study	NOUN
ajlm-1625	96	31	,	,	PUNCT
ajlm-1625	96	32	anti	anti	ADJ
ajlm-1625	96	33	-	-	ADJ
ajlm-1625	96	34	e	e	NOUN
ajlm-1625	96	35	was	be	AUX
ajlm-1625	96	36	the	the	DET
ajlm-1625	96	37	most	most	ADV
ajlm-1625	96	38	often	often	ADV
ajlm-1625	96	39	encountered	encounter	VERB
ajlm-1625	96	40	when	when	SCONJ
ajlm-1625	96	41	compared	compare	VERB
ajlm-1625	96	42	to	to	ADP
ajlm-1625	96	43	anti	anti	ADJ
ajlm-1625	96	44	-	-	ADJ
ajlm-1625	96	45	d	d	ADJ
ajlm-1625	96	46	and	and	CCONJ
ajlm-1625	96	47	anti	anti	ADJ
ajlm-1625	96	48	-	-	NOUN
ajlm-1625	96	49	c.	c.	NOUN
ajlm-1625	96	50	surprisingly	surprisingly	ADV
ajlm-1625	96	51	,	,	PUNCT
ajlm-1625	96	52	we	we	PRON
ajlm-1625	96	53	found	find	VERB
ajlm-1625	96	54	rh	rh	PROPN
ajlm-1625	96	55	anti	anti	ADJ
ajlm-1625	96	56	-	-	ADJ
ajlm-1625	96	57	d	d	ADJ
ajlm-1625	96	58	antibodies	antibody	NOUN
ajlm-1625	96	59	,	,	PUNCT
ajlm-1625	96	60	which	which	PRON
ajlm-1625	96	61	could	could	AUX
ajlm-1625	96	62	be	be	AUX
ajlm-1625	96	63	due	due	ADJ
ajlm-1625	96	64	to	to	ADP
ajlm-1625	96	65	errors	error	NOUN
ajlm-1625	96	66	occurring	occur	VERB
ajlm-1625	96	67	during	during	ADP
ajlm-1625	96	68	patients	patient	NOUN
ajlm-1625	96	69	’	'	PUNCT
ajlm-1625	96	70	blood	blood	NOUN
ajlm-1625	96	71	typing	typing	NOUN
ajlm-1625	96	72	.	.	PUNCT
ajlm-1625	97	1	our	our	PRON
ajlm-1625	97	2	hospital	hospital	NOUN
ajlm-1625	97	3	has	have	AUX
ajlm-1625	97	4	reported	report	VERB
ajlm-1625	97	5	as	as	ADV
ajlm-1625	97	6	many	many	ADJ
ajlm-1625	97	7	as	as	ADP
ajlm-1625	97	8	46	46	NUM
ajlm-1625	97	9	blood	blood	NOUN
ajlm-1625	97	10	typing	type	VERB
ajlm-1625	97	11	errors	error	NOUN
ajlm-1625	97	12	yearly	yearly	ADV
ajlm-1625	97	13	(	(	PUNCT
ajlm-1625	97	14	unpublished	unpublished	ADJ
ajlm-1625	97	15	data	datum	NOUN
ajlm-1625	97	16	)	)	PUNCT
ajlm-1625	97	17	.	.	PUNCT
ajlm-1625	98	1	another	another	DET
ajlm-1625	98	2	hypothesis	hypothesis	NOUN
ajlm-1625	98	3	is	be	AUX
ajlm-1625	98	4	that	that	SCONJ
ajlm-1625	98	5	partial	partial	ADJ
ajlm-1625	98	6	rhd	rhd	PROPN
ajlm-1625	98	7	antigen	antigen	PROPN
ajlm-1625	98	8	carriage	carriage	NOUN
ajlm-1625	98	9	is	be	AUX
ajlm-1625	98	10	frequent	frequent	ADJ
ajlm-1625	98	11	in	in	ADP
ajlm-1625	98	12	individuals	individual	NOUN
ajlm-1625	98	13	with	with	ADP
ajlm-1625	98	14	african	african	ADJ
ajlm-1625	98	15	ancestry	ancestry	NOUN
ajlm-1625	98	16	.	.	PUNCT
ajlm-1625	99	1	in	in	ADP
ajlm-1625	99	2	this	this	DET
ajlm-1625	99	3	case	case	NOUN
ajlm-1625	99	4	,	,	PUNCT
ajlm-1625	99	5	an	an	DET
ajlm-1625	99	6	rhd	rhd	PROPN
ajlm-1625	99	7	-	-	PUNCT
ajlm-1625	99	8	positive	positive	ADJ
ajlm-1625	99	9	patient	patient	NOUN
ajlm-1625	99	10	can	can	AUX
ajlm-1625	99	11	develop	develop	VERB
ajlm-1625	99	12	alloantibodies	alloantibody	NOUN
ajlm-1625	99	13	after	after	ADP
ajlm-1625	99	14	receiving	receive	VERB
ajlm-1625	99	15	rhd	rhd	PROPN
ajlm-1625	99	16	-	-	PUNCT
ajlm-1625	99	17	positive	positive	ADJ
ajlm-1625	99	18	rbc	rbc	PROPN
ajlm-1625	99	19	,	,	PUNCT
ajlm-1625	99	20	as	as	SCONJ
ajlm-1625	99	21	reported	report	VERB
ajlm-1625	99	22	by	by	ADP
ajlm-1625	99	23	chou	chou	PROPN
ajlm-1625	99	24	et	et	PROPN
ajlm-1625	99	25	al.30,48	al.30,48	PROPN
ajlm-1625	99	26	the	the	DET
ajlm-1625	99	27	same	same	ADJ
ajlm-1625	99	28	hypothesis	hypothesis	NOUN
ajlm-1625	99	29	applies	apply	VERB
ajlm-1625	99	30	to	to	ADP
ajlm-1625	99	31	partial	partial	ADJ
ajlm-1625	99	32	c	c	NOUN
ajlm-1625	99	33	carriers.49	carriers.49	NOUN
ajlm-1625	100	1	this	this	DET
ajlm-1625	100	2	study	study	NOUN
ajlm-1625	100	3	tried	try	VERB
ajlm-1625	100	4	to	to	PART
ajlm-1625	100	5	identify	identify	VERB
ajlm-1625	100	6	the	the	DET
ajlm-1625	100	7	risk	risk	NOUN
ajlm-1625	100	8	factors	factor	NOUN
ajlm-1625	100	9	associated	associate	VERB
ajlm-1625	100	10	with	with	ADP
ajlm-1625	100	11	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	100	12	.	.	PUNCT
ajlm-1625	101	1	neither	neither	PRON
ajlm-1625	101	2	gender	gender	NOUN
ajlm-1625	101	3	,	,	PUNCT
ajlm-1625	101	4	age	age	NOUN
ajlm-1625	101	5	,	,	PUNCT
ajlm-1625	101	6	nor	nor	CCONJ
ajlm-1625	101	7	the	the	DET
ajlm-1625	101	8	number	number	NOUN
ajlm-1625	101	9	of	of	ADP
ajlm-1625	101	10	blood	blood	NOUN
ajlm-1625	101	11	units	unit	NOUN
ajlm-1625	101	12	received	receive	VERB
ajlm-1625	101	13	was	be	AUX
ajlm-1625	101	14	associated	associate	VERB
ajlm-1625	101	15	with	with	ADP
ajlm-1625	101	16	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	101	17	in	in	ADP
ajlm-1625	101	18	our	our	PRON
ajlm-1625	101	19	study	study	NOUN
ajlm-1625	101	20	.	.	PUNCT
ajlm-1625	102	1	however	however	ADV
ajlm-1625	102	2	,	,	PUNCT
ajlm-1625	102	3	ifeoma	ifeoma	PROPN
ajlm-1625	102	4	et	et	NOUN
ajlm-1625	102	5	al.47	al.47	PROPN
ajlm-1625	102	6	in	in	ADP
ajlm-1625	102	7	nigeria	nigeria	PROPN
ajlm-1625	102	8	,	,	PUNCT
ajlm-1625	102	9	senghor	senghor	PROPN
ajlm-1625	102	10	et	et	PROPN
ajlm-1625	102	11	al.46	al.46	NOUN
ajlm-1625	102	12	in	in	ADP
ajlm-1625	102	13	senegal	senegal	PROPN
ajlm-1625	102	14	and	and	CCONJ
ajlm-1625	102	15	natukunda	natukunda	PROPN
ajlm-1625	102	16	et	et	PROPN
ajlm-1625	102	17	al.50	al.50	PROPN
ajlm-1625	102	18	in	in	ADP
ajlm-1625	102	19	uganda	uganda	PROPN
ajlm-1625	102	20	have	have	AUX
ajlm-1625	102	21	associated	associate	VERB
ajlm-1625	102	22	these	these	DET
ajlm-1625	102	23	factors	factor	NOUN
ajlm-1625	102	24	with	with	ADP
ajlm-1625	102	25	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	102	26	;	;	PUNCT
ajlm-1625	102	27	the	the	DET
ajlm-1625	102	28	small	small	ADJ
ajlm-1625	102	29	size	size	NOUN
ajlm-1625	102	30	of	of	ADP
ajlm-1625	102	31	our	our	PRON
ajlm-1625	102	32	sample	sample	NOUN
ajlm-1625	102	33	might	might	AUX
ajlm-1625	102	34	have	have	AUX
ajlm-1625	102	35	prevented	prevent	VERB
ajlm-1625	102	36	the	the	DET
ajlm-1625	102	37	observation	observation	NOUN
ajlm-1625	102	38	of	of	ADP
ajlm-1625	102	39	such	such	ADJ
ajlm-1625	102	40	associations	association	NOUN
ajlm-1625	102	41	.	.	PUNCT
ajlm-1625	103	1	limitations	limitation	NOUN
ajlm-1625	103	2	one	one	NUM
ajlm-1625	103	3	limitation	limitation	NOUN
ajlm-1625	103	4	of	of	ADP
ajlm-1625	103	5	this	this	DET
ajlm-1625	103	6	study	study	NOUN
ajlm-1625	103	7	was	be	AUX
ajlm-1625	103	8	that	that	SCONJ
ajlm-1625	103	9	we	we	PRON
ajlm-1625	103	10	could	could	AUX
ajlm-1625	103	11	not	not	PART
ajlm-1625	103	12	screen	screen	VERB
ajlm-1625	103	13	for	for	ADP
ajlm-1625	103	14	antibodies	antibody	NOUN
ajlm-1625	103	15	within	within	ADP
ajlm-1625	103	16	a	a	DET
ajlm-1625	103	17	reasonable	reasonable	ADJ
ajlm-1625	103	18	time	time	NOUN
ajlm-1625	103	19	after	after	ADP
ajlm-1625	103	20	each	each	DET
ajlm-1625	103	21	transfusion	transfusion	NOUN
ajlm-1625	103	22	.	.	PUNCT
ajlm-1625	104	1	for	for	ADP
ajlm-1625	104	2	many	many	ADJ
ajlm-1625	104	3	patients	patient	NOUN
ajlm-1625	104	4	,	,	PUNCT
ajlm-1625	104	5	screening	screen	VERB
ajlm-1625	104	6	occurred	occur	VERB
ajlm-1625	104	7	months	month	NOUN
ajlm-1625	104	8	or	or	CCONJ
ajlm-1625	104	9	years	year	NOUN
ajlm-1625	104	10	after	after	ADP
ajlm-1625	104	11	the	the	DET
ajlm-1625	104	12	last	last	ADJ
ajlm-1625	104	13	transfusion	transfusion	NOUN
ajlm-1625	104	14	event	event	NOUN
ajlm-1625	104	15	.	.	PUNCT
ajlm-1625	105	1	this	this	DET
ajlm-1625	105	2	delay	delay	NOUN
ajlm-1625	105	3	may	may	AUX
ajlm-1625	105	4	have	have	AUX
ajlm-1625	105	5	impacted	impact	VERB
ajlm-1625	105	6	the	the	DET
ajlm-1625	105	7	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	105	8	rate	rate	NOUN
ajlm-1625	105	9	.	.	PUNCT
ajlm-1625	106	1	conclusion	conclusion	NOUN
ajlm-1625	106	2	this	this	DET
ajlm-1625	106	3	study	study	NOUN
ajlm-1625	106	4	showed	show	VERB
ajlm-1625	106	5	that	that	SCONJ
ajlm-1625	106	6	rbc	rbc	PROPN
ajlm-1625	106	7	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	106	8	is	be	AUX
ajlm-1625	106	9	a	a	DET
ajlm-1625	106	10	reality	reality	NOUN
ajlm-1625	106	11	in	in	ADP
ajlm-1625	106	12	multi	multi	ADJ
ajlm-1625	106	13	-	-	ADJ
ajlm-1625	106	14	transfused	transfused	ADJ
ajlm-1625	106	15	patients	patient	NOUN
ajlm-1625	106	16	in	in	ADP
ajlm-1625	106	17	burkina	burkina	PROPN
ajlm-1625	106	18	faso	faso	PROPN
ajlm-1625	106	19	.	.	PUNCT
ajlm-1625	107	1	therefore	therefore	ADV
ajlm-1625	107	2	,	,	PUNCT
ajlm-1625	107	3	exhaustive	exhaustive	ADJ
ajlm-1625	107	4	donor	donor	NOUN
ajlm-1625	107	5	-	-	PUNCT
ajlm-1625	107	6	patient	patient	NOUN
ajlm-1625	107	7	blood	blood	NOUN
ajlm-1625	107	8	matching	match	VERB
ajlm-1625	107	9	beyond	beyond	ADP
ajlm-1625	107	10	abo	abo	NOUN
ajlm-1625	107	11	and	and	CCONJ
ajlm-1625	107	12	rhd	rhd	PROPN
ajlm-1625	107	13	is	be	AUX
ajlm-1625	107	14	necessary	necessary	ADJ
ajlm-1625	107	15	for	for	ADP
ajlm-1625	107	16	lifelong	lifelong	ADJ
ajlm-1625	107	17	transfused	transfused	ADJ
ajlm-1625	107	18	patients	patient	NOUN
ajlm-1625	107	19	,	,	PUNCT
ajlm-1625	107	20	such	such	ADJ
ajlm-1625	107	21	as	as	ADP
ajlm-1625	107	22	crf	crf	PROPN
ajlm-1625	107	23	and	and	CCONJ
ajlm-1625	107	24	scd	scd	NOUN
ajlm-1625	107	25	patients	patient	NOUN
ajlm-1625	107	26	.	.	PUNCT
ajlm-1625	108	1	further	further	ADJ
ajlm-1625	108	2	investigations	investigation	NOUN
ajlm-1625	108	3	are	be	AUX
ajlm-1625	108	4	needed	need	VERB
ajlm-1625	108	5	to	to	PART
ajlm-1625	108	6	efficiently	efficiently	ADV
ajlm-1625	108	7	establish	establish	VERB
ajlm-1625	108	8	the	the	DET
ajlm-1625	108	9	distribution	distribution	NOUN
ajlm-1625	108	10	of	of	ADP
ajlm-1625	108	11	rbc	rbc	PROPN
ajlm-1625	108	12	antigens	antigen	NOUN
ajlm-1625	108	13	and	and	CCONJ
ajlm-1625	108	14	phenotypes	phenotype	NOUN
ajlm-1625	108	15	among	among	ADP
ajlm-1625	108	16	blood	blood	NOUN
ajlm-1625	108	17	donors	donor	NOUN
ajlm-1625	108	18	and	and	CCONJ
ajlm-1625	108	19	patients	patient	NOUN
ajlm-1625	108	20	in	in	ADP
ajlm-1625	108	21	the	the	DET
ajlm-1625	108	22	country	country	NOUN
ajlm-1625	108	23	,	,	PUNCT
ajlm-1625	108	24	which	which	PRON
ajlm-1625	108	25	may	may	AUX
ajlm-1625	108	26	facilitate	facilitate	VERB
ajlm-1625	108	27	rbc	rbc	PROPN
ajlm-1625	108	28	reagent	reagent	ADJ
ajlm-1625	108	29	manufacturing	manufacturing	NOUN
ajlm-1625	108	30	.	.	PUNCT
ajlm-1625	109	1	acknowledgements	acknowledgement	NOUN
ajlm-1625	109	2	salfo	salfo	NOUN
ajlm-1625	109	3	kellé	kellé	PROPN
ajlm-1625	109	4	for	for	ADP
ajlm-1625	109	5	patients	patient	NOUN
ajlm-1625	109	6	interview	interview	NOUN
ajlm-1625	109	7	,	,	PUNCT
ajlm-1625	109	8	data	datum	NOUN
ajlm-1625	109	9	and	and	CCONJ
ajlm-1625	109	10	sample	sample	NOUN
ajlm-1625	109	11	collection	collection	NOUN
ajlm-1625	109	12	.	.	PUNCT
ajlm-1625	110	1	competing	compete	VERB
ajlm-1625	110	2	interests	interest	NOUN
ajlm-1625	110	3	the	the	DET
ajlm-1625	110	4	authors	author	NOUN
ajlm-1625	110	5	declare	declare	VERB
ajlm-1625	110	6	that	that	SCONJ
ajlm-1625	110	7	they	they	PRON
ajlm-1625	110	8	have	have	VERB
ajlm-1625	110	9	no	no	DET
ajlm-1625	110	10	financial	financial	ADJ
ajlm-1625	110	11	or	or	CCONJ
ajlm-1625	110	12	personal	personal	ADJ
ajlm-1625	110	13	relationships	relationship	NOUN
ajlm-1625	110	14	that	that	PRON
ajlm-1625	110	15	may	may	AUX
ajlm-1625	110	16	have	have	AUX
ajlm-1625	110	17	inappropriately	inappropriately	ADV
ajlm-1625	110	18	influenced	influence	VERB
ajlm-1625	110	19	them	they	PRON
ajlm-1625	110	20	in	in	ADP
ajlm-1625	110	21	writing	write	VERB
ajlm-1625	110	22	this	this	DET
ajlm-1625	110	23	article	article	NOUN
ajlm-1625	110	24	.	.	PUNCT
ajlm-1625	111	1	authors	author	NOUN
ajlm-1625	111	2	’	'	PUNCT
ajlm-1625	111	3	contributions	contribution	NOUN
ajlm-1625	111	4	k.n	k.n	PROPN
ajlm-1625	111	5	.	.	PROPN
ajlm-1625	111	6	designed	design	VERB
ajlm-1625	111	7	the	the	DET
ajlm-1625	111	8	study	study	NOUN
ajlm-1625	111	9	,	,	PUNCT
ajlm-1625	111	10	collected	collect	VERB
ajlm-1625	111	11	data	datum	NOUN
ajlm-1625	111	12	,	,	PUNCT
ajlm-1625	111	13	participated	participate	VERB
ajlm-1625	111	14	in	in	ADP
ajlm-1625	111	15	samples	sample	NOUN
ajlm-1625	111	16	testing	testing	NOUN
ajlm-1625	111	17	,	,	PUNCT
ajlm-1625	111	18	contributed	contribute	VERB
ajlm-1625	111	19	to	to	ADP
ajlm-1625	111	20	data	data	NOUN
ajlm-1625	111	21	analysis	analysis	NOUN
ajlm-1625	111	22	and	and	CCONJ
ajlm-1625	111	23	drafted	draft	VERB
ajlm-1625	111	24	the	the	DET
ajlm-1625	111	25	manuscript	manuscript	NOUN
ajlm-1625	111	26	.	.	PUNCT
ajlm-1625	112	1	salam	salam	PROPN
ajlm-1625	112	2	sawadogo	sawadogo	PROPN
ajlm-1625	112	3	,	,	PUNCT
ajlm-1625	112	4	salifo	salifo	PROPN
ajlm-1625	112	5	sawadogo	sawadogo	PROPN
ajlm-1625	112	6	,	,	PUNCT
ajlm-1625	112	7	j.k	j.k	PROPN
ajlm-1625	112	8	.	.	PROPN
ajlm-1625	112	9	,	,	PUNCT
ajlm-1625	112	10	j.b	j.b	PROPN
ajlm-1625	112	11	.	.	PROPN
ajlm-1625	112	12	,	,	PUNCT
ajlm-1625	112	13	h.y.a.l	h.y.a.l	PROPN
ajlm-1625	112	14	.	.	PUNCT
ajlm-1625	112	15	and	and	CCONJ
ajlm-1625	112	16	a.g.s	a.g.s	PROPN
ajlm-1625	112	17	.	.	PROPN
ajlm-1625	112	18	contributed	contribute	VERB
ajlm-1625	112	19	to	to	ADP
ajlm-1625	112	20	designing	design	VERB
ajlm-1625	112	21	the	the	DET
ajlm-1625	112	22	study	study	NOUN
ajlm-1625	112	23	,	,	PUNCT
ajlm-1625	112	24	data	data	VERB
ajlm-1625	112	25	analysis	analysis	NOUN
ajlm-1625	112	26	and	and	CCONJ
ajlm-1625	112	27	interpretation	interpretation	NOUN
ajlm-1625	112	28	.	.	PUNCT
ajlm-1625	113	1	m.k	m.k	PROPN
ajlm-1625	113	2	.	.	PROPN
ajlm-1625	113	3	,	,	PUNCT
ajlm-1625	113	4	s.d	s.d	PROPN
ajlm-1625	113	5	.	.	PROPN
ajlm-1625	113	6	and	and	CCONJ
ajlm-1625	113	7	e.k	e.k	PROPN
ajlm-1625	113	8	.	.	PROPN
ajlm-1625	113	9	critically	critically	ADV
ajlm-1625	113	10	reviewed	review	VERB
ajlm-1625	113	11	and	and	CCONJ
ajlm-1625	113	12	revised	revise	VERB
ajlm-1625	113	13	the	the	DET
ajlm-1625	113	14	manuscript	manuscript	NOUN
ajlm-1625	113	15	.	.	PUNCT
ajlm-1625	114	1	all	all	PRON
ajlm-1625	114	2	of	of	ADP
ajlm-1625	114	3	the	the	DET
ajlm-1625	114	4	authors	author	NOUN
ajlm-1625	114	5	approved	approve	VERB
ajlm-1625	114	6	the	the	DET
ajlm-1625	114	7	final	final	ADJ
ajlm-1625	114	8	version	version	NOUN
ajlm-1625	114	9	of	of	ADP
ajlm-1625	114	10	the	the	DET
ajlm-1625	114	11	manuscript	manuscript	NOUN
ajlm-1625	114	12	.	.	PUNCT
ajlm-1625	115	1	sources	source	NOUN
ajlm-1625	115	2	of	of	ADP
ajlm-1625	115	3	support	support	NOUN
ajlm-1625	115	4	this	this	DET
ajlm-1625	115	5	research	research	NOUN
ajlm-1625	115	6	received	receive	VERB
ajlm-1625	115	7	no	no	DET
ajlm-1625	115	8	specific	specific	ADJ
ajlm-1625	115	9	grant	grant	NOUN
ajlm-1625	115	10	from	from	ADP
ajlm-1625	115	11	any	any	DET
ajlm-1625	115	12	funding	funding	NOUN
ajlm-1625	115	13	agency	agency	NOUN
ajlm-1625	115	14	in	in	ADP
ajlm-1625	115	15	the	the	DET
ajlm-1625	115	16	public	public	ADJ
ajlm-1625	115	17	,	,	PUNCT
ajlm-1625	115	18	commercial	commercial	ADJ
ajlm-1625	115	19	or	or	CCONJ
ajlm-1625	115	20	not	not	PART
ajlm-1625	115	21	-	-	PUNCT
ajlm-1625	115	22	for	for	ADP
ajlm-1625	115	23	-	-	PUNCT
ajlm-1625	115	24	profit	profit	NOUN
ajlm-1625	115	25	sectors	sector	NOUN
ajlm-1625	115	26	.	.	PUNCT
ajlm-1625	116	1	data	datum	NOUN
ajlm-1625	116	2	availability	availability	NOUN
ajlm-1625	116	3	data	datum	NOUN
ajlm-1625	116	4	are	be	AUX
ajlm-1625	116	5	available	available	ADJ
ajlm-1625	116	6	from	from	ADP
ajlm-1625	116	7	the	the	DET
ajlm-1625	116	8	corresponding	corresponding	ADJ
ajlm-1625	116	9	author	author	NOUN
ajlm-1625	116	10	,	,	PUNCT
ajlm-1625	116	11	k.n	k.n	PROPN
ajlm-1625	116	12	.	.	PROPN
ajlm-1625	116	13	,	,	PUNCT
ajlm-1625	116	14	upon	upon	SCONJ
ajlm-1625	116	15	request	request	NOUN
ajlm-1625	116	16	.	.	PUNCT
ajlm-1625	117	1	disclaimer	disclaimer	VERB
ajlm-1625	117	2	the	the	DET
ajlm-1625	117	3	views	view	NOUN
ajlm-1625	117	4	and	and	CCONJ
ajlm-1625	117	5	opinions	opinion	NOUN
ajlm-1625	117	6	expressed	express	VERB
ajlm-1625	117	7	in	in	ADP
ajlm-1625	117	8	this	this	DET
ajlm-1625	117	9	article	article	NOUN
ajlm-1625	117	10	are	be	AUX
ajlm-1625	117	11	those	those	PRON
ajlm-1625	117	12	of	of	ADP
ajlm-1625	117	13	the	the	DET
ajlm-1625	117	14	authors	author	NOUN
ajlm-1625	117	15	and	and	CCONJ
ajlm-1625	117	16	do	do	AUX
ajlm-1625	117	17	not	not	PART
ajlm-1625	117	18	necessarily	necessarily	ADV
ajlm-1625	117	19	reflect	reflect	VERB
ajlm-1625	117	20	the	the	DET
ajlm-1625	117	21	official	official	ADJ
ajlm-1625	117	22	policy	policy	NOUN
ajlm-1625	117	23	or	or	CCONJ
ajlm-1625	117	24	position	position	NOUN
ajlm-1625	117	25	of	of	ADP
ajlm-1625	117	26	any	any	DET
ajlm-1625	117	27	affiliated	affiliated	ADJ
ajlm-1625	117	28	agency	agency	NOUN
ajlm-1625	117	29	of	of	ADP
ajlm-1625	117	30	the	the	DET
ajlm-1625	117	31	authors	author	NOUN
ajlm-1625	117	32	.	.	PUNCT
ajlm-1625	118	1	references	reference	NOUN
ajlm-1625	118	2	centre	centre	VERB
ajlm-1625	118	3	national	national	PROPN
ajlm-1625	118	4	de	de	ADP
ajlm-1625	118	5	transfusion	transfusion	NOUN
ajlm-1625	118	6	sanguine	sanguine	ADJ
ajlm-1625	118	7	(	(	PUNCT
ajlm-1625	118	8	cnts	cnts	PROPN
ajlm-1625	118	9	)	)	PUNCT
ajlm-1625	118	10	.	.	PUNCT
ajlm-1625	119	1	annuaire	annuaire	NOUN
ajlm-1625	119	2	statistiques	statistique	NOUN
ajlm-1625	119	3	de	de	X
ajlm-1625	119	4	la	la	X
ajlm-1625	119	5	transfusion	transfusion	NOUN
ajlm-1625	119	6	sanguine	sanguine	ADJ
ajlm-1625	119	7	2017	2017	NUM
ajlm-1625	119	8	.	.	PUNCT
ajlm-1625	120	1	ouagadougou	ouagadougou	PROPN
ajlm-1625	120	2	:	:	PUNCT
ajlm-1625	120	3	cnts	cnts	PROPN
ajlm-1625	120	4	/	/	SYM
ajlm-1625	120	5	ministère	ministère	PROPN
ajlm-1625	120	6	de	de	X
ajlm-1625	120	7	la	la	X
ajlm-1625	120	8	santé	santé	PROPN
ajlm-1625	120	9	,	,	PUNCT
ajlm-1625	120	10	2016	2016	NUM
ajlm-1625	120	11	;	;	PUNCT
ajlm-1625	120	12	p.	p.	NOUN
ajlm-1625	120	13	128	128	NUM
ajlm-1625	120	14	.	.	PUNCT
ajlm-1625	120	15	report	report	VERB
ajlm-1625	120	16	no	no	INTJ
ajlm-1625	120	17	.	.	PUNCT
ajlm-1625	120	18	:	:	PUNCT
ajlm-1625	121	1	n001	n001	NUM
ajlm-1625	121	2	.	.	PUNCT
ajlm-1625	122	1	institut	institut	PROPN
ajlm-1625	122	2	national	national	PROPN
ajlm-1625	122	3	de	de	X
ajlm-1625	122	4	la	la	X
ajlm-1625	122	5	statistique	statistique	X
ajlm-1625	122	6	et	et	PROPN
ajlm-1625	122	7	de	de	X
ajlm-1625	122	8	la	la	X
ajlm-1625	122	9	démographie	démographie	PROPN
ajlm-1625	122	10	(	(	PUNCT
ajlm-1625	122	11	insd	insd	ADV
ajlm-1625	122	12	)	)	PUNCT
ajlm-1625	122	13	.	.	PUNCT
ajlm-1625	123	1	projections	projection	NOUN
ajlm-1625	123	2	démographiques	démographique	NOUN
ajlm-1625	123	3	de	de	X
ajlm-1625	123	4	2007	2007	NUM
ajlm-1625	123	5	à	à	X
ajlm-1625	123	6	2020	2020	NUM
ajlm-1625	123	7	,	,	PUNCT
ajlm-1625	123	8	par	par	PROPN
ajlm-1625	123	9	région	région	NOUN
ajlm-1625	123	10	et	et	PROPN
ajlm-1625	123	11	province	province	NOUN
ajlm-1625	124	1	[	[	X
ajlm-1625	124	2	homepage	homepage	NOUN
ajlm-1625	124	3	on	on	ADP
ajlm-1625	124	4	the	the	DET
ajlm-1625	124	5	internet	internet	NOUN
ajlm-1625	124	6	]	]	PUNCT
ajlm-1625	124	7	.	.	PUNCT
ajlm-1625	125	1	ouagadougou	ouagadougou	PROPN
ajlm-1625	125	2	:	:	PUNCT
ajlm-1625	125	3	institut	institut	PROPN
ajlm-1625	125	4	national	national	PROPN
ajlm-1625	125	5	de	de	X
ajlm-1625	125	6	la	la	X
ajlm-1625	125	7	statistique	statistique	X
ajlm-1625	125	8	et	et	PROPN
ajlm-1625	125	9	de	de	X
ajlm-1625	125	10	la	la	PROPN
ajlm-1625	125	11	démographie	démographie	PROPN
ajlm-1625	125	12	,	,	PUNCT
ajlm-1625	125	13	2009	2009	NUM
ajlm-1625	125	14	[	[	X
ajlm-1625	125	15	cited	cite	VERB
ajlm-1625	125	16	2019	2019	NUM
ajlm-1625	125	17	july	july	PROPN
ajlm-1625	125	18	23	23	NUM
ajlm-1625	125	19	]	]	PUNCT
ajlm-1625	125	20	;	;	PUNCT
ajlm-1625	125	21	p.	p.	NOUN
ajlm-1625	125	22	69	69	NUM
ajlm-1625	125	23	.	.	PUNCT
ajlm-1625	126	1	available	available	ADJ
ajlm-1625	126	2	from	from	ADP
ajlm-1625	126	3	:	:	PUNCT
ajlm-1625	126	4	http://www.insd.bf/n/contenu/autres_publications/projections_demographiques_sous_nationales_2007-2020.pdf	http://www.insd.bf/n/contenu/autres_publications/projections_demographiques_sous_nationales_2007-2020.pdf	PROPN
ajlm-1625	126	5	barro	barro	PROPN
ajlm-1625	126	6	l	l	PROPN
ajlm-1625	126	7	,	,	PUNCT
ajlm-1625	126	8	drew	draw	VERB
ajlm-1625	126	9	vj	vj	PROPN
ajlm-1625	126	10	,	,	PUNCT
ajlm-1625	126	11	poda	poda	PROPN
ajlm-1625	126	12	gg	gg	PROPN
ajlm-1625	126	13	,	,	PUNCT
ajlm-1625	126	14	et	et	PROPN
ajlm-1625	126	15	al	al	PROPN
ajlm-1625	126	16	.	.	PUNCT
ajlm-1625	127	1	blood	blood	NOUN
ajlm-1625	127	2	transfusion	transfusion	NOUN
ajlm-1625	127	3	in	in	ADP
ajlm-1625	127	4	sub	sub	ADJ
ajlm-1625	127	5	-	-	ADJ
ajlm-1625	127	6	saharan	saharan	ADJ
ajlm-1625	127	7	africa	africa	PROPN
ajlm-1625	127	8	:	:	PUNCT
ajlm-1625	127	9	understanding	understand	VERB
ajlm-1625	127	10	the	the	DET
ajlm-1625	127	11	missing	miss	VERB
ajlm-1625	127	12	gap	gap	NOUN
ajlm-1625	127	13	and	and	CCONJ
ajlm-1625	127	14	responding	respond	VERB
ajlm-1625	127	15	to	to	ADP
ajlm-1625	127	16	present	present	ADJ
ajlm-1625	127	17	and	and	CCONJ
ajlm-1625	127	18	future	future	ADJ
ajlm-1625	127	19	challenges	challenge	NOUN
ajlm-1625	127	20	.	.	PUNCT
ajlm-1625	128	1	vox	vox	PROPN
ajlm-1625	128	2	sang	sing	VERB
ajlm-1625	128	3	.	.	PUNCT
ajlm-1625	129	1	2018;113(8):726–736	2018;113(8):726–736	X
ajlm-1625	129	2	.	.	PUNCT
ajlm-1625	130	1	https://doi.org/10.1111/vox.12705	https://doi.org/10.1111/vox.12705	PROPN
ajlm-1625	130	2	yooda	yooda	PROPN
ajlm-1625	130	3	ap	ap	PROPN
ajlm-1625	130	4	,	,	PUNCT
ajlm-1625	130	5	sawadogo	sawadogo	VERB
ajlm-1625	130	6	s	s	PROPN
ajlm-1625	130	7	,	,	PUNCT
ajlm-1625	130	8	soubeiga	soubeiga	PROPN
ajlm-1625	130	9	st	st	PROPN
ajlm-1625	130	10	,	,	PUNCT
ajlm-1625	130	11	et	et	PROPN
ajlm-1625	130	12	al	al	PROPN
ajlm-1625	130	13	.	.	PUNCT
ajlm-1625	131	1	residual	residual	ADJ
ajlm-1625	131	2	risk	risk	NOUN
ajlm-1625	131	3	of	of	ADP
ajlm-1625	131	4	hiv	hiv	PROPN
ajlm-1625	131	5	,	,	PUNCT
ajlm-1625	131	6	hcv	hcv	PROPN
ajlm-1625	131	7	,	,	PUNCT
ajlm-1625	131	8	and	and	CCONJ
ajlm-1625	131	9	hbv	hbv	NOUN
ajlm-1625	131	10	transmission	transmission	NOUN
ajlm-1625	131	11	by	by	ADP
ajlm-1625	131	12	blood	blood	NOUN
ajlm-1625	131	13	transfusion	transfusion	NOUN
ajlm-1625	131	14	between	between	ADP
ajlm-1625	131	15	2015	2015	NUM
ajlm-1625	131	16	and	and	CCONJ
ajlm-1625	131	17	2017	2017	NUM
ajlm-1625	131	18	at	at	ADP
ajlm-1625	131	19	the	the	DET
ajlm-1625	131	20	regional	regional	ADJ
ajlm-1625	131	21	blood	blood	NOUN
ajlm-1625	131	22	transfusion	transfusion	NOUN
ajlm-1625	131	23	center	center	NOUN
ajlm-1625	131	24	of	of	ADP
ajlm-1625	131	25	ouagadougou	ouagadougou	PROPN
ajlm-1625	131	26	,	,	PUNCT
ajlm-1625	131	27	burkina	burkina	PROPN
ajlm-1625	131	28	faso	faso	PROPN
ajlm-1625	131	29	.	.	PUNCT
ajlm-1625	132	1	j	j	PROPN
ajlm-1625	132	2	blood	blood	NOUN
ajlm-1625	132	3	med	me	VERB
ajlm-1625	132	4	.	.	PUNCT
ajlm-1625	132	5	2019;10:53–58	2019;10:53–58	NUM
ajlm-1625	132	6	.	.	PUNCT
ajlm-1625	133	1	https://doi.org/10.2147/jbm.s189079	https://doi.org/10.2147/jbm.s189079	X
ajlm-1625	133	2	yooda	yooda	PROPN
ajlm-1625	134	1	ap	ap	PROPN
ajlm-1625	134	2	,	,	PUNCT
ajlm-1625	134	3	soubeiga	soubeiga	PROPN
ajlm-1625	134	4	st	st	PROPN
ajlm-1625	134	5	,	,	PUNCT
ajlm-1625	134	6	nebie	nebie	PROPN
ajlm-1625	134	7	ky	ky	PROPN
ajlm-1625	134	8	,	,	PUNCT
ajlm-1625	135	1	et	et	PROPN
ajlm-1625	135	2	al	al	PROPN
ajlm-1625	135	3	.	.	PROPN
ajlm-1625	135	4	impact	impact	NOUN
ajlm-1625	135	5	of	of	ADP
ajlm-1625	135	6	multiplex	multiplex	PROPN
ajlm-1625	135	7	pcr	pcr	PROPN
ajlm-1625	135	8	in	in	ADP
ajlm-1625	135	9	reducing	reduce	VERB
ajlm-1625	135	10	the	the	DET
ajlm-1625	135	11	risk	risk	NOUN
ajlm-1625	135	12	of	of	ADP
ajlm-1625	135	13	residual	residual	ADJ
ajlm-1625	135	14	transfusion	transfusion	NOUN
ajlm-1625	135	15	-	-	PUNCT
ajlm-1625	135	16	transmitted	transmit	VERB
ajlm-1625	135	17	human	human	ADJ
ajlm-1625	135	18	immunodeficiency	immunodeficiency	NOUN
ajlm-1625	135	19	and	and	CCONJ
ajlm-1625	135	20	hepatitis	hepatitis	PROPN
ajlm-1625	135	21	b	b	PROPN
ajlm-1625	135	22	and	and	CCONJ
ajlm-1625	135	23	c	c	PROPN
ajlm-1625	135	24	viruses	virus	NOUN
ajlm-1625	135	25	in	in	ADP
ajlm-1625	135	26	burkina	burkina	PROPN
ajlm-1625	135	27	faso	faso	PROPN
ajlm-1625	135	28	.	.	PUNCT
ajlm-1625	136	1	mediterr	mediterr	PROPN
ajlm-1625	136	2	j	j	PROPN
ajlm-1625	136	3	hematol	hematol	PROPN
ajlm-1625	136	4	infect	infect	VERB
ajlm-1625	136	5	dis	dis	PROPN
ajlm-1625	136	6	.	.	PUNCT
ajlm-1625	137	1	2018;10(1):e2018041	2018;10(1):e2018041	X
ajlm-1625	137	2	.	.	PUNCT
ajlm-1625	138	1	https://doi.org/10.4084/mjhid.2018.041	https://doi.org/10.4084/mjhid.2018.041	PROPN
ajlm-1625	138	2	nébié	nébié	VERB
ajlm-1625	138	3	k	k	NOUN
ajlm-1625	138	4	,	,	PUNCT
ajlm-1625	138	5	ouattara	ouattara	NOUN
ajlm-1625	138	6	s	s	NOUN
ajlm-1625	138	7	,	,	PUNCT
ajlm-1625	138	8	sanou	sanou	NOUN
ajlm-1625	138	9	m	m	PROPN
ajlm-1625	138	10	,	,	PUNCT
ajlm-1625	138	11	et	et	PROPN
ajlm-1625	138	12	al	al	PROPN
ajlm-1625	138	13	.	.	PUNCT
ajlm-1625	139	1	poor	poor	ADJ
ajlm-1625	139	2	procedures	procedure	NOUN
ajlm-1625	139	3	and	and	CCONJ
ajlm-1625	139	4	quality	quality	NOUN
ajlm-1625	139	5	control	control	NOUN
ajlm-1625	139	6	among	among	ADP
ajlm-1625	139	7	nonaffiliated	nonaffiliate	VERB
ajlm-1625	139	8	blood	blood	NOUN
ajlm-1625	139	9	centers	center	NOUN
ajlm-1625	139	10	in	in	ADP
ajlm-1625	139	11	burkina	burkina	PROPN
ajlm-1625	139	12	faso	faso	PROPN
ajlm-1625	139	13	:	:	PUNCT
ajlm-1625	139	14	an	an	DET
ajlm-1625	139	15	argument	argument	NOUN
ajlm-1625	139	16	for	for	ADP
ajlm-1625	139	17	expanding	expand	VERB
ajlm-1625	139	18	the	the	DET
ajlm-1625	139	19	reach	reach	NOUN
ajlm-1625	139	20	of	of	ADP
ajlm-1625	139	21	the	the	DET
ajlm-1625	139	22	national	national	ADJ
ajlm-1625	139	23	blood	blood	NOUN
ajlm-1625	139	24	transfusion	transfusion	NOUN
ajlm-1625	139	25	center	center	NOUN
ajlm-1625	139	26	.	.	PUNCT
ajlm-1625	140	1	transfusion	transfusion	NOUN
ajlm-1625	140	2	.	.	PUNCT
ajlm-1625	141	1	2011;51(7	2011;51(7	NUM
ajlm-1625	141	2	pt	pt	NOUN
ajlm-1625	141	3	2):1613–1618	2):1613–1618	NUM
ajlm-1625	141	4	.	.	PUNCT
ajlm-1625	142	1	https://doi.org/10.1111/j.1537-2995.2011.03222.x	https://doi.org/10.1111/j.1537-2995.2011.03222.x	PROPN
ajlm-1625	142	2	sawadogo	sawadogo	PROPN
ajlm-1625	142	3	s	s	PART
ajlm-1625	142	4	,	,	PUNCT
ajlm-1625	142	5	nebie	nebie	PROPN
ajlm-1625	142	6	k	k	PROPN
ajlm-1625	142	7	,	,	PUNCT
ajlm-1625	142	8	millogo	millogo	PROPN
ajlm-1625	142	9	t	t	PROPN
ajlm-1625	142	10	,	,	PUNCT
ajlm-1625	142	11	et	et	PROPN
ajlm-1625	142	12	al	al	PROPN
ajlm-1625	142	13	.	.	PROPN
ajlm-1625	142	14	traceability	traceability	NOUN
ajlm-1625	142	15	of	of	ADP
ajlm-1625	142	16	blood	blood	NOUN
ajlm-1625	142	17	transfusions	transfusion	NOUN
ajlm-1625	142	18	and	and	CCONJ
ajlm-1625	142	19	reporting	reporting	NOUN
ajlm-1625	142	20	of	of	ADP
ajlm-1625	142	21	adverse	adverse	ADJ
ajlm-1625	142	22	reactions	reaction	NOUN
ajlm-1625	142	23	in	in	ADP
ajlm-1625	142	24	developing	develop	VERB
ajlm-1625	142	25	countries	country	NOUN
ajlm-1625	142	26	:	:	PUNCT
ajlm-1625	142	27	a	a	DET
ajlm-1625	142	28	six	six	NUM
ajlm-1625	142	29	-	-	PUNCT
ajlm-1625	142	30	year	year	NOUN
ajlm-1625	142	31	postpilot	postpilot	NOUN
ajlm-1625	142	32	phase	phase	NOUN
ajlm-1625	142	33	experience	experience	NOUN
ajlm-1625	142	34	in	in	ADP
ajlm-1625	142	35	burkina	burkina	PROPN
ajlm-1625	142	36	faso	faso	PROPN
ajlm-1625	142	37	.	.	PUNCT
ajlm-1625	143	1	adv	adv	PROPN
ajlm-1625	143	2	hematol	hematol	NOUN
ajlm-1625	143	3	.	.	PUNCT
ajlm-1625	144	1	2018;2018:1–9	2018;2018:1–9	NUM
ajlm-1625	144	2	.	.	PUNCT
ajlm-1625	145	1	https://doi.org/10.1155/2018/7938130	https://doi.org/10.1155/2018/7938130	PROPN
ajlm-1625	145	2	shander	shander	PROPN
ajlm-1625	145	3	a.	a.	NOUN
ajlm-1625	145	4	emerging	emerge	VERB
ajlm-1625	145	5	risks	risk	NOUN
ajlm-1625	145	6	and	and	CCONJ
ajlm-1625	145	7	outcomes	outcome	NOUN
ajlm-1625	145	8	of	of	ADP
ajlm-1625	145	9	blood	blood	NOUN
ajlm-1625	145	10	transfusion	transfusion	NOUN
ajlm-1625	145	11	in	in	ADP
ajlm-1625	145	12	surgery	surgery	NOUN
ajlm-1625	145	13	.	.	PUNCT
ajlm-1625	146	1	semin	semin	PROPN
ajlm-1625	146	2	hematology	hematology	PROPN
ajlm-1625	146	3	.	.	PUNCT
ajlm-1625	147	1	2004;41:117–124	2004;41:117–124	PROPN
ajlm-1625	147	2	.	.	PUNCT
ajlm-1625	148	1	https://doi.org/10.1053/j.seminhematol.2003.11.023	https://doi.org/10.1053/j.seminhematol.2003.11.023	NOUN
ajlm-1625	148	2	yooda	yooda	NOUN
ajlm-1625	148	3	ap	ap	PROPN
ajlm-1625	148	4	,	,	PUNCT
ajlm-1625	148	5	nebie	nebie	PROPN
ajlm-1625	148	6	k	k	PROPN
ajlm-1625	148	7	,	,	PUNCT
ajlm-1625	148	8	tranchot	tranchot	PROPN
ajlm-1625	148	9	-	-	PUNCT
ajlm-1625	148	10	diallo	diallo	PROPN
ajlm-1625	148	11	j	j	PROPN
ajlm-1625	148	12	,	,	PUNCT
ajlm-1625	148	13	et	et	PROPN
ajlm-1625	148	14	al	al	PROPN
ajlm-1625	148	15	.	.	PUNCT
ajlm-1625	148	16	evaluation	evaluation	NOUN
ajlm-1625	148	17	of	of	ADP
ajlm-1625	148	18	two	two	NUM
ajlm-1625	148	19	serological	serological	ADJ
ajlm-1625	148	20	screening	screening	NOUN
ajlm-1625	148	21	kits	kit	NOUN
ajlm-1625	148	22	for	for	ADP
ajlm-1625	148	23	hepatitis	hepatitis	PROPN
ajlm-1625	148	24	c	c	PROPN
ajlm-1625	148	25	virus	virus	NOUN
ajlm-1625	148	26	infection	infection	NOUN
ajlm-1625	148	27	at	at	ADP
ajlm-1625	148	28	the	the	DET
ajlm-1625	148	29	regional	regional	ADJ
ajlm-1625	148	30	blood	blood	NOUN
ajlm-1625	148	31	transfusion	transfusion	NOUN
ajlm-1625	148	32	center	center	NOUN
ajlm-1625	148	33	of	of	ADP
ajlm-1625	148	34	ouagadougou	ouagadougou	PROPN
ajlm-1625	148	35	,	,	PUNCT
ajlm-1625	148	36	burkina	burkina	PROPN
ajlm-1625	148	37	faso	faso	PROPN
ajlm-1625	148	38	.	.	PUNCT
ajlm-1625	149	1	adv	adv	PROPN
ajlm-1625	149	2	infect	infect	VERB
ajlm-1625	149	3	dis	dis	PROPN
ajlm-1625	149	4	.	.	PUNCT
ajlm-1625	150	1	2020;10(05):216–227	2020;10(05):216–227	NUM
ajlm-1625	150	2	.	.	PUNCT
ajlm-1625	151	1	https://doi.org/10.4236/aid.2020.105019	https://doi.org/10.4236/aid.2020.105019	PROPN
ajlm-1625	151	2	atterbury	atterbury	PROPN
ajlm-1625	151	3	c	c	PROPN
ajlm-1625	151	4	,	,	PUNCT
ajlm-1625	151	5	wilkinson	wilkinson	PROPN
ajlm-1625	151	6	j.	j.	PROPN
ajlm-1625	151	7	blood	blood	PROPN
ajlm-1625	151	8	transfusion	transfusion	NOUN
ajlm-1625	151	9	.	.	PUNCT
ajlm-1625	152	1	nursing	nursing	NOUN
ajlm-1625	152	2	standard	standard	NOUN
ajlm-1625	152	3	.	.	PUNCT
ajlm-1625	153	1	2000;14(34):47–52	2000;14(34):47–52	NUM
ajlm-1625	153	2	.	.	PUNCT
ajlm-1625	154	1	https://doi.org/10.7748/ns2000.05.14.34.47.c2837	https://doi.org/10.7748/ns2000.05.14.34.47.c2837	PROPN
ajlm-1625	154	2	fishbane	fishbane	PROPN
ajlm-1625	154	3	s	s	NOUN
ajlm-1625	154	4	,	,	PUNCT
ajlm-1625	154	5	nissenson	nissenson	PROPN
ajlm-1625	154	6	ar	ar	PROPN
ajlm-1625	154	7	.	.	PROPN
ajlm-1625	155	1	the	the	DET
ajlm-1625	155	2	new	new	ADJ
ajlm-1625	155	3	fda	fda	PROPN
ajlm-1625	155	4	label	label	NOUN
ajlm-1625	155	5	for	for	ADP
ajlm-1625	155	6	erythropoietin	erythropoietin	ADJ
ajlm-1625	155	7	treatment	treatment	NOUN
ajlm-1625	155	8	:	:	PUNCT
ajlm-1625	155	9	how	how	SCONJ
ajlm-1625	155	10	does	do	AUX
ajlm-1625	155	11	it	it	PRON
ajlm-1625	155	12	affect	affect	VERB
ajlm-1625	155	13	hemoglobin	hemoglobin	NOUN
ajlm-1625	155	14	target	target	NOUN
ajlm-1625	155	15	?	?	PUNCT
ajlm-1625	156	1	kidney	kidney	NOUN
ajlm-1625	156	2	int	int	NOUN
ajlm-1625	156	3	.	.	PUNCT
ajlm-1625	157	1	2007;72(7):806–813	2007;72(7):806–813	NUM
ajlm-1625	157	2	.	.	PUNCT
ajlm-1625	158	1	https://doi.org/10.1038/sj.ki.5002401	https://doi.org/10.1038/sj.ki.5002401	PROPN
ajlm-1625	158	2	shah	shah	PROPN
ajlm-1625	158	3	hh	hh	PROPN
ajlm-1625	158	4	,	,	PUNCT
ajlm-1625	158	5	fishbane	fishbane	PROPN
ajlm-1625	158	6	s.	s.	PROPN
ajlm-1625	158	7	biosimilar	biosimilar	PROPN
ajlm-1625	158	8	erythropoiesis	erythropoiesis	NOUN
ajlm-1625	158	9	-	-	PUNCT
ajlm-1625	158	10	stimulating	stimulate	VERB
ajlm-1625	158	11	agents	agent	NOUN
ajlm-1625	158	12	in	in	ADP
ajlm-1625	158	13	chronic	chronic	ADJ
ajlm-1625	158	14	kidney	kidney	NOUN
ajlm-1625	158	15	disease	disease	NOUN
ajlm-1625	158	16	.	.	PUNCT
ajlm-1625	159	1	adv	adv	PROPN
ajlm-1625	159	2	chronic	chronic	ADJ
ajlm-1625	159	3	kidney	kidney	PROPN
ajlm-1625	159	4	dis	dis	PROPN
ajlm-1625	159	5	.	.	PUNCT
ajlm-1625	160	1	2019;26(4):267–271	2019;26(4):267–271	NUM
ajlm-1625	160	2	.	.	PUNCT
ajlm-1625	161	1	https://doi.org/10.1053/j.ackd.2019.04.007	https://doi.org/10.1053/j.ackd.2019.04.007	PROPN
ajlm-1625	161	2	nguyen	nguyen	PROPN
ajlm-1625	161	3	tv	tv	PROPN
ajlm-1625	161	4	,	,	PUNCT
ajlm-1625	161	5	goldfarb	goldfarb	PROPN
ajlm-1625	161	6	ds	ds	PROPN
ajlm-1625	161	7	.	.	PROPN
ajlm-1625	161	8	implications	implication	NOUN
ajlm-1625	161	9	of	of	ADP
ajlm-1625	161	10	a	a	DET
ajlm-1625	161	11	reduction	reduction	NOUN
ajlm-1625	161	12	in	in	ADP
ajlm-1625	161	13	the	the	DET
ajlm-1625	161	14	hemoglobin	hemoglobin	NOUN
ajlm-1625	161	15	target	target	NOUN
ajlm-1625	161	16	in	in	ADP
ajlm-1625	161	17	erythropoiesis	erythropoiesis	NOUN
ajlm-1625	161	18	-	-	PUNCT
ajlm-1625	161	19	stimulating	stimulate	VERB
ajlm-1625	161	20	agent	agent	NOUN
ajlm-1625	161	21	-	-	PUNCT
ajlm-1625	161	22	treated	treat	VERB
ajlm-1625	161	23	hemodialysis	hemodialysis	NOUN
ajlm-1625	161	24	patients	patient	NOUN
ajlm-1625	161	25	.	.	PUNCT
ajlm-1625	162	1	nephron	nephron	PROPN
ajlm-1625	162	2	extra	extra	NOUN
ajlm-1625	162	3	.	.	PUNCT
ajlm-1625	163	1	2011;1(1):212–216	2011;1(1):212–216	NUM
ajlm-1625	163	2	.	.	PUNCT
ajlm-1625	164	1	https://doi.org/10.1159/000334228	https://doi.org/10.1159/000334228	PROPN
ajlm-1625	164	2	banzi	banzi	PROPN
ajlm-1625	164	3	r	r	PROPN
ajlm-1625	164	4	,	,	PUNCT
ajlm-1625	164	5	gerardi	gerardi	PROPN
ajlm-1625	164	6	c.	c.	PROPN
ajlm-1625	164	7	2016–2017	2016–2017	NUM
ajlm-1625	164	8	application	application	NOUN
ajlm-1625	164	9	for	for	ADP
ajlm-1625	164	10	erythropoietin	erythropoietin	NOUN
ajlm-1625	164	11	-	-	PUNCT
ajlm-1625	164	12	stimulating	stimulate	VERB
ajlm-1625	164	13	agents	agent	NOUN
ajlm-1625	164	14	.	.	PUNCT
ajlm-1625	165	1	geneva	geneva	NOUN
ajlm-1625	165	2	:	:	PUNCT
ajlm-1625	165	3	world	world	PROPN
ajlm-1625	165	4	health	health	NOUN
ajlm-1625	165	5	organization	organization	NOUN
ajlm-1625	165	6	;	;	PUNCT
ajlm-1625	165	7	2016	2016	NUM
ajlm-1625	165	8	.	.	PUNCT
ajlm-1625	166	1	minstère	minstère	PROPN
ajlm-1625	166	2	de	de	X
ajlm-1625	166	3	la	la	X
ajlm-1625	166	4	santé	santé	PROPN
ajlm-1625	166	5	.	.	PUNCT
ajlm-1625	167	1	arrêté	arrêté	PROPN
ajlm-1625	167	2	portant	portant	PROPN
ajlm-1625	167	3	directives	directive	NOUN
ajlm-1625	167	4	nationales	nationales	X
ajlm-1625	167	5	de	de	X
ajlm-1625	167	6	bonnes	bonnes	NOUN
ajlm-1625	167	7	pratiques	pratique	NOUN
ajlm-1625	167	8	transfusionnelles	transfusionnelle	NOUN
ajlm-1625	167	9	.	.	PUNCT
ajlm-1625	168	1	n2014	n2014	NOUN
ajlm-1625	168	2	-	-	PUNCT
ajlm-1625	168	3	589	589	NUM
ajlm-1625	168	4	/	/	SYM
ajlm-1625	168	5	ms	ms	NOUN
ajlm-1625	168	6	juin	juin	PROPN
ajlm-1625	168	7	4	4	NUM
ajlm-1625	168	8	.	.	PUNCT
ajlm-1625	169	1	ouagadougou	ouagadougou	PROPN
ajlm-1625	169	2	:	:	PUNCT
ajlm-1625	169	3	minstère	minstère	PROPN
ajlm-1625	169	4	de	de	X
ajlm-1625	169	5	la	la	X
ajlm-1625	169	6	santé	santé	X
ajlm-1625	169	7	;	;	PUNCT
ajlm-1625	169	8	2014	2014	NUM
ajlm-1625	169	9	;	;	PUNCT
ajlm-1625	169	10	p.	p.	NOUN
ajlm-1625	169	11	89	89	NUM
ajlm-1625	169	12	.	.	PUNCT
ajlm-1625	170	1	eggington	eggington	PROPN
ajlm-1625	170	2	ja	ja	PROPN
ajlm-1625	170	3	,	,	PUNCT
ajlm-1625	170	4	bromilow	bromilow	PROPN
ajlm-1625	170	5	i	i	PRON
ajlm-1625	170	6	m	m	PROPN
ajlm-1625	170	7	,	,	PUNCT
ajlm-1625	170	8	duguid	duguid	PROPN
ajlm-1625	170	9	jkm	jkm	PROPN
ajlm-1625	170	10	.	.	PUNCT
ajlm-1625	171	1	the	the	DET
ajlm-1625	171	2	use	use	NOUN
ajlm-1625	171	3	of	of	ADP
ajlm-1625	171	4	pooled	pool	VERB
ajlm-1625	171	5	red	red	ADJ
ajlm-1625	171	6	cells	cell	NOUN
ajlm-1625	171	7	and	and	CCONJ
ajlm-1625	171	8	column	column	NOUN
ajlm-1625	171	9	techniques	technique	NOUN
ajlm-1625	171	10	for	for	ADP
ajlm-1625	171	11	routine	routine	ADJ
ajlm-1625	171	12	red	red	ADJ
ajlm-1625	171	13	cell	cell	NOUN
ajlm-1625	171	14	antibody	antibody	NOUN
ajlm-1625	171	15	detection	detection	NOUN
ajlm-1625	171	16	.	.	PUNCT
ajlm-1625	172	1	transfus	transfus	PROPN
ajlm-1625	172	2	med	med	PROPN
ajlm-1625	172	3	.	.	PUNCT
ajlm-1625	173	1	1996;6(4):345–349	1996;6(4):345–349	NUM
ajlm-1625	173	2	.	.	PUNCT
ajlm-1625	174	1	https://doi.org/10.1111/j.1365-3148.1996.tb00094.x	https://doi.org/10.1111/j.1365-3148.1996.tb00094.x	PROPN
ajlm-1625	174	2	blomme	blomme	VERB
ajlm-1625	174	3	s	s	PROPN
ajlm-1625	174	4	,	,	PUNCT
ajlm-1625	174	5	de	de	X
ajlm-1625	174	6	maertelaere	maertelaere	NOUN
ajlm-1625	174	7	e	e	NOUN
ajlm-1625	174	8	,	,	PUNCT
ajlm-1625	174	9	verhoye	verhoye	VERB
ajlm-1625	174	10	e.	e.	PROPN
ajlm-1625	174	11	a	a	DET
ajlm-1625	174	12	comparison	comparison	NOUN
ajlm-1625	174	13	of	of	ADP
ajlm-1625	174	14	three	three	NUM
ajlm-1625	174	15	column	column	NOUN
ajlm-1625	174	16	agglutination	agglutination	NOUN
ajlm-1625	174	17	tests	test	NOUN
ajlm-1625	174	18	for	for	ADP
ajlm-1625	174	19	red	red	ADJ
ajlm-1625	174	20	blood	blood	NOUN
ajlm-1625	174	21	cell	cell	NOUN
ajlm-1625	174	22	alloantibody	alloantibody	ADJ
ajlm-1625	174	23	identification	identification	NOUN
ajlm-1625	174	24	.	.	PUNCT
ajlm-1625	175	1	bmc	bmc	ADJ
ajlm-1625	175	2	res	re	NOUN
ajlm-1625	175	3	notes	note	NOUN
ajlm-1625	175	4	.	.	PUNCT
ajlm-1625	176	1	2020;13(1):129	2020;13(1):129	NUM
ajlm-1625	176	2	.	.	PUNCT
ajlm-1625	177	1	https://doi.org/10.1186/s13104-020-04974-x	https://doi.org/10.1186/s13104-020-04974-x	PROPN
ajlm-1625	177	2	dahourou	dahourou	PROPN
ajlm-1625	177	3	h	h	PROPN
ajlm-1625	177	4	,	,	PUNCT
ajlm-1625	177	5	tapko	tapko	PROPN
ajlm-1625	177	6	j	j	PROPN
ajlm-1625	177	7	-	-	PUNCT
ajlm-1625	177	8	b	b	PROPN
ajlm-1625	177	9	,	,	PUNCT
ajlm-1625	177	10	kienou	kienou	NOUN
ajlm-1625	177	11	k	k	NOUN
ajlm-1625	177	12	,	,	PUNCT
ajlm-1625	177	13	nebie	nebie	PROPN
ajlm-1625	177	14	k	k	PROPN
ajlm-1625	177	15	,	,	PUNCT
ajlm-1625	177	16	sanou	sanou	ADJ
ajlm-1625	177	17	m.	m.	NOUN
ajlm-1625	177	18	recruitment	recruitment	NOUN
ajlm-1625	177	19	of	of	ADP
ajlm-1625	177	20	blood	blood	NOUN
ajlm-1625	177	21	donors	donor	NOUN
ajlm-1625	177	22	in	in	ADP
ajlm-1625	177	23	burkina	burkina	PROPN
ajlm-1625	177	24	faso	faso	PROPN
ajlm-1625	177	25	:	:	PUNCT
ajlm-1625	177	26	how	how	SCONJ
ajlm-1625	177	27	to	to	PART
ajlm-1625	177	28	avoid	avoid	VERB
ajlm-1625	177	29	donations	donation	NOUN
ajlm-1625	177	30	from	from	ADP
ajlm-1625	177	31	family	family	NOUN
ajlm-1625	177	32	members	member	NOUN
ajlm-1625	177	33	?	?	PUNCT
ajlm-1625	178	1	biologicals	biological	NOUN
ajlm-1625	178	2	.	.	PUNCT
ajlm-1625	179	1	2010;38(1):39–42	2010;38(1):39–42	NUM
ajlm-1625	179	2	.	.	PROPN
ajlm-1625	179	3	https://doi.org/10.1016/j.biologicals.2009.10.017	https://doi.org/10.1016/j.biologicals.2009.10.017	PROPN
ajlm-1625	179	4	dahourou	dahourou	PROPN
ajlm-1625	179	5	h	h	PROPN
ajlm-1625	179	6	,	,	PUNCT
ajlm-1625	179	7	tapko	tapko	PROPN
ajlm-1625	179	8	j	j	PROPN
ajlm-1625	179	9	-	-	PUNCT
ajlm-1625	179	10	b	b	PROPN
ajlm-1625	179	11	,	,	PUNCT
ajlm-1625	179	12	nebie	nebie	PROPN
ajlm-1625	179	13	y	y	PROPN
ajlm-1625	179	14	,	,	PUNCT
ajlm-1625	179	15	et	et	PROPN
ajlm-1625	179	16	al	al	PROPN
ajlm-1625	179	17	.	.	PROPN
ajlm-1625	179	18	mise	mise	PROPN
ajlm-1625	179	19	en	en	X
ajlm-1625	179	20	place	place	PROPN
ajlm-1625	179	21	de	de	ADP
ajlm-1625	179	22	l’hémovigilance	l’hémovigilance	PROPN
ajlm-1625	179	23	en	en	PROPN
ajlm-1625	179	24	afrique	afrique	PROPN
ajlm-1625	179	25	subsaharienne	subsaharienne	PROPN
ajlm-1625	179	26	.	.	PUNCT
ajlm-1625	180	1	transfusion	transfusion	NOUN
ajlm-1625	180	2	clinique	clinique	NOUN
ajlm-1625	180	3	et	et	PROPN
ajlm-1625	180	4	biologique	biologique	PROPN
ajlm-1625	180	5	.	.	PUNCT
ajlm-1625	181	1	2012;19(1):39–45	2012;19(1):39–45	X
ajlm-1625	181	2	.	.	PUNCT
ajlm-1625	182	1	https://doi.org/10.1016/j.tracli.2011.11.001	https://doi.org/10.1016/j.tracli.2011.11.001	PROPN
ajlm-1625	182	2	world	world	PROPN
ajlm-1625	182	3	health	health	NOUN
ajlm-1625	182	4	organization	organization	NOUN
ajlm-1625	182	5	.	.	PUNCT
ajlm-1625	183	1	twenty	twenty	NUM
ajlm-1625	183	2	-	-	PUNCT
ajlm-1625	183	3	eigth	eigth	NOUN
ajlm-1625	183	4	world	world	NOUN
ajlm-1625	183	5	health	health	NOUN
ajlm-1625	183	6	assembly	assembly	NOUN
ajlm-1625	183	7	,	,	PUNCT
ajlm-1625	183	8	geneva	geneva	PROPN
ajlm-1625	183	9	,	,	PUNCT
ajlm-1625	183	10	13–30	13–30	PROPN
ajlm-1625	183	11	may	may	PROPN
ajlm-1625	183	12	1975	1975	NUM
ajlm-1625	183	13	wha28.72	wha28.72	NOUN
ajlm-1625	183	14	utilisation	utilisation	NOUN
ajlm-1625	183	15	and	and	CCONJ
ajlm-1625	183	16	supply	supply	NOUN
ajlm-1625	183	17	of	of	ADP
ajlm-1625	183	18	human	human	ADJ
ajlm-1625	183	19	blood	blood	NOUN
ajlm-1625	183	20	and	and	CCONJ
ajlm-1625	183	21	blood	blood	NOUN
ajlm-1625	183	22	products	product	NOUN
ajlm-1625	184	1	[	[	X
ajlm-1625	184	2	homepage	homepage	NOUN
ajlm-1625	184	3	on	on	ADP
ajlm-1625	184	4	the	the	DET
ajlm-1625	184	5	internet	internet	NOUN
ajlm-1625	184	6	]	]	PUNCT
ajlm-1625	184	7	.	.	PUNCT
ajlm-1625	185	1	[	[	X
ajlm-1625	185	2	cited	cite	VERB
ajlm-1625	185	3	2021	2021	NUM
ajlm-1625	185	4	apr	apr	NOUN
ajlm-1625	185	5	14	14	NUM
ajlm-1625	185	6	]	]	PUNCT
ajlm-1625	185	7	.	.	PUNCT
ajlm-1625	186	1	available	available	ADJ
ajlm-1625	186	2	from	from	ADP
ajlm-1625	186	3	:	:	PUNCT
ajlm-1625	186	4	https://www.who.int/bloodsafety/en/wha28.72.pdf?ua=1	https://www.who.int/bloodsafety/en/wha28.72.pdf?ua=1	PROPN
ajlm-1625	186	5	hill	hill	PROPN
ajlm-1625	186	6	bc	bc	PROPN
ajlm-1625	186	7	,	,	PUNCT
ajlm-1625	186	8	hanna	hanna	PROPN
ajlm-1625	186	9	ca	can	AUX
ajlm-1625	186	10	,	,	PUNCT
ajlm-1625	186	11	adamski	adamski	PROPN
ajlm-1625	186	12	j	j	PROPN
ajlm-1625	186	13	,	,	PUNCT
ajlm-1625	186	14	pham	pham	PROPN
ajlm-1625	186	15	hp	hp	PROPN
ajlm-1625	186	16	,	,	PUNCT
ajlm-1625	186	17	marques	marque	NOUN
ajlm-1625	186	18	mb	mb	PROPN
ajlm-1625	186	19	,	,	PUNCT
ajlm-1625	186	20	williams	williams	PROPN
ajlm-1625	186	21	la	la	PROPN
ajlm-1625	186	22	.	.	PUNCT
ajlm-1625	186	23	ficin	ficin	PROPN
ajlm-1625	186	24	-	-	PUNCT
ajlm-1625	186	25	treated	treat	VERB
ajlm-1625	186	26	red	red	ADJ
ajlm-1625	186	27	cells	cell	NOUN
ajlm-1625	186	28	help	help	AUX
ajlm-1625	186	29	identify	identify	VERB
ajlm-1625	186	30	clinically	clinically	ADV
ajlm-1625	186	31	significant	significant	ADJ
ajlm-1625	186	32	alloantibodies	alloantibody	NOUN
ajlm-1625	186	33	masked	mask	VERB
ajlm-1625	186	34	as	as	ADP
ajlm-1625	186	35	reactions	reaction	NOUN
ajlm-1625	186	36	of	of	ADP
ajlm-1625	186	37	undetermined	undetermined	ADJ
ajlm-1625	186	38	specificity	specificity	NOUN
ajlm-1625	186	39	in	in	ADP
ajlm-1625	186	40	gel	gel	NOUN
ajlm-1625	186	41	microtubes	microtube	NOUN
ajlm-1625	186	42	.	.	PUNCT
ajlm-1625	187	1	lab	lab	PROPN
ajlm-1625	187	2	med	med	PROPN
ajlm-1625	187	3	.	.	PUNCT
ajlm-1625	188	1	2017;48(1):24–28	2017;48(1):24–28	X
ajlm-1625	188	2	.	.	PUNCT
ajlm-1625	189	1	https://doi.org/10.1093/labmed/lmw062	https://doi.org/10.1093/labmed/lmw062	PROPN
ajlm-1625	189	2	boateng	boateng	PROPN
ajlm-1625	189	3	la	la	PROPN
ajlm-1625	189	4	,	,	PUNCT
ajlm-1625	189	5	ngoma	ngoma	PROPN
ajlm-1625	189	6	am	am	PROPN
ajlm-1625	189	7	,	,	PUNCT
ajlm-1625	189	8	bates	bates	PROPN
ajlm-1625	189	9	i	i	PRON
ajlm-1625	189	10	,	,	PUNCT
ajlm-1625	189	11	schonewille	schonewille	VERB
ajlm-1625	189	12	h.	h.	PROPN
ajlm-1625	189	13	red	red	PROPN
ajlm-1625	189	14	blood	blood	NOUN
ajlm-1625	189	15	cell	cell	NOUN
ajlm-1625	189	16	alloimmunization	alloimmunization	NOUN
ajlm-1625	189	17	in	in	ADP
ajlm-1625	189	18	transfused	transfused	ADJ
ajlm-1625	189	19	patients	patient	NOUN
ajlm-1625	189	20	with	with	ADP
ajlm-1625	189	21	sickle	sickle	NOUN
ajlm-1625	189	22	cell	cell	NOUN
ajlm-1625	189	23	disease	disease	NOUN
ajlm-1625	189	24	in	in	ADP
ajlm-1625	189	25	sub	sub	ADJ
ajlm-1625	189	26	-	-	ADJ
ajlm-1625	189	27	saharan	saharan	ADJ
ajlm-1625	189	28	africa	africa	PROPN
ajlm-1625	189	29	:	:	PUNCT
ajlm-1625	189	30	a	a	DET
ajlm-1625	189	31	systematic	systematic	ADJ
ajlm-1625	189	32	review	review	NOUN
ajlm-1625	189	33	and	and	CCONJ
ajlm-1625	189	34	meta	meta	ADJ
ajlm-1625	189	35	-	-	PUNCT
ajlm-1625	189	36	analysis	analysis	NOUN
ajlm-1625	189	37	.	.	PUNCT
ajlm-1625	190	1	transfus	transfus	PROPN
ajlm-1625	190	2	med	med	PROPN
ajlm-1625	190	3	rev	rev	PROPN
ajlm-1625	190	4	.	.	PROPN
ajlm-1625	190	5	2019;33(3):162–169	2019;33(3):162–169	NUM
ajlm-1625	190	6	.	.	PUNCT
ajlm-1625	191	1	https://doi.org/10.1016/j.tmrv.2019.06.003	https://doi.org/10.1016/j.tmrv.2019.06.003	VERB
ajlm-1625	191	2	ngoma	ngoma	PROPN
ajlm-1625	191	3	am	am	PROPN
ajlm-1625	191	4	,	,	PUNCT
ajlm-1625	191	5	mutombo	mutombo	VERB
ajlm-1625	191	6	pb	pb	ADP
ajlm-1625	191	7	,	,	PUNCT
ajlm-1625	191	8	ikeda	ikeda	PROPN
ajlm-1625	191	9	k	k	PROPN
ajlm-1625	191	10	,	,	PUNCT
ajlm-1625	191	11	nollet	nollet	NOUN
ajlm-1625	191	12	ke	ke	PROPN
ajlm-1625	191	13	,	,	PUNCT
ajlm-1625	191	14	natukunda	natukunda	PROPN
ajlm-1625	191	15	b	b	PROPN
ajlm-1625	191	16	,	,	PUNCT
ajlm-1625	191	17	ohto	ohto	PROPN
ajlm-1625	191	18	h.	h.	PROPN
ajlm-1625	191	19	red	red	PROPN
ajlm-1625	191	20	blood	blood	NOUN
ajlm-1625	191	21	cell	cell	NOUN
ajlm-1625	191	22	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	191	23	in	in	ADP
ajlm-1625	191	24	transfused	transfused	ADJ
ajlm-1625	191	25	patients	patient	NOUN
ajlm-1625	191	26	in	in	ADP
ajlm-1625	191	27	sub	sub	ADJ
ajlm-1625	191	28	-	-	ADJ
ajlm-1625	191	29	saharan	saharan	ADJ
ajlm-1625	191	30	africa	africa	PROPN
ajlm-1625	191	31	:	:	PUNCT
ajlm-1625	191	32	a	a	DET
ajlm-1625	191	33	systematic	systematic	ADJ
ajlm-1625	191	34	review	review	NOUN
ajlm-1625	191	35	and	and	CCONJ
ajlm-1625	191	36	meta	meta	ADJ
ajlm-1625	191	37	-	-	PUNCT
ajlm-1625	191	38	analysis	analysis	NOUN
ajlm-1625	191	39	.	.	PUNCT
ajlm-1625	192	1	transfus	transfus	PROPN
ajlm-1625	192	2	apher	apher	PROPN
ajlm-1625	192	3	sci	sci	PROPN
ajlm-1625	192	4	.	.	PUNCT
ajlm-1625	193	1	2016;54(2):296–302	2016;54(2):296–302	NUM
ajlm-1625	193	2	.	.	PUNCT
ajlm-1625	194	1	https://doi.org/10.1016/j.transci.2015.10.017	https://doi.org/10.1016/j.transci.2015.10.017	PROPN
ajlm-1625	194	2	kafando	kafando	PROPN
ajlm-1625	194	3	e	e	PROPN
ajlm-1625	194	4	,	,	PUNCT
ajlm-1625	194	5	wandji	wandji	PROPN
ajlm-1625	194	6	nana	nana	PROPN
ajlm-1625	194	7	lr	lr	PROPN
ajlm-1625	194	8	,	,	PUNCT
ajlm-1625	194	9	domo	domo	PROPN
ajlm-1625	194	10	y	y	PROPN
ajlm-1625	194	11	,	,	PUNCT
ajlm-1625	194	12	nebie	nebie	PROPN
ajlm-1625	194	13	y	y	NOUN
ajlm-1625	194	14	,	,	PUNCT
ajlm-1625	194	15	obiri	obiri	NOUN
ajlm-1625	194	16	-	-	PUNCT
ajlm-1625	194	17	yeboah	yeboah	NOUN
ajlm-1625	194	18	d	d	PROPN
ajlm-1625	194	19	,	,	PUNCT
ajlm-1625	194	20	simporé	simporé	PROPN
ajlm-1625	194	21	j.	j.	PROPN
ajlm-1625	194	22	incompatible	incompatible	ADJ
ajlm-1625	194	23	blood	blood	NOUN
ajlm-1625	194	24	transfusion	transfusion	NOUN
ajlm-1625	194	25	in	in	ADP
ajlm-1625	194	26	children	child	NOUN
ajlm-1625	194	27	in	in	ADP
ajlm-1625	194	28	burkina	burkina	PROPN
ajlm-1625	194	29	faso	faso	PROPN
ajlm-1625	194	30	.	.	PUNCT
ajlm-1625	195	1	open	open	ADJ
ajlm-1625	195	2	j	j	PROPN
ajlm-1625	195	3	hematol	hematol	NOUN
ajlm-1625	195	4	.	.	PUNCT
ajlm-1625	196	1	2017;6	2017;6	NOUN
ajlm-1625	196	2	.	.	PUNCT
ajlm-1625	197	1	https://doi.org/10.13055/ojhmt_8_1_1.170123	https://doi.org/10.13055/ojhmt_8_1_1.170123	VERB
ajlm-1625	197	2	natukunda	natukunda	PROPN
ajlm-1625	197	3	b	b	PROPN
ajlm-1625	197	4	,	,	PUNCT
ajlm-1625	197	5	schonewille	schonewille	NOUN
ajlm-1625	197	6	h	h	NOUN
ajlm-1625	197	7	,	,	PUNCT
ajlm-1625	197	8	ndugwa	ndugwa	NOUN
ajlm-1625	197	9	c	c	NOUN
ajlm-1625	197	10	,	,	PUNCT
ajlm-1625	197	11	brand	brand	NOUN
ajlm-1625	197	12	a.	a.	NOUN
ajlm-1625	197	13	red	red	PROPN
ajlm-1625	197	14	blood	blood	NOUN
ajlm-1625	197	15	cell	cell	NOUN
ajlm-1625	197	16	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	197	17	in	in	ADP
ajlm-1625	197	18	sickle	sickle	NOUN
ajlm-1625	197	19	cell	cell	NOUN
ajlm-1625	197	20	disease	disease	NOUN
ajlm-1625	197	21	patients	patient	NOUN
ajlm-1625	197	22	in	in	ADP
ajlm-1625	197	23	uganda	uganda	PROPN
ajlm-1625	197	24	.	.	PUNCT
ajlm-1625	198	1	transfusion	transfusion	NOUN
ajlm-1625	198	2	.	.	PUNCT
ajlm-1625	199	1	2010;50(1):20–25	2010;50(1):20–25	X
ajlm-1625	199	2	.	.	PUNCT
ajlm-1625	200	1	https://doi.org/10.1111/j.1537-2995.2009.02435.x	https://doi.org/10.1111/j.1537-2995.2009.02435.x	ADJ
ajlm-1625	200	2	baby	baby	NOUN
ajlm-1625	200	3	m	m	PROPN
ajlm-1625	200	4	,	,	PUNCT
ajlm-1625	200	5	fongoro	fongoro	PROPN
ajlm-1625	200	6	s	s	PROPN
ajlm-1625	200	7	,	,	PUNCT
ajlm-1625	200	8	cissé	cissé	VERB
ajlm-1625	200	9	m	m	PROPN
ajlm-1625	200	10	,	,	PUNCT
ajlm-1625	200	11	et	et	PROPN
ajlm-1625	200	12	al	al	PROPN
ajlm-1625	200	13	.	.	PROPN
ajlm-1625	200	14	fréquence	fréquence	PROPN
ajlm-1625	200	15	de	de	PROPN
ajlm-1625	200	16	l’allo	l’allo	PROPN
ajlm-1625	200	17	-	-	PUNCT
ajlm-1625	200	18	immunisation	immunisation	NOUN
ajlm-1625	200	19	érythrocytaire	érythrocytaire	NOUN
ajlm-1625	200	20	chez	chez	PROPN
ajlm-1625	200	21	les	les	PROPN
ajlm-1625	200	22	malades	malades	PROPN
ajlm-1625	200	23	polytransfusés	polytransfusés	PROPN
ajlm-1625	200	24	au	au	PROPN
ajlm-1625	200	25	centre	centre	PROPN
ajlm-1625	200	26	hospitalo	hospitalo	PROPN
ajlm-1625	200	27	-	-	PUNCT
ajlm-1625	200	28	universitaire	universitaire	NOUN
ajlm-1625	200	29	du	du	NOUN
ajlm-1625	200	30	point	point	NOUN
ajlm-1625	200	31	g	g	PROPN
ajlm-1625	200	32	,	,	PUNCT
ajlm-1625	200	33	bamako	bamako	PROPN
ajlm-1625	200	34	,	,	PUNCT
ajlm-1625	200	35	mali	mali	PROPN
ajlm-1625	200	36	.	.	PUNCT
ajlm-1625	201	1	transfusion	transfusion	NOUN
ajlm-1625	201	2	clinique	clinique	NOUN
ajlm-1625	201	3	et	et	PROPN
ajlm-1625	201	4	biologique	biologique	PROPN
ajlm-1625	201	5	.	.	PUNCT
ajlm-1625	202	1	2010;17(4):218–222	2010;17(4):218–222	X
ajlm-1625	202	2	.	.	PUNCT
ajlm-1625	203	1	https://doi.org/10.1016/j.tracli.2010.06.026	https://doi.org/10.1016/j.tracli.2010.06.026	PROPN
ajlm-1625	203	2	ugwu	ugwu	PROPN
ajlm-1625	203	3	n	n	CCONJ
ajlm-1625	203	4	,	,	PUNCT
ajlm-1625	203	5	awodu	awodu	NOUN
ajlm-1625	203	6	o	o	NOUN
ajlm-1625	203	7	,	,	PUNCT
ajlm-1625	203	8	bazuaye	bazuaye	VERB
ajlm-1625	203	9	g	g	NOUN
ajlm-1625	203	10	,	,	PUNCT
ajlm-1625	203	11	okoye	okoye	PROPN
ajlm-1625	203	12	a.	a.	NOUN
ajlm-1625	203	13	red	red	PROPN
ajlm-1625	203	14	cell	cell	PROPN
ajlm-1625	203	15	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	203	16	in	in	ADP
ajlm-1625	203	17	multi	multi	ADJ
ajlm-1625	203	18	-	-	ADJ
ajlm-1625	203	19	transfused	transfused	ADJ
ajlm-1625	203	20	patients	patient	NOUN
ajlm-1625	203	21	with	with	ADP
ajlm-1625	203	22	sickle	sickle	PROPN
ajlm-1625	203	23	cell	cell	NOUN
ajlm-1625	203	24	anemia	anemia	NOUN
ajlm-1625	203	25	in	in	ADP
ajlm-1625	203	26	benin	benin	PROPN
ajlm-1625	203	27	city	city	PROPN
ajlm-1625	203	28	,	,	PUNCT
ajlm-1625	203	29	nigeria	nigeria	PROPN
ajlm-1625	203	30	.	.	PUNCT
ajlm-1625	204	1	niger	niger	PROPN
ajlm-1625	204	2	j	j	PROPN
ajlm-1625	204	3	clin	clin	PROPN
ajlm-1625	204	4	pract	pract	PROPN
ajlm-1625	204	5	.	.	PUNCT
ajlm-1625	205	1	2015;18(4):522–526	2015;18(4):522–526	X
ajlm-1625	205	2	.	.	PUNCT
ajlm-1625	206	1	https://doi.org/10.4103/1119-3077.154204	https://doi.org/10.4103/1119-3077.154204	ADJ
ajlm-1625	206	2	ndahimana	ndahimana	PROPN
ajlm-1625	206	3	e	e	NOUN
ajlm-1625	206	4	,	,	PUNCT
ajlm-1625	206	5	gothot	gothot	VERB
ajlm-1625	206	6	a	a	NOUN
ajlm-1625	206	7	,	,	PUNCT
ajlm-1625	206	8	gerard	gerard	PROPN
ajlm-1625	206	9	c	c	PROPN
ajlm-1625	206	10	,	,	PUNCT
ajlm-1625	206	11	et	et	PROPN
ajlm-1625	206	12	al	al	PROPN
ajlm-1625	206	13	.	.	PROPN
ajlm-1625	207	1	risk	risk	NOUN
ajlm-1625	207	2	of	of	ADP
ajlm-1625	207	3	red	red	ADJ
ajlm-1625	207	4	blood	blood	NOUN
ajlm-1625	207	5	cell	cell	NOUN
ajlm-1625	207	6	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	207	7	in	in	ADP
ajlm-1625	207	8	rwanda	rwanda	PROPN
ajlm-1625	207	9	:	:	PUNCT
ajlm-1625	207	10	assessment	assessment	NOUN
ajlm-1625	207	11	of	of	ADP
ajlm-1625	207	12	pretransfusion	pretransfusion	PROPN
ajlm-1625	207	13	cross	cross	ADJ
ajlm-1625	207	14	-	-	ADJ
ajlm-1625	207	15	match	match	ADJ
ajlm-1625	207	16	techniques	technique	NOUN
ajlm-1625	207	17	used	use	VERB
ajlm-1625	207	18	in	in	ADP
ajlm-1625	207	19	district	district	NOUN
ajlm-1625	207	20	hospitals	hospital	NOUN
ajlm-1625	207	21	.	.	PUNCT
ajlm-1625	208	1	east	east	PROPN
ajlm-1625	208	2	afr	afr	PROPN
ajlm-1625	208	3	med	med	PROPN
ajlm-1625	208	4	j.	j.	PROPN
ajlm-1625	208	5	2013;90(4):124–129	2013;90(4):124–129	PROPN
ajlm-1625	208	6	.	.	PUNCT
ajlm-1625	209	1	chou	chou	PROPN
ajlm-1625	209	2	st	st	PROPN
ajlm-1625	209	3	,	,	PUNCT
ajlm-1625	209	4	liem	liem	PROPN
ajlm-1625	209	5	ri	ri	PROPN
ajlm-1625	209	6	,	,	PUNCT
ajlm-1625	209	7	thompson	thompson	PROPN
ajlm-1625	209	8	aa	aa	NOUN
ajlm-1625	209	9	.	.	PUNCT
ajlm-1625	210	1	challenges	challenge	NOUN
ajlm-1625	210	2	of	of	ADP
ajlm-1625	210	3	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	210	4	in	in	ADP
ajlm-1625	210	5	patients	patient	NOUN
ajlm-1625	210	6	with	with	ADP
ajlm-1625	210	7	haemoglobinopathies	haemoglobinopathy	NOUN
ajlm-1625	210	8	.	.	PUNCT
ajlm-1625	211	1	br	br	PROPN
ajlm-1625	211	2	j	j	PROPN
ajlm-1625	211	3	haematol	haematol	NOUN
ajlm-1625	211	4	.	.	PUNCT
ajlm-1625	212	1	2012;159(4):394–404	2012;159(4):394–404	PROPN
ajlm-1625	212	2	.	.	PUNCT
ajlm-1625	213	1	https://doi.org/10.1111/bjh.12061	https://doi.org/10.1111/bjh.12061	PROPN
ajlm-1625	213	2	chou	chou	PROPN
ajlm-1625	213	3	st	st	PROPN
ajlm-1625	213	4	,	,	PUNCT
ajlm-1625	213	5	jackson	jackson	PROPN
ajlm-1625	213	6	t	t	PROPN
ajlm-1625	213	7	,	,	PUNCT
ajlm-1625	213	8	vege	vege	PROPN
ajlm-1625	213	9	s	s	PROPN
ajlm-1625	213	10	,	,	PUNCT
ajlm-1625	213	11	smith	smith	PROPN
ajlm-1625	213	12	-	-	PUNCT
ajlm-1625	213	13	whitley	whitley	PROPN
ajlm-1625	213	14	k	k	PROPN
ajlm-1625	213	15	,	,	PUNCT
ajlm-1625	213	16	friedman	friedman	PROPN
ajlm-1625	213	17	df	df	PROPN
ajlm-1625	213	18	,	,	PUNCT
ajlm-1625	213	19	westhoff	westhoff	PROPN
ajlm-1625	213	20	cm	cm	PROPN
ajlm-1625	213	21	.	.	PUNCT
ajlm-1625	214	1	high	high	ADJ
ajlm-1625	214	2	prevalence	prevalence	NOUN
ajlm-1625	214	3	of	of	ADP
ajlm-1625	214	4	red	red	ADJ
ajlm-1625	214	5	blood	blood	NOUN
ajlm-1625	214	6	cell	cell	NOUN
ajlm-1625	214	7	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	214	8	in	in	ADP
ajlm-1625	214	9	sickle	sickle	NOUN
ajlm-1625	214	10	cell	cell	NOUN
ajlm-1625	214	11	disease	disease	NOUN
ajlm-1625	214	12	despite	despite	SCONJ
ajlm-1625	214	13	transfusion	transfusion	NOUN
ajlm-1625	214	14	from	from	ADP
ajlm-1625	214	15	rh	rh	PROPN
ajlm-1625	214	16	-	-	PUNCT
ajlm-1625	214	17	matched	match	VERB
ajlm-1625	214	18	minority	minority	NOUN
ajlm-1625	214	19	donors	donor	NOUN
ajlm-1625	214	20	.	.	PUNCT
ajlm-1625	215	1	blood	blood	NOUN
ajlm-1625	215	2	.	.	PUNCT
ajlm-1625	216	1	2013;122(6):1062–1071	2013;122(6):1062–1071	NUM
ajlm-1625	216	2	.	.	PUNCT
ajlm-1625	216	3	https://doi.org/10.1182/blood-2013-03-490623	https://doi.org/10.1182/blood-2013-03-490623	AUX
ajlm-1625	216	4	aygun	aygun	PROPN
ajlm-1625	216	5	b	b	X
ajlm-1625	216	6	,	,	PUNCT
ajlm-1625	216	7	padmanabhan	padmanabhan	PROPN
ajlm-1625	216	8	s	s	PROPN
ajlm-1625	216	9	,	,	PUNCT
ajlm-1625	216	10	paley	paley	PROPN
ajlm-1625	216	11	c	c	PROPN
ajlm-1625	216	12	,	,	PUNCT
ajlm-1625	216	13	chandrasekaran	chandrasekaran	ADJ
ajlm-1625	216	14	v.	v.	ADP
ajlm-1625	216	15	clinical	clinical	ADJ
ajlm-1625	216	16	significance	significance	NOUN
ajlm-1625	216	17	of	of	ADP
ajlm-1625	216	18	rbc	rbc	PROPN
ajlm-1625	216	19	alloantibodies	alloantibody	NOUN
ajlm-1625	216	20	and	and	CCONJ
ajlm-1625	216	21	autoantibodies	autoantibody	NOUN
ajlm-1625	216	22	in	in	ADP
ajlm-1625	216	23	sickle	sickle	NOUN
ajlm-1625	216	24	cell	cell	NOUN
ajlm-1625	216	25	patients	patient	NOUN
ajlm-1625	216	26	who	who	PRON
ajlm-1625	216	27	received	receive	VERB
ajlm-1625	216	28	transfusions	transfusion	NOUN
ajlm-1625	216	29	.	.	PUNCT
ajlm-1625	217	1	transfusion	transfusion	NOUN
ajlm-1625	217	2	.	.	PUNCT
ajlm-1625	218	1	2002;42(1):37–43	2002;42(1):37–43	X
ajlm-1625	218	2	.	.	PUNCT
ajlm-1625	218	3	https://doi.org/10.1046/j.1537-2995.2002.00007.x	https://doi.org/10.1046/j.1537-2995.2002.00007.x	PROPN
ajlm-1625	218	4	vichinsky	vichinsky	ADJ
ajlm-1625	218	5	ep	ep	PROPN
ajlm-1625	218	6	,	,	PUNCT
ajlm-1625	218	7	earles	earles	PROPN
ajlm-1625	218	8	a	a	PROPN
ajlm-1625	218	9	,	,	PUNCT
ajlm-1625	218	10	johnson	johnson	PROPN
ajlm-1625	218	11	ra	ra	PROPN
ajlm-1625	218	12	,	,	PUNCT
ajlm-1625	218	13	hoag	hoag	PROPN
ajlm-1625	218	14	ms	ms	PROPN
ajlm-1625	218	15	,	,	PUNCT
ajlm-1625	218	16	williams	williams	PROPN
ajlm-1625	218	17	a	a	PROPN
ajlm-1625	218	18	,	,	PUNCT
ajlm-1625	218	19	lubin	lubin	PROPN
ajlm-1625	218	20	b.	b.	PROPN
ajlm-1625	218	21	alloimmunization	alloimmunization	NOUN
ajlm-1625	218	22	in	in	ADP
ajlm-1625	218	23	sickle	sickle	PROPN
ajlm-1625	218	24	cell	cell	NOUN
ajlm-1625	218	25	anemia	anemia	NOUN
ajlm-1625	218	26	and	and	CCONJ
ajlm-1625	218	27	transfusion	transfusion	NOUN
ajlm-1625	218	28	of	of	ADP
ajlm-1625	218	29	racially	racially	ADV
ajlm-1625	218	30	unmatched	unmatched	ADJ
ajlm-1625	218	31	blood	blood	NOUN
ajlm-1625	218	32	.	.	PUNCT
ajlm-1625	219	1	n	n	PROPN
ajlm-1625	219	2	engl	engl	PROPN
ajlm-1625	219	3	j	j	PROPN
ajlm-1625	219	4	med	med	PROPN
ajlm-1625	219	5	.	.	PUNCT
ajlm-1625	220	1	1990;322(23):1617–1621	1990;322(23):1617–1621	NUM
ajlm-1625	220	2	.	.	PUNCT
ajlm-1625	221	1	https://doi.org/10.1056/nejm199006073222301	https://doi.org/10.1056/nejm199006073222301	PROPN
ajlm-1625	221	2	badjie	badjie	PROPN
ajlm-1625	221	3	ksw	ksw	PROPN
ajlm-1625	221	4	,	,	PUNCT
ajlm-1625	221	5	tauscher	tauscher	PROPN
ajlm-1625	221	6	cd	cd	PROPN
ajlm-1625	221	7	,	,	PUNCT
ajlm-1625	221	8	van	van	PROPN
ajlm-1625	221	9	buskirk	buskirk	PROPN
ajlm-1625	221	10	cm	cm	PROPN
ajlm-1625	221	11	,	,	PUNCT
ajlm-1625	221	12	et	et	PROPN
ajlm-1625	221	13	al	al	PROPN
ajlm-1625	221	14	.	.	PROPN
ajlm-1625	221	15	red	red	ADJ
ajlm-1625	221	16	blood	blood	NOUN
ajlm-1625	221	17	cell	cell	NOUN
ajlm-1625	221	18	phenotype	phenotype	NOUN
ajlm-1625	221	19	matching	match	VERB
ajlm-1625	221	20	for	for	ADP
ajlm-1625	221	21	various	various	ADJ
ajlm-1625	221	22	ethnic	ethnic	ADJ
ajlm-1625	221	23	groups	group	NOUN
ajlm-1625	221	24	.	.	PUNCT
ajlm-1625	222	1	immunohematology	immunohematology	NOUN
ajlm-1625	222	2	.	.	PUNCT
ajlm-1625	223	1	2011;27(1):12–19	2011;27(1):12–19	NUM
ajlm-1625	223	2	.	.	PUNCT
ajlm-1625	224	1	https://doi.org/10.21307/immunohematology-2019-169	https://doi.org/10.21307/immunohematology-2019-169	PROPN
ajlm-1625	225	1	zheng	zheng	PROPN
ajlm-1625	225	2	y	y	PROPN
ajlm-1625	225	3	,	,	PUNCT
ajlm-1625	225	4	maitta	maitta	VERB
ajlm-1625	225	5	rw	rw	PROPN
ajlm-1625	225	6	.	.	PUNCT
ajlm-1625	225	7	alloimmunisation	alloimmunisation	PROPN
ajlm-1625	225	8	rates	rate	NOUN
ajlm-1625	225	9	of	of	ADP
ajlm-1625	225	10	sickle	sickle	NOUN
ajlm-1625	225	11	cell	cell	NOUN
ajlm-1625	225	12	disease	disease	NOUN
ajlm-1625	225	13	patients	patient	NOUN
ajlm-1625	225	14	in	in	ADP
ajlm-1625	225	15	the	the	DET
ajlm-1625	225	16	united	united	PROPN
ajlm-1625	225	17	states	states	PROPN
ajlm-1625	225	18	differ	differ	VERB
ajlm-1625	225	19	from	from	ADP
ajlm-1625	225	20	those	those	PRON
ajlm-1625	225	21	in	in	ADP
ajlm-1625	225	22	other	other	ADJ
ajlm-1625	225	23	geographical	geographical	ADJ
ajlm-1625	225	24	regions	region	NOUN
ajlm-1625	225	25	.	.	PUNCT
ajlm-1625	226	1	transfus	transfus	PROPN
ajlm-1625	226	2	med	med	PROPN
ajlm-1625	226	3	.	.	PUNCT
ajlm-1625	227	1	2016;26(3):225–230	2016;26(3):225–230	X
ajlm-1625	227	2	.	.	PUNCT
ajlm-1625	228	1	https://doi.org/10.1111/tme.12314	https://doi.org/10.1111/tme.12314	PROPN
ajlm-1625	228	2	norol	norol	ADP
ajlm-1625	228	3	f	f	PROPN
ajlm-1625	228	4	,	,	PUNCT
ajlm-1625	228	5	nadjahi	nadjahi	PROPN
ajlm-1625	228	6	j	j	PROPN
ajlm-1625	228	7	,	,	PUNCT
ajlm-1625	228	8	bachir	bachir	ADJ
ajlm-1625	228	9	d	d	NOUN
ajlm-1625	228	10	,	,	PUNCT
ajlm-1625	228	11	et	et	PROPN
ajlm-1625	228	12	al	al	PROPN
ajlm-1625	228	13	.	.	PUNCT
ajlm-1625	229	1	transfusion	transfusion	NOUN
ajlm-1625	229	2	et	et	PROPN
ajlm-1625	229	3	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	229	4	chez	chez	PROPN
ajlm-1625	229	5	les	les	PROPN
ajlm-1625	229	6	patients	patient	NOUN
ajlm-1625	229	7	drépanocytaires	drépanocytaire	NOUN
ajlm-1625	229	8	.	.	PUNCT
ajlm-1625	230	1	transfusion	transfusion	NOUN
ajlm-1625	230	2	clinique	clinique	NOUN
ajlm-1625	230	3	et	et	PROPN
ajlm-1625	230	4	biologique	biologique	PROPN
ajlm-1625	230	5	.	.	PUNCT
ajlm-1625	231	1	1994;1(1):27–34	1994;1(1):27–34	NUM
ajlm-1625	231	2	.	.	PUNCT
ajlm-1625	232	1	https://doi.org/10.1016/s1246-7820(05)80054-0	https://doi.org/10.1016/s1246-7820(05)80054-0	PROPN
ajlm-1625	232	2	noizat	noizat	PROPN
ajlm-1625	232	3	-	-	PUNCT
ajlm-1625	232	4	pirenne	pirenne	NOUN
ajlm-1625	232	5	f.	f.	PROPN
ajlm-1625	232	6	relevance	relevance	NOUN
ajlm-1625	232	7	of	of	ADP
ajlm-1625	232	8	blood	blood	NOUN
ajlm-1625	232	9	groups	group	NOUN
ajlm-1625	232	10	in	in	ADP
ajlm-1625	232	11	transfusion	transfusion	NOUN
ajlm-1625	232	12	of	of	ADP
ajlm-1625	232	13	sickle	sickle	NOUN
ajlm-1625	232	14	cell	cell	NOUN
ajlm-1625	232	15	disease	disease	NOUN
ajlm-1625	232	16	patients	patient	NOUN
ajlm-1625	232	17	.	.	PUNCT
ajlm-1625	233	1	comptes	compte	VERB
ajlm-1625	233	2	rendus	rendus	PROPN
ajlm-1625	233	3	–	–	PUNCT
ajlm-1625	233	4	biologies	biology	NOUN
ajlm-1625	233	5	.	.	PUNCT
ajlm-1625	234	1	2013;336(3):152–158	2013;336(3):152–158	NUM
ajlm-1625	234	2	.	.	PUNCT
ajlm-1625	235	1	https://doi.org/10.1016/j.crvi.2012.09.011	https://doi.org/10.1016/j.crvi.2012.09.011	ADJ
ajlm-1625	235	2	meunier	meunier	PROPN
ajlm-1625	235	3	n	n	CCONJ
ajlm-1625	235	4	,	,	PUNCT
ajlm-1625	235	5	rodet	rodet	PROPN
ajlm-1625	235	6	m	m	PROPN
ajlm-1625	235	7	,	,	PUNCT
ajlm-1625	235	8	bonin	bonin	VERB
ajlm-1625	235	9	p	p	NOUN
ajlm-1625	235	10	,	,	PUNCT
ajlm-1625	235	11	et	et	PROPN
ajlm-1625	235	12	al	al	PROPN
ajlm-1625	235	13	.	.	PROPN
ajlm-1625	235	14	étude	étude	PROPN
ajlm-1625	235	15	d’une	d’une	PROPN
ajlm-1625	235	16	cohorte	cohorte	NOUN
ajlm-1625	235	17	de	de	ADP
ajlm-1625	235	18	206	206	NUM
ajlm-1625	235	19	patients	patient	NOUN
ajlm-1625	235	20	drépanocytaires	drépanocytaire	NOUN
ajlm-1625	235	21	adultes	adulte	NOUN
ajlm-1625	235	22	transfusés	transfusés	NOUN
ajlm-1625	235	23	:	:	PUNCT
ajlm-1625	236	1	immunisation	immunisation	NOUN
ajlm-1625	236	2	,	,	PUNCT
ajlm-1625	236	3	risque	risque	PROPN
ajlm-1625	236	4	transfusionnel	transfusionnel	PROPN
ajlm-1625	236	5	et	et	PROPN
ajlm-1625	236	6	ressources	ressource	NOUN
ajlm-1625	236	7	en	en	ADP
ajlm-1625	236	8	concentrés	concentrés	NOUN
ajlm-1625	236	9	globulaires	globulaire	NOUN
ajlm-1625	236	10	.	.	PUNCT
ajlm-1625	237	1	transfusion	transfusion	NOUN
ajlm-1625	237	2	clinique	clinique	NOUN
ajlm-1625	237	3	et	et	PROPN
ajlm-1625	237	4	biologique	biologique	PROPN
ajlm-1625	237	5	.	.	PUNCT
ajlm-1625	238	1	2008;15(6):377–382	2008;15(6):377–382	X
ajlm-1625	238	2	.	.	PUNCT
ajlm-1625	238	3	https://doi.org/10.1016/j.tracli.2008.10.002	https://doi.org/10.1016/j.tracli.2008.10.002	PROPN
ajlm-1625	238	4	allali	allali	NOUN
ajlm-1625	238	5	s	s	PROPN
ajlm-1625	238	6	,	,	PUNCT
ajlm-1625	238	7	peyrard	peyrard	PROPN
ajlm-1625	238	8	t	t	PROPN
ajlm-1625	238	9	,	,	PUNCT
ajlm-1625	238	10	amiranoff	amiranoff	PROPN
ajlm-1625	238	11	d	d	PROPN
ajlm-1625	238	12	,	,	PUNCT
ajlm-1625	238	13	et	et	PROPN
ajlm-1625	238	14	al	al	PROPN
ajlm-1625	238	15	.	.	PUNCT
ajlm-1625	239	1	prevalence	prevalence	NOUN
ajlm-1625	239	2	and	and	CCONJ
ajlm-1625	239	3	risk	risk	NOUN
ajlm-1625	239	4	factors	factor	NOUN
ajlm-1625	239	5	for	for	ADP
ajlm-1625	239	6	red	red	ADJ
ajlm-1625	239	7	blood	blood	NOUN
ajlm-1625	239	8	cell	cell	NOUN
ajlm-1625	239	9	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	239	10	in	in	ADP
ajlm-1625	239	11	175	175	NUM
ajlm-1625	239	12	children	child	NOUN
ajlm-1625	239	13	with	with	ADP
ajlm-1625	239	14	sickle	sickle	NOUN
ajlm-1625	239	15	cell	cell	NOUN
ajlm-1625	239	16	disease	disease	NOUN
ajlm-1625	239	17	in	in	ADP
ajlm-1625	239	18	a	a	DET
ajlm-1625	239	19	french	french	ADJ
ajlm-1625	239	20	university	university	NOUN
ajlm-1625	239	21	hospital	hospital	NOUN
ajlm-1625	239	22	reference	reference	NOUN
ajlm-1625	239	23	centre	centre	NOUN
ajlm-1625	239	24	.	.	PUNCT
ajlm-1625	240	1	br	br	PROPN
ajlm-1625	240	2	j	j	PROPN
ajlm-1625	240	3	haematol	haematol	NOUN
ajlm-1625	240	4	.	.	PUNCT
ajlm-1625	241	1	2017;177(4):641–647	2017;177(4):641–647	NUM
ajlm-1625	241	2	.	.	PUNCT
ajlm-1625	242	1	https://doi.org/10.1111/bjh.14609	https://doi.org/10.1111/bjh.14609	PROPN
ajlm-1625	242	2	sarihi	sarihi	PROPN
ajlm-1625	242	3	r	r	NOUN
ajlm-1625	242	4	,	,	PUNCT
ajlm-1625	242	5	amirizadeh	amirizadeh	NOUN
ajlm-1625	242	6	n	n	CCONJ
ajlm-1625	242	7	,	,	PUNCT
ajlm-1625	242	8	oodi	oodi	ADV
ajlm-1625	242	9	a	a	PRON
ajlm-1625	242	10	,	,	PUNCT
ajlm-1625	242	11	azarkeivan	azarkeivan	ADJ
ajlm-1625	242	12	a.	a.	NOUN
ajlm-1625	242	13	distribution	distribution	NOUN
ajlm-1625	242	14	of	of	ADP
ajlm-1625	242	15	red	red	ADJ
ajlm-1625	242	16	blood	blood	NOUN
ajlm-1625	242	17	cell	cell	NOUN
ajlm-1625	242	18	alloantibodies	alloantibody	NOUN
ajlm-1625	242	19	among	among	ADP
ajlm-1625	242	20	transfusion	transfusion	NOUN
ajlm-1625	242	21	-	-	PUNCT
ajlm-1625	242	22	dependent	dependent	ADJ
ajlm-1625	242	23	β	β	X
ajlm-1625	242	24	-	-	PUNCT
ajlm-1625	242	25	thalassemia	thalassemia	NOUN
ajlm-1625	242	26	patients	patient	NOUN
ajlm-1625	242	27	in	in	ADP
ajlm-1625	242	28	different	different	ADJ
ajlm-1625	242	29	population	population	NOUN
ajlm-1625	242	30	of	of	ADP
ajlm-1625	242	31	iran	iran	PROPN
ajlm-1625	242	32	:	:	PUNCT
ajlm-1625	242	33	effect	effect	NOUN
ajlm-1625	242	34	of	of	ADP
ajlm-1625	242	35	ethnicity	ethnicity	NOUN
ajlm-1625	242	36	.	.	PUNCT
ajlm-1625	243	1	hemoglobin	hemoglobin	NOUN
ajlm-1625	243	2	.	.	PUNCT
ajlm-1625	244	1	2020;44(1):31–36	2020;44(1):31–36	NUM
ajlm-1625	244	2	.	.	PUNCT
ajlm-1625	244	3	https://doi.org/10.1080/03630269.2019.1709205	https://doi.org/10.1080/03630269.2019.1709205	X
ajlm-1625	245	1	sawadogo	sawadogo	PROPN
ajlm-1625	245	2	s	s	PROPN
ajlm-1625	245	3	,	,	PUNCT
ajlm-1625	245	4	nebie	nebie	PROPN
ajlm-1625	245	5	k	k	PROPN
ajlm-1625	245	6	,	,	PUNCT
ajlm-1625	245	7	millogo	millogo	PROPN
ajlm-1625	245	8	t	t	PROPN
ajlm-1625	245	9	,	,	PUNCT
ajlm-1625	245	10	et	et	PROPN
ajlm-1625	245	11	al	al	PROPN
ajlm-1625	245	12	.	.	PUNCT
ajlm-1625	245	13	distribution	distribution	NOUN
ajlm-1625	245	14	of	of	ADP
ajlm-1625	245	15	abo	abo	NOUN
ajlm-1625	245	16	and	and	CCONJ
ajlm-1625	245	17	rhd	rhd	PROPN
ajlm-1625	245	18	blood	blood	NOUN
ajlm-1625	245	19	group	group	NOUN
ajlm-1625	245	20	antigens	antigen	NOUN
ajlm-1625	245	21	in	in	ADP
ajlm-1625	245	22	blood	blood	NOUN
ajlm-1625	245	23	donors	donor	NOUN
ajlm-1625	245	24	in	in	ADP
ajlm-1625	245	25	burkina	burkina	PROPN
ajlm-1625	245	26	faso	faso	PROPN
ajlm-1625	245	27	.	.	PUNCT
ajlm-1625	246	1	int	int	PROPN
ajlm-1625	246	2	j	j	PROPN
ajlm-1625	246	3	immunogenet	immunogenet	PROPN
ajlm-1625	246	4	.	.	PUNCT
ajlm-1625	247	1	2019;46(1):1–6	2019;46(1):1–6	NUM
ajlm-1625	247	2	.	.	PUNCT
ajlm-1625	248	1	https://doi.org/10.1111/iji.12408	https://doi.org/10.1111/iji.12408	PROPN
ajlm-1625	248	2	kouloudiati	kouloudiati	PROPN
ajlm-1625	248	3	j	j	PROPN
ajlm-1625	248	4	,	,	PUNCT
ajlm-1625	248	5	miningou	miningou	PROPN
ajlm-1625	248	6	m	m	PROPN
ajlm-1625	248	7	,	,	PUNCT
ajlm-1625	248	8	sawadogo	sawadogo	PROPN
ajlm-1625	248	9	s	s	PART
ajlm-1625	248	10	,	,	PUNCT
ajlm-1625	248	11	et	et	PROPN
ajlm-1625	248	12	al	al	PROPN
ajlm-1625	248	13	.	.	PUNCT
ajlm-1625	249	1	prévalence	prévalence	NOUN
ajlm-1625	249	2	des	des	X
ajlm-1625	249	3	groupes	groupes	PROPN
ajlm-1625	249	4	sanguins	sanguin	NOUN
ajlm-1625	249	5	érythrocytaires	érythrocytaires	PROPN
ajlm-1625	249	6	des	des	PROPN
ajlm-1625	249	7	systèmes	systèmes	PROPN
ajlm-1625	249	8	abo	abo	VERB
ajlm-1625	249	9	et	et	PROPN
ajlm-1625	249	10	rhésus	rhésus	PROPN
ajlm-1625	249	11	d	d	PROPN
ajlm-1625	249	12	au	au	PROPN
ajlm-1625	249	13	laboratoire	laboratoire	PROPN
ajlm-1625	249	14	du	du	PROPN
ajlm-1625	249	15	centre	centre	PROPN
ajlm-1625	249	16	médical	médical	PROPN
ajlm-1625	249	17	du	du	PROPN
ajlm-1625	249	18	camp	camp	PROPN
ajlm-1625	249	19	général	général	PROPN
ajlm-1625	249	20	aboubacar	aboubacar	NOUN
ajlm-1625	249	21	sangoulé	sangoulé	VERB
ajlm-1625	249	22	lamizana	lamizana	PROPN
ajlm-1625	249	23	de	de	PROPN
ajlm-1625	249	24	ouagadougou	ouagadougou	PROPN
ajlm-1625	249	25	(	(	PUNCT
ajlm-1625	249	26	burkina	burkina	PROPN
ajlm-1625	249	27	faso	faso	PROPN
ajlm-1625	249	28	)	)	PUNCT
ajlm-1625	249	29	.	.	PUNCT
ajlm-1625	250	1	médecine	médecine	NOUN
ajlm-1625	250	2	d’afrique	d’afrique	PROPN
ajlm-1625	250	3	noire	noire	NOUN
ajlm-1625	250	4	.	.	PUNCT
ajlm-1625	251	1	2020;67(4):175–182	2020;67(4):175–182	PROPN
ajlm-1625	251	2	.	.	PUNCT
ajlm-1625	251	3	salamat	salamat	PROPN
ajlm-1625	251	4	n	n	CCONJ
ajlm-1625	251	5	,	,	PUNCT
ajlm-1625	251	6	bhatti	bhatti	PROPN
ajlm-1625	251	7	fa	fa	PROPN
ajlm-1625	251	8	,	,	PUNCT
ajlm-1625	251	9	yaqub	yaqub	NOUN
ajlm-1625	251	10	m	m	PROPN
ajlm-1625	251	11	,	,	PUNCT
ajlm-1625	251	12	hafeez	hafeez	PROPN
ajlm-1625	251	13	m	m	PROPN
ajlm-1625	251	14	,	,	PUNCT
ajlm-1625	251	15	hussain	hussain	PROPN
ajlm-1625	251	16	a	a	PRON
ajlm-1625	251	17	,	,	PUNCT
ajlm-1625	251	18	ziaullah	ziaullah	PROPN
ajlm-1625	251	19	null	null	NOUN
ajlm-1625	251	20	.	.	PUNCT
ajlm-1625	252	1	indigenous	indigenous	ADJ
ajlm-1625	252	2	development	development	NOUN
ajlm-1625	252	3	of	of	ADP
ajlm-1625	252	4	antibody	antibody	NOUN
ajlm-1625	252	5	screening	screen	VERB
ajlm-1625	252	6	cell	cell	NOUN
ajlm-1625	252	7	panels	panel	NOUN
ajlm-1625	252	8	at	at	ADP
ajlm-1625	252	9	armed	armed	ADJ
ajlm-1625	252	10	forces	force	NOUN
ajlm-1625	252	11	institute	institute	PROPN
ajlm-1625	252	12	of	of	ADP
ajlm-1625	252	13	transfusion	transfusion	NOUN
ajlm-1625	252	14	(	(	PUNCT
ajlm-1625	252	15	afit	afit	NOUN
ajlm-1625	252	16	)	)	PUNCT
ajlm-1625	252	17	.	.	PUNCT
ajlm-1625	253	1	j	j	PROPN
ajlm-1625	253	2	pak	pak	PROPN
ajlm-1625	253	3	med	med	PROPN
ajlm-1625	253	4	assoc	assoc	PROPN
ajlm-1625	253	5	.	.	PUNCT
ajlm-1625	254	1	2005;55(10):439–443	2005;55(10):439–443	X
ajlm-1625	254	2	.	.	PUNCT
ajlm-1625	255	1	sawierucha	sawierucha	PROPN
ajlm-1625	255	2	j	j	PROPN
ajlm-1625	255	3	,	,	PUNCT
ajlm-1625	255	4	posset	posset	NOUN
ajlm-1625	255	5	m	m	PROPN
ajlm-1625	255	6	,	,	PUNCT
ajlm-1625	255	7	hähnel	hähnel	NOUN
ajlm-1625	255	8	v	v	PROPN
ajlm-1625	255	9	,	,	PUNCT
ajlm-1625	255	10	johnson	johnson	PROPN
ajlm-1625	255	11	cl	cl	PROPN
ajlm-1625	255	12	,	,	PUNCT
ajlm-1625	255	13	hutchinson	hutchinson	PROPN
ajlm-1625	255	14	ja	ja	PROPN
ajlm-1625	255	15	,	,	PUNCT
ajlm-1625	255	16	ahrens	ahren	VERB
ajlm-1625	255	17	n.	n.	PROPN
ajlm-1625	255	18	comparison	comparison	NOUN
ajlm-1625	255	19	of	of	ADP
ajlm-1625	255	20	two	two	NUM
ajlm-1625	255	21	column	column	NOUN
ajlm-1625	255	22	agglutination	agglutination	NOUN
ajlm-1625	255	23	tests	test	NOUN
ajlm-1625	255	24	for	for	ADP
ajlm-1625	255	25	red	red	ADJ
ajlm-1625	255	26	blood	blood	NOUN
ajlm-1625	255	27	cell	cell	NOUN
ajlm-1625	255	28	antibody	antibody	NOUN
ajlm-1625	255	29	testing	testing	NOUN
ajlm-1625	255	30	.	.	PUNCT
ajlm-1625	256	1	plos	plos	PROPN
ajlm-1625	256	2	one	one	NUM
ajlm-1625	256	3	.	.	PUNCT
ajlm-1625	257	1	2018;13(12):e0210099	2018;13(12):e0210099	NUM
ajlm-1625	257	2	.	.	PUNCT
ajlm-1625	258	1	https://doi.org/10.1371/journal.pone.0210099	https://doi.org/10.1371/journal.pone.0210099	VERB
ajlm-1625	258	2	yu	yu	PROPN
ajlm-1625	258	3	y	y	PROPN
ajlm-1625	258	4	,	,	PUNCT
ajlm-1625	258	5	ma	ma	PROPN
ajlm-1625	258	6	c	c	PROPN
ajlm-1625	258	7	,	,	PUNCT
ajlm-1625	258	8	sun	sun	PROPN
ajlm-1625	258	9	x	x	AUX
ajlm-1625	258	10	,	,	PUNCT
ajlm-1625	258	11	et	et	PROPN
ajlm-1625	258	12	al	al	PROPN
ajlm-1625	258	13	.	.	PUNCT
ajlm-1625	258	14	frequencies	frequency	NOUN
ajlm-1625	258	15	of	of	ADP
ajlm-1625	258	16	red	red	ADJ
ajlm-1625	258	17	blood	blood	NOUN
ajlm-1625	258	18	cell	cell	NOUN
ajlm-1625	258	19	major	major	ADJ
ajlm-1625	258	20	blood	blood	NOUN
ajlm-1625	258	21	group	group	NOUN
ajlm-1625	258	22	antigens	antigen	NOUN
ajlm-1625	258	23	and	and	CCONJ
ajlm-1625	258	24	phenotypes	phenotype	NOUN
ajlm-1625	258	25	in	in	ADP
ajlm-1625	258	26	the	the	DET
ajlm-1625	258	27	chinese	chinese	ADJ
ajlm-1625	258	28	han	han	PROPN
ajlm-1625	258	29	population	population	PROPN
ajlm-1625	258	30	from	from	ADP
ajlm-1625	258	31	mainland	mainland	PROPN
ajlm-1625	258	32	china	china	PROPN
ajlm-1625	258	33	.	.	PUNCT
ajlm-1625	259	1	int	int	PROPN
ajlm-1625	259	2	j	j	PROPN
ajlm-1625	259	3	immunogenet	immunogenet	PROPN
ajlm-1625	259	4	.	.	PUNCT
ajlm-1625	260	1	2016;43(4):226–235	2016;43(4):226–235	X
ajlm-1625	260	2	.	.	PUNCT
ajlm-1625	260	3	https://doi.org/10.1111/iji.12277	https://doi.org/10.1111/iji.12277	PROPN
ajlm-1625	260	4	sekongo	sekongo	NOUN
ajlm-1625	260	5	ym	ym	PROPN
ajlm-1625	260	6	,	,	PUNCT
ajlm-1625	260	7	kouacou	kouacou	PROPN
ajlm-1625	260	8	ap	ap	PROPN
ajlm-1625	260	9	,	,	PUNCT
ajlm-1625	260	10	kouamenan	kouamenan	PROPN
ajlm-1625	260	11	s	s	PROPN
ajlm-1625	260	12	,	,	PUNCT
ajlm-1625	260	13	et	et	PROPN
ajlm-1625	260	14	al	al	PROPN
ajlm-1625	260	15	.	.	PROPN
ajlm-1625	261	1	allo	allo	PROPN
ajlm-1625	261	2	-	-	PUNCT
ajlm-1625	261	3	immunisation	immunisation	NOUN
ajlm-1625	261	4	anti	anti	ADJ
ajlm-1625	261	5	-	-	ADJ
ajlm-1625	261	6	érythrocytaire	érythrocytaire	ADJ
ajlm-1625	261	7	chez	chez	PROPN
ajlm-1625	261	8	les	les	PROPN
ajlm-1625	261	9	drépanocytaires	drépanocytaires	PROPN
ajlm-1625	261	10	suivis	suivis	PROPN
ajlm-1625	261	11	dans	dan	NOUN
ajlm-1625	261	12	l’unité	l’unité	PROPN
ajlm-1625	261	13	de	de	X
ajlm-1625	261	14	thérapeutique	thérapeutique	ADJ
ajlm-1625	261	15	transfusionnelle	transfusionnelle	PROPN
ajlm-1625	261	16	du	du	PROPN
ajlm-1625	261	17	centre	centre	PROPN
ajlm-1625	261	18	national	national	PROPN
ajlm-1625	261	19	de	de	ADP
ajlm-1625	261	20	transfusion	transfusion	NOUN
ajlm-1625	261	21	sanguine	sanguine	ADJ
ajlm-1625	261	22	de	de	X
ajlm-1625	261	23	côte	côte	PROPN
ajlm-1625	261	24	d’ivoire	d’ivoire	PROPN
ajlm-1625	261	25	.	.	PUNCT
ajlm-1625	262	1	transfusion	transfusion	NOUN
ajlm-1625	262	2	clinique	clinique	NOUN
ajlm-1625	262	3	et	et	PROPN
ajlm-1625	262	4	biologique	biologique	PROPN
ajlm-1625	262	5	.	.	PUNCT
ajlm-1625	263	1	2015;22(4):244–245	2015;22(4):244–245	X
ajlm-1625	263	2	.	.	PUNCT
ajlm-1625	264	1	https://doi.org/10.1016/j.tracli.2015.06.098	https://doi.org/10.1016/j.tracli.2015.06.098	PROPN
ajlm-1625	264	2	senghor	senghor	PROPN
ajlm-1625	264	3	ab	ab	PROPN
ajlm-1625	264	4	,	,	PUNCT
ajlm-1625	264	5	seck	seck	PROPN
ajlm-1625	264	6	m	m	PROPN
ajlm-1625	264	7	,	,	PUNCT
ajlm-1625	264	8	faye	faye	PROPN
ajlm-1625	264	9	bf	bf	PROPN
ajlm-1625	264	10	,	,	PUNCT
ajlm-1625	264	11	et	et	PROPN
ajlm-1625	264	12	al	al	PROPN
ajlm-1625	264	13	.	.	PUNCT
ajlm-1625	265	1	séroprévalence	séroprévalence	PROPN
ajlm-1625	265	2	virale	virale	PROPN
ajlm-1625	265	3	et	et	PROPN
ajlm-1625	265	4	allo	allo	ADJ
ajlm-1625	265	5	-	-	PUNCT
ajlm-1625	265	6	immunisation	immunisation	NOUN
ajlm-1625	265	7	post	post	ADJ
ajlm-1625	265	8	-	-	ADJ
ajlm-1625	265	9	transfusionnelle	transfusionnelle	ADJ
ajlm-1625	265	10	chez	chez	PROPN
ajlm-1625	265	11	les	les	PROPN
ajlm-1625	265	12	patients	patient	NOUN
ajlm-1625	265	13	suivis	suivis	PROPN
ajlm-1625	265	14	pour	pour	PROPN
ajlm-1625	265	15	syndrome	syndrome	PROPN
ajlm-1625	265	16	drépanocytaire	drépanocytaire	PROPN
ajlm-1625	265	17	majeur	majeur	PROPN
ajlm-1625	265	18	.	.	PUNCT
ajlm-1625	266	1	transfusion	transfusion	NOUN
ajlm-1625	266	2	clinique	clinique	NOUN
ajlm-1625	266	3	et	et	PROPN
ajlm-1625	266	4	biologique	biologique	PROPN
ajlm-1625	266	5	.	.	PUNCT
ajlm-1625	267	1	2017;24(3):355	2017;24(3):355	NUM
ajlm-1625	267	2	.	.	PUNCT
ajlm-1625	268	1	https://doi.org/10.1016/j.tracli.2017.06.234	https://doi.org/10.1016/j.tracli.2017.06.234	PROPN
ajlm-1625	268	2	obi	obi	PROPN
ajlm-1625	268	3	ei	ei	PROPN
ajlm-1625	268	4	,	,	PUNCT
ajlm-1625	268	5	pughikumo	pughikumo	ADJ
ajlm-1625	268	6	co	co	NOUN
ajlm-1625	268	7	,	,	PUNCT
ajlm-1625	268	8	oko	oko	PROPN
ajlm-1625	268	9	-	-	PUNCT
ajlm-1625	268	10	jaja	jaja	PROPN
ajlm-1625	268	11	ri	ri	PROPN
ajlm-1625	268	12	.	.	PROPN
ajlm-1625	268	13	red	red	ADJ
ajlm-1625	268	14	blood	blood	NOUN
ajlm-1625	268	15	cell	cell	NOUN
ajlm-1625	268	16	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	268	17	in	in	ADP
ajlm-1625	268	18	multi	multi	ADJ
ajlm-1625	268	19	-	-	ADJ
ajlm-1625	268	20	transfused	transfused	ADJ
ajlm-1625	268	21	patients	patient	NOUN
ajlm-1625	268	22	with	with	ADP
ajlm-1625	268	23	chronic	chronic	ADJ
ajlm-1625	268	24	kidney	kidney	NOUN
ajlm-1625	268	25	disease	disease	NOUN
ajlm-1625	268	26	in	in	ADP
ajlm-1625	268	27	port	port	NOUN
ajlm-1625	268	28	harcourt	harcourt	PROPN
ajlm-1625	268	29	,	,	PUNCT
ajlm-1625	268	30	south	south	PROPN
ajlm-1625	268	31	-	-	PUNCT
ajlm-1625	268	32	south	south	NOUN
ajlm-1625	268	33	nigeria	nigeria	PROPN
ajlm-1625	268	34	.	.	PUNCT
ajlm-1625	269	1	afr	afr	PROPN
ajlm-1625	269	2	health	health	PROPN
ajlm-1625	269	3	sci	sci	PROPN
ajlm-1625	269	4	.	.	PUNCT
ajlm-1625	270	1	2018;18(4):979	2018;18(4):979	NUM
ajlm-1625	270	2	.	.	PUNCT
ajlm-1625	270	3	https://doi.org/10.4314/ahs.v18i4.18	https://doi.org/10.4314/ahs.v18i4.18	VERB
ajlm-1625	270	4	ipe	ipe	PROPN
ajlm-1625	270	5	ts	ts	NOUN
ajlm-1625	270	6	,	,	PUNCT
ajlm-1625	270	7	wilkes	wilkes	PROPN
ajlm-1625	270	8	jj	jj	PROPN
ajlm-1625	270	9	,	,	PUNCT
ajlm-1625	270	10	hartung	hartung	PROPN
ajlm-1625	270	11	hd	hd	PROPN
ajlm-1625	270	12	,	,	PUNCT
ajlm-1625	270	13	westhoff	westhoff	NOUN
ajlm-1625	270	14	cm	cm	PROPN
ajlm-1625	270	15	,	,	PUNCT
ajlm-1625	270	16	chou	chou	PROPN
ajlm-1625	270	17	st	st	PROPN
ajlm-1625	270	18	,	,	PUNCT
ajlm-1625	270	19	friedman	friedman	PROPN
ajlm-1625	270	20	df	df	PROPN
ajlm-1625	270	21	.	.	PUNCT
ajlm-1625	271	1	severe	severe	ADJ
ajlm-1625	271	2	hemolytic	hemolytic	ADJ
ajlm-1625	271	3	transfusion	transfusion	NOUN
ajlm-1625	271	4	reaction	reaction	NOUN
ajlm-1625	271	5	due	due	ADP
ajlm-1625	271	6	to	to	ADP
ajlm-1625	271	7	anti	anti	ADJ
ajlm-1625	271	8	-	-	NOUN
ajlm-1625	271	9	d	d	NOUN
ajlm-1625	271	10	in	in	ADP
ajlm-1625	271	11	a	a	DET
ajlm-1625	271	12	d+	d+	NOUN
ajlm-1625	271	13	patient	patient	NOUN
ajlm-1625	271	14	with	with	ADP
ajlm-1625	271	15	sickle	sickle	NOUN
ajlm-1625	271	16	cell	cell	NOUN
ajlm-1625	271	17	disease	disease	NOUN
ajlm-1625	271	18	.	.	PUNCT
ajlm-1625	272	1	j	j	PROPN
ajlm-1625	272	2	pediatr	pediatr	PROPN
ajlm-1625	272	3	hematol	hematol	PROPN
ajlm-1625	272	4	oncol	oncol	ADJ
ajlm-1625	272	5	.	.	PUNCT
ajlm-1625	273	1	2015;37(2):e135	2015;37(2):e135	NOUN
ajlm-1625	273	2	–	–	PUNCT
ajlm-1625	273	3	e137	e137	NUM
ajlm-1625	273	4	.	.	PUNCT
ajlm-1625	274	1	https://doi.org/10.1097/mph.0000000000000241	https://doi.org/10.1097/mph.0000000000000241	PROPN
ajlm-1625	274	2	tournamille	tournamille	PROPN
ajlm-1625	274	3	c	c	NOUN
ajlm-1625	274	4	,	,	PUNCT
ajlm-1625	274	5	meunier	meunier	NOUN
ajlm-1625	274	6	-	-	PUNCT
ajlm-1625	274	7	costes	coste	NOUN
ajlm-1625	274	8	n	n	CCONJ
ajlm-1625	274	9	,	,	PUNCT
ajlm-1625	274	10	costes	cost	VERB
ajlm-1625	274	11	b	b	NOUN
ajlm-1625	274	12	,	,	PUNCT
ajlm-1625	274	13	et	et	PROPN
ajlm-1625	274	14	al	al	PROPN
ajlm-1625	274	15	.	.	PROPN
ajlm-1625	275	1	partial	partial	PROPN
ajlm-1625	275	2	c	c	NOUN
ajlm-1625	275	3	antigen	antigen	PROPN
ajlm-1625	275	4	in	in	ADP
ajlm-1625	275	5	sickle	sickle	NOUN
ajlm-1625	275	6	cell	cell	NOUN
ajlm-1625	275	7	disease	disease	NOUN
ajlm-1625	275	8	patients	patient	NOUN
ajlm-1625	275	9	:	:	PUNCT
ajlm-1625	275	10	clinical	clinical	ADJ
ajlm-1625	275	11	relevance	relevance	NOUN
ajlm-1625	275	12	and	and	CCONJ
ajlm-1625	275	13	prevention	prevention	NOUN
ajlm-1625	275	14	of	of	ADP
ajlm-1625	275	15	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	275	16	.	.	PUNCT
ajlm-1625	276	1	transfusion	transfusion	NOUN
ajlm-1625	276	2	.	.	PUNCT
ajlm-1625	277	1	2010;50(1):13–19	2010;50(1):13–19	NUM
ajlm-1625	277	2	.	.	PUNCT
ajlm-1625	278	1	https://doi.org/10.1111/j.1537-2995.2009.02382.x	https://doi.org/10.1111/j.1537-2995.2009.02382.x	PROPN
ajlm-1625	278	2	natukunda	natukunda	PROPN
ajlm-1625	278	3	b	b	PROPN
ajlm-1625	278	4	,	,	PUNCT
ajlm-1625	278	5	mugyenyi	mugyenyi	PROPN
ajlm-1625	278	6	g	g	PROPN
ajlm-1625	278	7	,	,	PUNCT
ajlm-1625	278	8	brand	brand	NOUN
ajlm-1625	278	9	a	a	NOUN
ajlm-1625	278	10	,	,	PUNCT
ajlm-1625	278	11	schonewille	schonewille	VERB
ajlm-1625	278	12	h.	h.	PROPN
ajlm-1625	278	13	maternal	maternal	ADJ
ajlm-1625	278	14	red	red	ADJ
ajlm-1625	278	15	blood	blood	NOUN
ajlm-1625	278	16	cell	cell	NOUN
ajlm-1625	278	17	alloimmunisation	alloimmunisation	NOUN
ajlm-1625	278	18	in	in	ADP
ajlm-1625	278	19	south	south	ADJ
ajlm-1625	278	20	western	western	PROPN
ajlm-1625	278	21	uganda	uganda	PROPN
ajlm-1625	278	22	.	.	PUNCT
ajlm-1625	279	1	transfus	transfus	PROPN
ajlm-1625	279	2	med	med	PROPN
ajlm-1625	279	3	.	.	PUNCT
ajlm-1625	280	1	2011;21(4):262–266	2011;21(4):262–266	NUM
ajlm-1625	280	2	.	.	PUNCT
ajlm-1625	280	3	https://doi.org/10.1111/j.1365-3148.2011.01073.x	https://doi.org/10.1111/j.1365-3148.2011.01073.x	NOUN